| NCT05093972 | Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) | NOT_YET_RECRUITING | PHASE1 | 2026-04-07 | 2026-09-10 | 2026-09-10 |
| NCT07209111 | A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014) | NOT_YET_RECRUITING | PHASE2 | 2025-11-24 | 2032-04-09 | 2032-04-09 |
| NCT07199465 | A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) | NOT_YET_RECRUITING | PHASE1 | 2025-11-19 | 2028-05-19 | 2028-04-14 |
| NCT07071623 | A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | NOT_YET_RECRUITING | PHASE3 | 2025-10-31 | 2027-10-18 | 2027-10-18 |
| NCT07199452 | A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) | NOT_YET_RECRUITING | PHASE1 | 2025-10-28 | 2025-12-27 | 2025-12-27 |
| NCT07190248 | A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | NOT_YET_RECRUITING | PHASE3 | 2025-10-27 | 2032-08-06 | 2029-12-07 |
| NCT07176390 | A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | NOT_YET_RECRUITING | PHASE2 | 2025-10-14 | 2029-09-03 | 2027-03-08 |
| NCT06655883 | A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | NOT_YET_RECRUITING | PHASE3 | 2025-10-13 | 2027-06-24 | 2027-04-15 |
| NCT07168915 | A Study of V118E in Healthy Participants (V118E-003) | NOT_YET_RECRUITING | PHASE1 | 2025-10-10 | 2027-02-09 | 2027-02-09 |
| NCT07086079 | A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) | RECRUITING | PHASE1 | 2025-09-26 | 2026-06-01 | 2026-06-01 |
| NCT07089784 | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | RECRUITING | PHASE1 | 2025-09-22 | 2026-01-12 | 2026-01-12 |
| NCT07025551 | A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) | RECRUITING | PHASE1 | 2025-09-19 | 2026-01-07 | 2025-12-08 |
| NCT07133633 | A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | NOT_YET_RECRUITING | PHASE2 | 2025-09-18 | 2030-02-05 | 2027-06-15 |
| NCT07058077 | A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) | RECRUITING | PHASE2, PHASE3 | 2025-08-21 | 2037-01-24 | 2033-12-04 |
| NCT07049939 | A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) | RECRUITING | PHASE1 | 2025-08-20 | 2026-03-16 | 2025-11-16 |
| NCT07121959 | A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-08-18 | 2025-09-26 | 2025-09-13 |
| NCT07063238 | A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-08-12 | 2025-12-15 | 2025-11-25 |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | RECRUITING | PHASE2 | 2025-08-11 | 2027-11-04 | 2027-11-04 |
| NCT07044297 | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | RECRUITING | PHASE3 | 2025-07-31 | 2027-10-20 | 2027-10-20 |
| NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | RECRUITING | PHASE1, PHASE2 | 2025-07-30 | 2032-01-04 | 2032-01-04 |
| NCT07030712 | A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) | RECRUITING | PHASE1 | 2025-07-23 | 2027-08-23 | 2027-08-23 |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | RECRUITING | PHASE3 | 2025-07-21 | 2033-07-14 | 2033-07-14 |
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | RECRUITING | PHASE1, PHASE2 | 2025-07-20 | 2031-10-26 | 2031-10-26 |
| NCT06997497 | A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | RECRUITING | PHASE3 | 2025-07-16 | 2030-10-27 | 2029-08-27 |
| NCT07033494 | A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | RECRUITING | PHASE2 | 2025-07-16 | 2029-04-30 | 2029-04-30 |
| NCT07042945 | MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) | RECRUITING | PHASE1 | 2025-07-09 | 2026-04-06 | 2026-04-06 |
| NCT06863272 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | RECRUITING | PHASE1, PHASE2 | 2025-07-03 | 2030-02-24 | 2030-02-18 |
| NCT07044479 | A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) | COMPLETED | PHASE1 | 2025-07-03 | 2025-08-28 | 2025-08-13 |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | RECRUITING | PHASE3 | 2025-06-30 | 2034-12-29 | 2033-03-23 |
| NCT07013487 | A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) | RECRUITING | PHASE3 | 2025-06-11 | 2032-02-02 | 2032-02-02 |
| NCT06956235 | Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) | RECRUITING | PHASE2 | 2025-06-09 | 2029-01-22 | 2026-11-16 |
| NCT06961006 | A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | RECRUITING | PHASE2 | 2025-05-29 | 2031-09-05 | 2028-07-22 |
| NCT06780098 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | RECRUITING | PHASE2 | 2025-05-28 | 2032-03-02 | 2032-03-02 |
| NCT06941272 | A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | RECRUITING | PHASE1, PHASE2 | 2025-05-26 | 2030-12-30 | 2030-12-30 |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | RECRUITING | PHASE3 | 2025-05-22 | 2032-05-24 | 2032-05-24 |
| NCT06930664 | A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-05-16 | 2025-11-19 | 2025-11-19 |
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | RECRUITING | PHASE2 | 2025-05-13 | 2032-03-12 | 2032-03-12 |
| NCT06860243 | A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) | RECRUITING | PHASE1 | 2025-05-13 | 2025-12-01 | 2025-11-22 |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | RECRUITING | PHASE3 | 2025-05-13 | 2031-01-06 | 2028-06-26 |
| NCT06942741 | A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-05-13 | 2025-07-03 | 2025-06-21 |
| NCT06925750 | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) | RECRUITING | PHASE2 | 2025-05-12 | 2027-09-30 | 2027-09-30 |
| NCT06893081 | A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012) | COMPLETED | PHASE1 | 2025-04-28 | 2025-07-17 | 2025-06-19 |
| NCT06894771 | A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-04-23 | 2025-11-24 | 2025-11-24 |
| NCT06814145 | Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | RECRUITING | PHASE2 | 2025-04-16 | 2029-03-30 | 2029-03-30 |
| NCT06843447 | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | RECRUITING | PHASE1, PHASE2 | 2025-04-15 | 2029-03-27 | 2029-03-27 |
| NCT06580587 | A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009) | RECRUITING | PHASE1 | 2025-04-15 | 2025-12-19 | 2025-12-19 |
| NCT06891066 | A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) | ACTIVE_NOT_RECRUITING | PHASE2 | 2025-04-14 | 2027-09-24 | 2027-09-24 |
| NCT06890884 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | RECRUITING | PHASE2 | 2025-04-11 | 2032-12-16 | 2027-12-13 |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | RECRUITING | PHASE3 | 2025-04-09 | 2032-10-15 | 2029-04-27 |
| NCT06814132 | A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-04-07 | 2025-10-15 | 2025-10-04 |
| NCT06814119 | A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010) | RECRUITING | PHASE1 | 2025-04-07 | 2025-11-21 | 2025-11-10 |
| NCT06880874 | A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035) | COMPLETED | PHASE1 | 2025-04-02 | 2025-05-31 | 2025-05-16 |
| NCT06864169 | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | RECRUITING | PHASE2 | 2025-04-01 | 2029-01-04 | 2026-07-06 |
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | RECRUITING | PHASE2 | 2025-03-30 | 2032-03-12 | 2032-03-12 |
| NCT06903715 | A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035) | COMPLETED | PHASE1 | 2025-03-28 | 2025-05-27 | 2025-05-08 |
| NCT06829199 | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) | WITHDRAWN | PHASE2 | 2025-03-26 | 2031-03-18 | 2029-01-18 |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | RECRUITING | PHASE1, PHASE2 | 2025-03-25 | 2028-01-28 | 2028-01-28 |
| NCT06797635 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | RECRUITING | PHASE2 | 2025-03-20 | 2034-12-31 | 2029-12-31 |
| NCT06788912 | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) | RECRUITING | PHASE2 | 2025-03-20 | 2032-02-06 | 2032-02-06 |
| NCT06826989 | A Study of MK-8527 in Healthy Adult Participants (MK-8527-013) | COMPLETED | PHASE1 | 2025-03-19 | 2025-06-04 | 2025-06-04 |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | RECRUITING | PHASE3 | 2025-03-16 | 2030-05-18 | 2030-05-18 |
| NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | RECRUITING | PHASE2 | 2025-03-11 | 2031-09-03 | 2031-09-03 |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | RECRUITING | PHASE1, PHASE2 | 2025-02-27 | 2029-08-31 | 2029-08-31 |
| NCT06818968 | A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005) | COMPLETED | PHASE1 | 2025-02-27 | 2025-08-08 | 2025-08-08 |
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | RECRUITING | PHASE1, PHASE2 | 2025-02-26 | 2029-09-10 | 2029-09-10 |
| NCT06816043 | A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants | COMPLETED | PHASE1 | 2025-02-21 | 2025-06-17 | 2025-06-05 |
| NCT06797674 | A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005) | COMPLETED | PHASE1 | 2025-02-10 | 2025-08-12 | 2025-08-12 |
| NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | RECRUITING | PHASE3 | 2025-01-27 | 2032-03-29 | 2029-07-02 |
| NCT06395090 | A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | WITHDRAWN | PHASE1, PHASE2 | 2025-01-15 | 2029-06-30 | 2029-06-30 |
| NCT06719544 | A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034) | COMPLETED | PHASE1 | 2025-01-02 | 2025-02-06 | 2025-01-27 |
| NCT06688058 | A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) | RECRUITING | PHASE1 | 2024-12-20 | 2026-11-30 | 2026-11-30 |
| NCT06637423 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | RECRUITING | PHASE1, PHASE2 | 2024-12-20 | 2028-07-31 | 2026-06-30 |
| NCT06806046 | Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02) | RECRUITING | PHASE1 | 2024-12-20 | 2026-05-07 | 2026-05-07 |
| NCT06633419 | A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) | COMPLETED | PHASE1 | 2024-12-18 | 2025-05-13 | 2025-02-12 |
| NCT06721156 | A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | RECRUITING | PHASE2 | 2024-12-16 | 2027-01-12 | 2027-01-12 |
| NCT06655324 | A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001). | RECRUITING | PHASE1 | 2024-12-05 | 2027-07-16 | 2027-07-16 |
| NCT06667700 | A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) | RECRUITING | PHASE3 | 2024-12-02 | 2031-01-26 | 2031-01-26 |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | RECRUITING | PHASE2 | 2024-11-27 | 2028-10-07 | 2027-05-05 |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | RECRUITING | PHASE3 | 2024-11-25 | 2037-12-17 | 2037-12-17 |
| NCT06643377 | A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) | COMPLETED | PHASE1 | 2024-11-22 | 2025-06-25 | 2025-06-25 |
| NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | RECRUITING | PHASE3 | 2024-11-21 | 2030-02-11 | 2026-06-22 |
| NCT06664801 | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-11-14 | 2025-11-20 | 2025-11-20 |
| NCT06623409 | Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-11-12 | 2026-11-20 | 2026-11-20 |
| NCT06647628 | A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005) | COMPLETED | PHASE1 | 2024-11-04 | 2025-03-31 | 2025-03-31 |
| NCT06596694 | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | RECRUITING | PHASE1, PHASE2 | 2024-11-03 | 2028-07-24 | 2028-07-24 |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | RECRUITING | PHASE3 | 2024-10-21 | 2038-01-26 | 2033-05-16 |
| NCT06609512 | A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033) | COMPLETED | PHASE1 | 2024-10-21 | 2025-01-31 | 2025-01-13 |
| NCT06582602 | A Study of MK-2060 in Healthy Participants (MK-2060-016) | COMPLETED | PHASE1 | 2024-10-15 | 2025-04-18 | 2025-04-18 |
| NCT06504394 | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | RECRUITING | PHASE2 | 2024-10-14 | 2028-11-08 | 2028-11-08 |
| NCT06597760 | A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031) | COMPLETED | PHASE1 | 2024-10-07 | 2024-11-15 | 2024-11-01 |
| NCT06586606 | A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) | COMPLETED | PHASE1 | 2024-10-03 | 2024-12-10 | 2024-12-10 |
| NCT06596668 | Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) | COMPLETED | PHASE1 | 2024-10-02 | 2025-03-11 | 2025-02-05 |
| NCT06611033 | A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-09-25 | 2025-12-16 | 2025-12-16 |
| NCT06589713 | Effect of Renal Impairment on Enpatoran Pharmacokinetics | RECRUITING | PHASE1 | 2024-09-24 | 2026-04-22 | 2026-04-22 |
| NCT06575595 | Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) | COMPLETED | PHASE1 | 2024-09-24 | 2025-01-31 | 2025-01-31 |
| NCT06469944 | Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | RECRUITING | PHASE1, PHASE2 | 2024-09-20 | 2029-04-12 | 2027-01-17 |
| NCT06575959 | A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) | COMPLETED | PHASE1 | 2024-09-20 | 2025-05-08 | 2025-05-01 |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | COMPLETED | PHASE1 | 2024-09-19 | 2024-10-17 | 2024-10-17 |
| NCT06577337 | Single and Multiple Ascending Doses of M5542 Administered in Healthy Volunteers | SUSPENDED | PHASE1 | 2024-09-12 | 2028-03-31 | 2027-03-08 |
| NCT06589726 | A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants | COMPLETED | PHASE1 | 2024-09-10 | 2024-12-02 | 2024-12-02 |
| NCT06567002 | A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006) | TERMINATED | PHASE1 | 2024-09-09 | 2024-11-15 | 2024-11-15 |
| NCT06575933 | A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009) | COMPLETED | PHASE1 | 2024-09-03 | 2024-10-28 | 2024-10-28 |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | RECRUITING | PHASE1, PHASE2 | 2024-08-16 | 2029-03-31 | 2029-03-31 |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | RECRUITING | PHASE1, PHASE2 | 2024-08-07 | 2028-10-27 | 2026-12-28 |
| NCT06492291 | Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-08-05 | 2028-10-13 | 2028-10-13 |
| NCT06482112 | Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | COMPLETED | PHASE2 | 2024-07-29 | 2025-06-27 | 2025-06-27 |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | RECRUITING | PHASE3 | 2024-07-24 | 2028-10-23 | 2028-10-23 |
| NCT06442436 | A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) | RECRUITING | PHASE1 | 2024-07-24 | 2025-12-12 | 2025-12-12 |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | RECRUITING | PHASE1, PHASE2 | 2024-07-17 | 2028-07-28 | 2028-07-28 |
| NCT06456346 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | RECRUITING | PHASE3 | 2024-07-16 | 2029-04-15 | 2027-04-15 |
| NCT06609161 | A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) | COMPLETED | PHASE1 | 2024-07-16 | 2024-08-08 | 2024-08-08 |
| NCT06460961 | A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) | RECRUITING | PHASE1 | 2024-07-14 | 2029-07-13 | 2029-07-13 |
| NCT06465186 | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | RECRUITING | PHASE2 | 2024-07-12 | 2026-09-21 | 2026-09-21 |
| NCT06554639 | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | COMPLETED | PHASE1 | 2024-07-11 | 2024-08-29 | 2024-08-05 |
| NCT06450366 | A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn | COMPLETED | PHASE3 | 2024-07-08 | 2025-03-28 | 2025-02-14 |
| NCT06625814 | A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) | COMPLETED | PHASE1 | 2024-07-08 | 2024-09-11 | 2024-08-19 |
| NCT06687759 | A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006) | COMPLETED | PHASE1 | 2024-06-26 | 2024-08-07 | 2024-08-07 |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | RECRUITING | PHASE3 | 2024-06-25 | 2030-08-19 | 2028-05-19 |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING | PHASE3 | 2024-06-24 | 2037-12-14 | 2030-12-16 |
| NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | RECRUITING | PHASE1, PHASE2 | 2024-06-20 | 2029-10-16 | 2029-10-16 |
| NCT06295796 | A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) | COMPLETED | PHASE1 | 2024-06-20 | 2025-01-31 | 2025-01-31 |
| NCT06701305 | A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) | COMPLETED | PHASE1 | 2024-06-13 | 2025-02-18 | 2025-02-18 |
| NCT06829225 | Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) | COMPLETED | PHASE1 | 2024-06-13 | 2024-11-11 | 2024-11-11 |
| NCT06662396 | A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007) | COMPLETED | PHASE1 | 2024-06-13 | 2024-09-27 | 2024-09-27 |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | RECRUITING | PHASE3 | 2024-06-11 | 2030-06-14 | 2028-09-12 |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | RECRUITING | PHASE3 | 2024-06-10 | 2031-02-12 | 2029-01-12 |
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) | RECRUITING | PHASE3 | 2024-06-05 | 2029-11-12 | 2028-10-30 |
| NCT06345729 | A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | RECRUITING | PHASE3 | 2024-05-24 | 2031-02-18 | 2029-02-19 |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | RECRUITING | PHASE3 | 2024-05-23 | 2034-12-04 | 2034-12-04 |
| NCT06353386 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | RECRUITING | PHASE1, PHASE2 | 2024-05-20 | 2028-03-31 | 2028-03-31 |
| NCT06719557 | A Study of the Effect of Itraconazole and Phenytoin on MK-1084 in Healthy Adults (MK-1084-008) | COMPLETED | PHASE1 | 2024-05-20 | 2024-07-30 | 2024-07-30 |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | RECRUITING | PHASE3 | 2024-05-03 | 2027-05-06 | 2027-01-04 |
| NCT06821334 | A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014) | COMPLETED | PHASE1 | 2024-04-23 | 2024-08-09 | 2024-08-09 |
| NCT06772792 | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027) | COMPLETED | PHASE1 | 2024-04-23 | 2024-06-21 | 2024-06-21 |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2024-04-18 | 2026-03-05 | 2026-03-05 |
| NCT06294912 | A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) | COMPLETED | PHASE1 | 2024-04-18 | 2025-01-06 | 2025-01-06 |
| NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | RECRUITING | PHASE3 | 2024-04-14 | 2031-04-12 | 2027-07-11 |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-04-10 | 2032-06-08 | 2028-01-08 |
| NCT06273774 | A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020) | COMPLETED | PHASE1 | 2024-04-08 | 2024-08-21 | 2024-08-21 |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | RECRUITING | PHASE3 | 2024-04-03 | 2034-10-23 | 2034-02-21 |
| NCT06772779 | A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026) | COMPLETED | PHASE1 | 2024-04-01 | 2024-06-04 | 2024-06-04 |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | RECRUITING | PHASE1, PHASE2 | 2024-03-28 | 2031-10-20 | 2027-04-23 |
| NCT06285240 | Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) | COMPLETED | PHASE1 | 2024-03-28 | 2024-09-23 | 2024-09-23 |
| NCT06308263 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | RECRUITING | PHASE1 | 2024-03-25 | 2026-03-13 | 2026-03-13 |
| NCT06619665 | A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) | COMPLETED | PHASE1 | 2024-03-19 | 2024-07-16 | 2024-07-16 |
| NCT06691906 | A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025) | COMPLETED | PHASE1 | 2024-03-18 | 2024-05-01 | 2024-05-01 |
| NCT06630117 | A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001) | RECRUITING | PHASE1 | 2024-03-01 | 2027-01-25 | 2026-07-23 |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | COMPLETED | PHASE1, PHASE2 | 2024-02-28 | 2025-06-17 | 2025-06-17 |
| NCT06692647 | A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003) | COMPLETED | PHASE1 | 2024-02-09 | 2024-04-11 | 2024-04-11 |
| NCT06811246 | A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) | COMPLETED | PHASE1 | 2024-02-07 | 2024-07-14 | 2024-07-14 |
| NCT06136598 | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-01-30 | 2027-03-14 | 2025-09-30 |
| NCT06179407 | Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) | TERMINATED | PHASE1 | 2024-01-24 | 2024-10-23 | 2024-10-23 |
| NCT06719570 | A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) | COMPLETED | PHASE1 | 2024-01-23 | 2024-03-15 | 2024-03-15 |
| NCT06699329 | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | COMPLETED | PHASE1 | 2024-01-22 | 2024-05-24 | 2024-05-24 |
| NCT06177912 | A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) | COMPLETED | PHASE3 | 2024-01-18 | 2025-02-26 | 2025-02-26 |
| NCT06619678 | A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) | COMPLETED | PHASE1 | 2024-01-17 | 2024-06-23 | 2024-06-23 |
| NCT05115838 | Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) | WITHDRAWN | PHASE2 | 2024-01-04 | 2025-10-02 | 2025-10-02 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | RECRUITING | PHASE3 | 2023-12-31 | 2028-08-02 | 2028-08-02 |
| NCT06079879 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | RECRUITING | PHASE3 | 2023-12-31 | 2028-08-18 | 2026-09-10 |
| NCT06161116 | Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) | TERMINATED | PHASE2 | 2023-12-27 | 2025-07-30 | 2025-07-30 |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-12-26 | 2026-11-16 | 2025-04-09 |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-18 | 2030-12-02 | 2028-05-10 |
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | RECRUITING | PHASE3 | 2023-12-15 | 2030-05-27 | 2028-01-25 |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | RECRUITING | PHASE3 | 2023-12-13 | 2032-09-07 | 2032-09-07 |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | RECRUITING | PHASE3 | 2023-12-06 | 2035-12-21 | 2030-06-25 |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-06 | 2028-01-10 | 2028-01-10 |
| NCT05974267 | Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) | COMPLETED | PHASE2 | 2023-11-28 | 2024-12-29 | 2024-12-29 |
| NCT06113328 | A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) | TERMINATED | PHASE2 | 2023-11-27 | 2025-07-30 | 2025-03-20 |
| NCT06843460 | A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021) | COMPLETED | PHASE1 | 2023-11-22 | 2024-05-21 | 2024-05-21 |
| NCT06052566 | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) | COMPLETED | PHASE1 | 2023-11-21 | 2024-12-05 | 2024-12-05 |
| NCT06643390 | A Study of MK-2225 in Healthy Participants (MK-2225-003) | COMPLETED | PHASE1 | 2023-11-21 | 2025-07-14 | 2025-07-14 |
| NCT06104449 | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-11-14 | 2026-04-12 | 2026-04-12 |
| NCT06074588 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | RECRUITING | PHASE3 | 2023-11-12 | 2030-03-11 | 2027-05-10 |
| NCT06045507 | Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) | COMPLETED | PHASE2 | 2023-11-08 | 2025-02-12 | 2024-12-12 |
| NCT06699355 | A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024) | COMPLETED | PHASE1 | 2023-11-08 | 2023-12-29 | 2023-12-29 |
| NCT06625827 | A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) | COMPLETED | PHASE1 | 2023-11-07 | 2024-01-22 | 2024-01-22 |
| NCT06688045 | A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) | COMPLETED | PHASE1 | 2023-10-30 | 2024-01-06 | 2024-01-06 |
| NCT06049212 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | RECRUITING | PHASE1 | 2023-10-26 | 2027-01-29 | 2026-06-30 |
| NCT06052059 | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | RECRUITING | PHASE3 | 2023-10-25 | 2029-12-17 | 2026-11-21 |
| NCT06658652 | The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022) | COMPLETED | PHASE1 | 2023-10-24 | 2023-12-26 | 2023-12-26 |
| NCT06041802 | A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) | RECRUITING | PHASE2 | 2023-10-20 | 2028-03-31 | 2028-03-31 |
| NCT06703463 | A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) | COMPLETED | PHASE1 | 2023-10-17 | 2024-02-02 | 2024-02-02 |
| NCT06008756 | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-10-09 | 2029-11-29 | 2029-11-29 |
| NCT06772818 | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) | COMPLETED | PHASE1 | 2023-10-02 | 2024-02-16 | 2023-12-20 |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-09-29 | 2027-03-09 | 2027-03-09 |
| NCT06809569 | A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420) | COMPLETED | PHASE1 | 2023-09-25 | 2023-12-15 | 2023-12-15 |
| NCT06665230 | A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005) | COMPLETED | PHASE1 | 2023-09-20 | 2023-11-20 | 2023-11-20 |
| NCT06619314 | A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003) | COMPLETED | PHASE1 | 2023-09-20 | 2023-11-25 | 2023-11-25 |
| NCT06625840 | A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) | COMPLETED | PHASE1 | 2023-09-18 | 2024-05-08 | 2024-05-08 |
| NCT05953740 | A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) | COMPLETED | PHASE1 | 2023-09-15 | 2024-02-15 | 2024-02-15 |
| NCT05558696 | A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004) | COMPLETED | PHASE2 | 2023-09-07 | 2025-07-10 | 2025-03-24 |
| NCT06586671 | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) | COMPLETED | PHASE1 | 2023-08-28 | 2023-11-13 | 2023-11-13 |
| NCT05818124 | Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) | COMPLETED | PHASE1 | 2023-08-21 | 2024-06-28 | 2024-06-28 |
| NCT06783192 | A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) | COMPLETED | PHASE1 | 2023-08-14 | 2023-10-11 | 2023-10-11 |
| NCT05952856 | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids | COMPLETED | PHASE3 | 2023-08-10 | 2025-07-28 | 2025-07-28 |
| NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | RECRUITING | PHASE3 | 2023-08-08 | 2035-03-14 | 2035-03-14 |
| NCT05952869 | A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH | COMPLETED | PHASE3 | 2023-08-08 | 2025-04-07 | 2025-04-07 |
| NCT06698016 | A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) | COMPLETED | PHASE1 | 2023-07-25 | 2023-10-30 | 2023-10-30 |
| NCT06772805 | A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) | COMPLETED | PHASE1 | 2023-07-24 | 2023-12-12 | 2023-12-12 |
| NCT05934292 | Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) | COMPLETED | PHASE1 | 2023-07-20 | 2024-01-19 | 2024-01-19 |
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-07-19 | 2030-09-26 | 2029-10-26 |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | RECRUITING | PHASE1 | 2023-07-06 | 2028-02-12 | 2028-02-12 |
| NCT06816030 | A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) | COMPLETED | PHASE1 | 2023-06-28 | 2023-08-05 | 2023-08-05 |
| NCT05893862 | A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019) | COMPLETED | PHASE1 | 2023-06-26 | 2024-02-22 | 2024-02-22 |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-06-23 | 2027-05-31 | 2027-05-31 |
| NCT05877547 | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-06-23 | 2025-12-29 | 2025-12-29 |
| NCT05769595 | Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012) | COMPLETED | PHASE1 | 2023-06-14 | 2024-02-15 | 2024-02-15 |
| NCT06212752 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-13 | 2028-05-22 | 2024-11-06 |
| NCT05714085 | Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | RECRUITING | PHASE2, PHASE3 | 2023-05-31 | 2032-04-15 | 2032-04-15 |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | RECRUITING | PHASE1, PHASE2 | 2023-05-16 | 2029-04-10 | 2026-11-07 |
| NCT05818137 | A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-05-10 | 2026-02-27 | 2024-03-12 |
| NCT05700734 | MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002) | WITHDRAWN | PHASE1 | 2023-04-17 | 2024-02-14 | 2024-02-14 |
| NCT05689047 | Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) | COMPLETED | PHASE2 | 2023-03-29 | 2024-05-28 | 2024-05-28 |
| NCT05763823 | A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) | COMPLETED | PHASE3 | 2023-03-24 | 2024-04-18 | 2024-04-18 |
| NCT06649877 | MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013) | COMPLETED | PHASE1 | 2023-03-20 | 2023-07-13 | 2023-07-13 |
| NCT05766501 | A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-03-17 | 2028-09-06 | 2025-12-03 |
| NCT05612035 | Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-03-16 | 2029-10-07 | 2026-04-07 |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-03-16 | 2031-03-17 | 2027-05-19 |
| NCT06658626 | A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016) | COMPLETED | PHASE1 | 2023-03-10 | 2023-08-02 | 2023-08-02 |
| NCT04948554 | A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) | TERMINATED | PHASE1 | 2023-03-10 | 2023-10-18 | 2023-10-18 |
| NCT05705349 | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-03-08 | 2029-08-05 | 2025-10-19 |
| NCT06814106 | A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010) | COMPLETED | PHASE1 | 2023-03-06 | 2023-05-08 | 2023-05-08 |
| NCT06843993 | Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009) | COMPLETED | PHASE1 | 2023-03-01 | 2023-10-27 | 2023-10-27 |
| NCT05930808 | Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong) | COMPLETED | PHASE1 | 2023-02-28 | 2023-06-18 | 2023-06-18 |
| NCT05631093 | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-02-20 | 2028-07-11 | 2024-10-10 |
| NCT05630755 | A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-02-17 | 2028-08-04 | 2024-10-25 |
| NCT05722015 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-02-14 | 2028-05-22 | 2024-07-12 |
| NCT05673460 | A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) | COMPLETED | PHASE1 | 2023-02-13 | 2025-09-03 | 2025-04-28 |
| NCT05696080 | Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) | COMPLETED | PHASE3 | 2023-02-13 | 2024-02-16 | 2024-02-16 |
| NCT05656040 | A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) | COMPLETED | PHASE1 | 2023-02-08 | 2024-08-12 | 2024-08-12 |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | RECRUITING | PHASE3 | 2023-02-06 | 2028-08-23 | 2027-01-12 |
| NCT06615869 | A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) | COMPLETED | PHASE1 | 2023-01-20 | 2023-03-15 | 2023-02-27 |
| NCT05587712 | Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) | RECRUITING | PHASE2 | 2023-01-19 | 2028-09-21 | 2028-09-21 |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-01-19 | 2025-09-26 | 2024-03-06 |
| NCT07214922 | Relative Bioavailability of Evobrutinib Tablet Batches | COMPLETED | PHASE1 | 2023-01-18 | 2023-02-24 | 2023-02-24 |
| NCT05633992 | Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) | COMPLETED | PHASE3 | 2023-01-10 | 2023-05-24 | 2023-05-24 |
| NCT05594043 | A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) | COMPLETED | PHASE1 | 2022-12-21 | 2025-05-21 | 2025-05-21 |
| NCT05655832 | A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD | COMPLETED | NA | 2022-12-05 | 2023-10-31 | 2023-10-31 |
| NCT05602727 | Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) | TERMINATED | PHASE2 | 2022-12-02 | 2023-09-27 | 2023-09-27 |
| NCT05494736 | MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) | COMPLETED | PHASE1 | 2022-11-17 | 2024-01-31 | 2024-01-31 |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-11-16 | 2028-06-20 | 2028-06-20 |
| NCT07214935 | A TQT Study of Effect of M2951 on Cardiac Repolarization | COMPLETED | PHASE1 | 2022-11-08 | 2023-08-25 | 2023-08-25 |
| NCT05569954 | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) | COMPLETED | PHASE3 | 2022-11-07 | 2025-01-30 | 2023-10-30 |
| NCT05603182 | A Study of PRA052 in Healthy Volunteers | COMPLETED | PHASE1 | 2022-11-07 | 2024-02-21 | 2024-02-21 |
| NCT05559905 | Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) | COMPLETED | PHASE2 | 2022-11-02 | 2023-06-08 | 2023-04-18 |
| NCT06592339 | A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) | COMPLETED | PHASE1 | 2022-10-25 | 2022-12-29 | 2022-12-29 |
| NCT05508867 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-10-18 | 2026-01-08 | 2025-09-03 |
| NCT05130086 | A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) | WITHDRAWN | PHASE2 | 2022-10-17 | 2024-03-25 | 2024-03-25 |
| NCT06655311 | A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) | COMPLETED | PHASE1 | 2022-09-30 | 2024-01-02 | 2024-01-02 |
| NCT05519540 | PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants | COMPLETED | PHASE1 | 2022-09-26 | 2023-04-21 | 2023-04-21 |
| NCT05514444 | Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) | COMPLETED | PHASE1 | 2022-09-25 | 2025-09-18 | 2025-09-18 |
| NCT05526716 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) | COMPLETED | PHASE3 | 2022-09-23 | 2023-06-21 | 2023-06-21 |
| NCT05466422 | A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) | COMPLETED | PHASE1 | 2022-09-20 | 2025-07-03 | 2025-07-03 |
| NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-09-16 | 2028-08-12 | 2028-08-12 |
| NCT05507450 | Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) | COMPLETED | PHASE2 | 2022-09-07 | 2024-05-07 | 2023-06-05 |
| NCT06836037 | A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011) | COMPLETED | PHASE1 | 2022-09-05 | 2023-02-02 | 2023-02-02 |
| NCT06777602 | A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011) | COMPLETED | PHASE1 | 2022-08-15 | 2022-10-25 | 2022-09-30 |
| NCT05464420 | A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) | COMPLETED | PHASE3 | 2022-08-12 | 2023-05-25 | 2023-05-25 |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-08-10 | 2026-07-21 | 2026-07-21 |
| NCT05450198 | Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) | COMPLETED | PHASE1 | 2022-08-08 | 2024-05-22 | 2024-05-22 |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-07-27 | 2025-11-13 | 2025-11-13 |
| NCT05899049 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-27 | 2026-12-01 | 2026-12-01 |
| NCT05446870 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | COMPLETED | PHASE2 | 2022-07-25 | 2024-10-16 | 2023-12-20 |
| NCT05463094 | GXR RM China BE Study (Darmstadt - Jiangsu) | COMPLETED | PHASE1 | 2022-07-25 | 2023-01-03 | 2023-01-03 |
| NCT05450705 | V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-22 | 2029-08-03 | 2029-08-03 |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | RECRUITING | PHASE2 | 2022-07-21 | 2029-05-17 | 2029-03-13 |
| NCT05406401 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-14 | 2029-04-26 | 2029-04-26 |
| NCT05393037 | Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) | COMPLETED | PHASE3 | 2022-07-13 | 2024-01-25 | 2023-07-13 |
| NCT05425732 | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) | COMPLETED | PHASE3 | 2022-07-13 | 2023-05-18 | 2023-05-18 |
| NCT04994522 | A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) | COMPLETED | PHASE1 | 2022-07-12 | 2024-04-11 | 2024-04-01 |
| NCT05420961 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) | COMPLETED | PHASE3 | 2022-07-12 | 2023-05-16 | 2023-05-16 |
| NCT05406440 | A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014) | COMPLETED | PHASE1 | 2022-07-12 | 2023-02-24 | 2023-02-24 |
| NCT05394350 | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | TERMINATED | PHASE1, PHASE2 | 2022-07-07 | 2023-09-07 | 2023-09-07 |
| NCT05227118 | MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017) | COMPLETED | PHASE1 | 2022-07-01 | 2023-01-10 | 2023-01-10 |
| NCT05386758 | A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) | COMPLETED | PHASE1 | 2022-06-29 | 2023-03-01 | 2023-02-04 |
| NCT04995484 | A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020) | COMPLETED | PHASE1 | 2022-06-24 | 2024-01-03 | 2023-12-25 |
| NCT05382325 | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-06-16 | 2026-07-31 | 2026-07-31 |
| NCT05600309 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | COMPLETED | PHASE3 | 2022-06-14 | 2025-02-21 | 2024-08-15 |
| NCT05386589 | A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) | COMPLETED | PHASE1 | 2022-06-14 | 2023-01-05 | 2022-12-18 |
| NCT05347225 | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-06-09 | 2027-04-30 | 2027-04-30 |
| NCT05335005 | MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008) | COMPLETED | PHASE1 | 2022-05-30 | 2023-02-14 | 2023-02-14 |
| NCT06626464 | A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010) | COMPLETED | PHASE1 | 2022-05-13 | 2022-07-08 | 2022-07-08 |
| NCT06833879 | Activity Tracking Study in Healthy Volunteers (MK-0000-419) | COMPLETED | PHASE1 | 2022-05-12 | 2022-06-16 | 2022-06-16 |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-05-07 | 2029-02-19 | 2029-02-19 |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-05-03 | 2026-08-19 | 2026-08-19 |
| NCT05136690 | Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) | COMPLETED | PHASE1 | 2022-04-27 | 2022-11-04 | 2022-09-23 |
| NCT05354349 | Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023 | COMPLETED | PHASE1 | 2022-04-06 | 2022-08-31 | 2022-08-31 |
| NCT05239741 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | RECRUITING | PHASE3 | 2022-04-02 | 2028-09-19 | 2028-09-19 |
| NCT05270668 | Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-03-29 | 2029-07-31 | 2026-05-30 |
| NCT05119855 | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) | COMPLETED | PHASE3 | 2022-03-28 | 2023-12-12 | 2023-12-12 |
| NCT05289271 | Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) | COMPLETED | PHASE4 | 2022-03-25 | 2022-08-30 | 2022-08-30 |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-03-24 | 2027-06-07 | 2024-06-04 |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-03-24 | 2026-01-09 | 2024-09-24 |
| NCT06733688 | A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) | COMPLETED | PHASE1 | 2022-03-23 | 2022-04-15 | 2022-04-15 |
| NCT04811092 | Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) | COMPLETED | PHASE3 | 2022-03-18 | 2025-04-03 | 2025-04-03 |
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-03-15 | 2029-09-28 | 2026-10-28 |
| NCT05261126 | A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) | COMPLETED | PHASE2 | 2022-03-10 | 2022-11-28 | 2022-11-28 |
| NCT04665037 | Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) | RECRUITING | PHASE2 | 2022-02-22 | 2026-12-31 | 2026-12-16 |
| NCT05285826 | Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-02-18 | 2029-05-25 | 2029-05-25 |
| NCT05246111 | Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) | COMPLETED | PHASE1 | 2022-02-15 | 2023-06-28 | 2023-06-28 |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-02-03 | 2027-05-27 | 2027-05-27 |
| NCT05245396 | Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants | COMPLETED | PHASE1 | 2022-02-02 | 2023-02-14 | 2023-02-14 |
| NCT05203822 | Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants | COMPLETED | PHASE1 | 2022-01-21 | 2022-07-05 | 2022-07-05 |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | RECRUITING | PHASE2, PHASE3 | 2022-01-14 | 2027-09-24 | 2027-09-24 |
| NCT05248945 | DDI Study of Evobrutinib and Carbamazepine | COMPLETED | PHASE1 | 2022-01-13 | 2022-07-18 | 2022-07-18 |
| NCT05158140 | Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) | COMPLETED | PHASE3 | 2022-01-12 | 2023-02-21 | 2023-02-21 |
| NCT05174000 | BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites) | COMPLETED | PHASE1 | 2022-01-10 | 2022-10-18 | 2022-10-18 |
| NCT05144841 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-01-08 | 2026-01-09 | 2026-01-09 |
| NCT04945460 | A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-12-29 | 2026-01-30 | 2025-09-05 |
| NCT05067283 | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | RECRUITING | PHASE1 | 2021-12-17 | 2030-02-25 | 2030-02-25 |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | COMPLETED | PHASE2 | 2021-12-15 | 2024-08-22 | 2024-08-22 |
| NCT05213481 | Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants | COMPLETED | PHASE1 | 2021-12-15 | 2022-05-06 | 2022-05-06 |
| NCT05116189 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-12-13 | 2028-10-25 | 2025-03-05 |
| NCT04896008 | A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) | COMPLETED | PHASE3 | 2021-12-01 | 2025-02-18 | 2024-07-26 |
| NCT04938830 | Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) | COMPLETED | PHASE3 | 2021-11-30 | 2025-08-01 | 2025-04-28 |
| NCT05070390 | A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007) | COMPLETED | PHASE1 | 2021-11-16 | 2023-05-03 | 2023-05-03 |
| NCT05064059 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | COMPLETED | PHASE3 | 2021-11-10 | 2025-02-21 | 2024-08-15 |
| NCT05110027 | Enpatoran Human Mass Balance and Absolute Bioavailability Study | COMPLETED | PHASE1 | 2021-11-05 | 2021-12-24 | 2021-12-24 |
| NCT05093933 | A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) | COMPLETED | PHASE3 | 2021-11-02 | 2025-02-05 | 2024-11-20 |
| NCT04980872 | A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-11-02 | 2030-02-07 | 2030-02-07 |
| NCT04924114 | A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) | COMPLETED | PHASE1 | 2021-10-14 | 2024-07-15 | 2024-01-08 |
| NCT05030506 | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-10-13 | 2026-10-21 | 2026-10-21 |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | COMPLETED | PHASE2 | 2021-10-07 | 2024-05-26 | 2023-10-11 |
| NCT05064488 | Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates | COMPLETED | PHASE1 | 2021-10-04 | 2021-12-10 | 2021-12-10 |
| NCT05005442 | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | COMPLETED | PHASE2 | 2021-09-28 | 2024-12-10 | 2024-12-10 |
| NCT05038800 | A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) | TERMINATED | PHASE1 | 2021-09-26 | 2023-12-11 | 2023-12-11 |
| NCT05017012 | A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-09-21 | 2026-09-26 | 2026-09-26 |
| NCT05027074 | Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) | COMPLETED | PHASE2 | 2021-09-17 | 2025-02-13 | 2024-10-30 |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | COMPLETED | PHASE2 | 2021-09-16 | 2025-08-05 | 2025-08-05 |
| NCT04776252 | Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-09-15 | 2028-05-17 | 2028-05-17 |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | RECRUITING | PHASE1, PHASE2 | 2021-08-19 | 2029-12-10 | 2026-05-20 |
| NCT04976634 | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-08-18 | 2027-03-22 | 2027-03-22 |
| NCT04924075 | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | RECRUITING | PHASE2 | 2021-08-12 | 2029-06-04 | 2029-06-04 |
| NCT04939428 | Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) | COMPLETED | PHASE3 | 2021-08-11 | 2022-11-16 | 2022-11-16 |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-08-05 | 2026-10-14 | 2023-04-04 |
| NCT04944992 | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | COMPLETED | PHASE2 | 2021-08-04 | 2022-10-19 | 2022-10-19 |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-07-28 | 2027-01-31 | 2025-05-08 |
| NCT05013905 | A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE2 | 2021-07-28 | 2025-05-27 | 2022-09-23 |
| NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | COMPLETED | PHASE2 | 2021-07-15 | 2025-06-23 | 2025-06-23 |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | COMPLETED | PHASE2 | 2021-07-14 | 2025-07-14 | 2023-06-06 |
| NCT04895722 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-06-25 | 2026-04-30 | 2025-05-21 |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-18 | 2027-12-18 | 2027-12-18 |
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | WITHDRAWN | PHASE1, PHASE2 | 2021-06-15 | 2023-12-30 | 2022-12-30 |
| NCT04846920 | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-06-14 | 2026-07-21 | 2026-07-21 |
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-06-07 | 2025-10-13 | 2023-12-14 |
| NCT04934722 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | COMPLETED | PHASE3 | 2021-05-25 | 2025-09-10 | 2022-10-31 |
| NCT04663321 | Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) | TERMINATED | PHASE2 | 2021-05-20 | 2023-09-08 | 2023-09-08 |
| NCT04732221 | A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) | COMPLETED | PHASE2, PHASE3 | 2021-05-19 | 2024-07-02 | 2024-01-04 |
| NCT04772534 | Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) | COMPLETED | PHASE3 | 2021-05-17 | 2024-04-06 | 2024-04-06 |
| NCT04796337 | A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-05-12 | 2026-02-27 | 2026-02-27 |
| NCT04899193 | Pergoveris FD and Liquid China BE Study | COMPLETED | PHASE1 | 2021-05-08 | 2022-05-28 | 2022-05-28 |
| NCT04880213 | Study of M5049 in Healthy Japanese and Caucasian Participants | COMPLETED | PHASE1 | 2021-05-06 | 2021-11-23 | 2021-11-23 |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-05-03 | 2030-04-03 | 2030-04-03 |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-04-21 | 2026-12-23 | 2026-12-23 |
| NCT04725188 | Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) | COMPLETED | PHASE2 | 2021-04-20 | 2024-10-17 | 2023-01-26 |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-04-14 | 2026-10-29 | 2026-10-29 |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-04-07 | 2026-01-26 | 2024-09-05 |
| NCT04767373 | Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) | COMPLETED | PHASE2, PHASE3 | 2021-04-07 | 2024-07-09 | 2024-07-09 |
| NCT04728893 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | RECRUITING | PHASE2 | 2021-04-05 | 2027-03-19 | 2027-03-19 |
| NCT04776148 | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | COMPLETED | PHASE3 | 2021-03-29 | 2024-09-27 | 2024-09-27 |
| NCT04730635 | Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) | COMPLETED | PHASE1 | 2021-03-23 | 2023-02-06 | 2023-01-20 |
| NCT04676425 | A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012) | COMPLETED | PHASE1 | 2021-03-17 | 2022-01-25 | 2022-01-16 |
| NCT04740307 | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) | COMPLETED | PHASE2 | 2021-03-16 | 2025-07-29 | 2025-07-29 |
| NCT04708041 | Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-03-15 | 2029-10-23 | 2029-10-23 |
| NCT04652700 | Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) | TERMINATED | PHASE3 | 2021-03-15 | 2023-08-04 | 2023-08-04 |
| NCT04783935 | Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) | COMPLETED | PHASE4 | 2021-03-10 | 2023-09-21 | 2023-09-21 |
| NCT04564547 | Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] | COMPLETED | PHASE2 | 2021-03-09 | 2025-01-30 | 2025-01-30 |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-02-25 | 2027-02-11 | 2026-02-11 |
| NCT04644029 | Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) | TERMINATED | PHASE3 | 2021-02-24 | 2024-06-11 | 2023-07-18 |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-02-23 | 2025-10-25 | 2025-01-27 |
| NCT04776213 | Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) | COMPLETED | PHASE4 | 2021-02-23 | 2023-06-20 | 2023-06-20 |
| NCT04308304 | MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) | COMPLETED | PHASE1 | 2021-02-16 | 2022-05-18 | 2022-05-18 |
| NCT04633226 | Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) | COMPLETED | PHASE3 | 2021-02-10 | 2022-11-04 | 2022-11-04 |
| NCT04678505 | Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004) | TERMINATED | PHASE1 | 2021-02-10 | 2021-04-27 | 2021-04-15 |
| NCT04665050 | Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) | COMPLETED | PHASE1 | 2021-02-04 | 2021-04-06 | 2021-04-06 |
| NCT04375800 | Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066) | RECRUITING | PHASE2 | 2021-02-03 | 2034-04-11 | 2028-03-04 |
| NCT04576988 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) | COMPLETED | PHASE3 | 2021-01-25 | 2022-12-06 | 2022-08-26 |
| NCT04702698 | Effect of Food on Peposertib PK | COMPLETED | PHASE1 | 2021-01-14 | 2021-03-03 | 2021-03-03 |
| NCT04697511 | Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants | COMPLETED | PHASE1 | 2021-01-11 | 2021-02-25 | 2021-02-25 |
| NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-01-10 | 2026-09-15 | 2026-09-15 |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) | TERMINATED | PHASE3 | 2021-01-05 | 2021-11-05 | 2021-11-05 |
| NCT04662710 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-12-30 | 2026-03-31 | 2024-10-29 |
| NCT04165083 | KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-12-22 | 2025-10-31 | 2025-10-31 |
| NCT04684420 | GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study | COMPLETED | PHASE1 | 2020-12-22 | 2022-03-11 | 2022-03-11 |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-12-17 | 2026-05-31 | 2026-05-31 |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-12-16 | 2026-05-31 | 2026-05-31 |
| NCT04647708 | Study of M5049 in CLE and SLE Participants | COMPLETED | PHASE1 | 2020-12-16 | 2023-12-19 | 2023-12-19 |
| NCT04624243 | Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) | COMPLETED | PHASE2 | 2020-12-15 | 2024-06-21 | 2024-06-21 |
| NCT04676178 | A Study of PRA023 in Healthy Volunteers | COMPLETED | PHASE1 | 2020-12-15 | 2021-09-23 | 2021-09-23 |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | RECRUITING | PHASE1, PHASE2 | 2020-12-14 | 2027-11-03 | 2027-11-03 |
| NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-12-08 | 2027-10-28 | 2027-10-28 |
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064) | COMPLETED | PHASE3 | 2020-11-30 | 2025-07-23 | 2023-12-31 |
| NCT04295772 | Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) | COMPLETED | PHASE2 | 2020-11-26 | 2023-01-25 | 2021-12-21 |
| NCT04583423 | A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) | TERMINATED | PHASE2 | 2020-11-11 | 2023-04-13 | 2023-04-13 |
| NCT04515641 | Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) | COMPLETED | PHASE1 | 2020-11-05 | 2021-09-13 | 2021-09-13 |
| NCT05523323 | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension | COMPLETED | PHASE3 | 2020-10-30 | 2025-03-28 | 2023-08-25 |
| NCT04569786 | Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) | TERMINATED | PHASE1 | 2020-10-29 | 2021-02-18 | 2021-02-18 |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | TERMINATED | PHASE1, PHASE2 | 2020-10-28 | 2023-07-25 | 2023-07-25 |
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | COMPLETED | PHASE4 | 2020-10-27 | 2024-06-28 | 2023-02-20 |
| NCT04571944 | Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085) | COMPLETED | PHASE3 | 2020-10-22 | 2022-12-23 | 2022-12-23 |
| NCT04575597 | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) | COMPLETED | PHASE2, PHASE3 | 2020-10-19 | 2022-05-05 | 2022-05-05 |
| NCT04575584 | Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) | TERMINATED | PHASE2, PHASE3 | 2020-10-19 | 2021-08-11 | 2021-08-11 |
| NCT04568603 | Islatravir and Methadone Pharmacokinetics (MK-8591-029) | COMPLETED | PHASE1 | 2020-10-16 | 2021-07-09 | 2021-07-09 |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | TERMINATED | PHASE2 | 2020-10-07 | 2023-06-12 | 2023-06-12 |
| NCT04546789 | Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK | COMPLETED | PHASE1 | 2020-09-30 | 2021-05-16 | 2021-05-16 |
| NCT04907227 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension | TERMINATED | PHASE3 | 2020-09-23 | 2023-07-18 | 2022-08-03 |
| NCT04489771 | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-09-13 | 2026-10-04 | 2023-02-10 |
| NCT04193215 | V114 and Acute Otitis Media (V114-032/PNEU-ERA) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-12 | 2026-01-19 | 2026-01-19 |
| NCT04254978 | Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) | COMPLETED | PHASE2 | 2020-09-08 | 2023-03-23 | 2023-03-23 |
| NCT04490499 | A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) | COMPLETED | PHASE3 | 2020-09-02 | 2020-12-29 | 2020-12-29 |
| NCT03960541 | Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) | TERMINATED | PHASE2 | 2020-08-31 | 2021-05-27 | 2021-05-27 |
| NCT04506905 | Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011) | COMPLETED | PHASE1 | 2020-08-28 | 2022-03-22 | 2022-03-22 |
| NCT04054544 | Gluten Challenge Study in Celiac Disease Participants (MK-0000-402) | COMPLETED | EARLY_PHASE1 | 2020-08-28 | 2021-06-23 | 2021-06-23 |
| NCT04498247 | A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) | TERMINATED | PHASE1, PHASE2 | 2020-08-27 | 2021-03-05 | 2021-03-05 |
| NCT04481191 | Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074) | COMPLETED | PHASE3 | 2020-08-25 | 2021-05-08 | 2021-05-08 |
| NCT04456699 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | COMPLETED | PHASE3 | 2020-08-19 | 2023-11-06 | 2023-03-27 |
| NCT04428151 | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-08-06 | 2025-12-22 | 2024-05-31 |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) | COMPLETED | PHASE2 | 2020-07-30 | 2025-02-13 | 2022-09-16 |
| NCT04882241 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | COMPLETED | PHASE3 | 2020-07-29 | 2025-04-23 | 2024-02-16 |
| NCT04889118 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | COMPLETED | PHASE3 | 2020-07-14 | 2024-11-01 | 2023-01-18 |
| NCT04924062 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | COMPLETED | PHASE3 | 2020-07-10 | 2025-03-25 | 2022-12-15 |
| NCT04425733 | Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) | WITHDRAWN | PHASE1 | 2020-07-07 | 2020-11-10 | 2020-11-10 |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-07-06 | 2027-02-15 | 2026-07-06 |
| NCT04338061 | Study of Evobrutinib in Participants With RMS (evolutionRMS 2) | TERMINATED | PHASE3 | 2020-07-02 | 2024-03-19 | 2023-10-02 |
| NCT04218851 | Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) | COMPLETED | PHASE2 | 2020-07-02 | 2023-12-18 | 2023-12-18 |
| NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-07-01 | 2026-04-20 | 2026-04-20 |
| NCT04384107 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) | COMPLETED | PHASE3 | 2020-07-01 | 2021-12-01 | 2021-12-01 |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-06-26 | 2025-10-06 | 2025-10-06 |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | COMPLETED | PHASE1, PHASE2 | 2020-06-26 | 2025-08-25 | 2025-08-25 |
| NCT04317066 | A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) | COMPLETED | PHASE1 | 2020-06-26 | 2024-04-11 | 2024-04-11 |
| NCT04303156 | Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) | COMPLETED | PHASE1 | 2020-06-18 | 2020-10-19 | 2020-10-19 |
| NCT04314037 | Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide | COMPLETED | PHASE1 | 2020-06-17 | 2020-07-30 | 2020-07-30 |
| NCT04338022 | Study of Evobrutinib in Participants With RMS (evolutionRMS 1) | TERMINATED | PHASE3 | 2020-06-12 | 2024-03-08 | 2023-10-02 |
| NCT04370873 | Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006) | COMPLETED | PHASE1 | 2020-06-05 | 2022-01-12 | 2022-01-12 |
| NCT04152863 | Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | TERMINATED | PHASE2 | 2020-06-05 | 2023-07-12 | 2023-07-12 |
| NCT04314024 | Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets | COMPLETED | PHASE1 | 2020-05-25 | 2020-06-23 | 2020-06-23 |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-05-22 | 2029-12-31 | 2028-06-30 |
| NCT04193202 | Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) | COMPLETED | PHASE3 | 2020-05-21 | 2021-11-03 | 2021-10-19 |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-05-19 | 2031-11-01 | 2027-01-31 |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-05-12 | 2026-01-17 | 2025-01-07 |
| NCT04193176 | Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) | COMPLETED | PHASE3 | 2020-05-10 | 2022-09-02 | 2022-08-18 |
| NCT04317040 | Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) | COMPLETED | PHASE3 | 2020-04-24 | 2020-10-20 | 2020-10-20 |
| NCT04223752 | Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) | COMPLETED | PHASE1 | 2020-04-17 | 2024-09-14 | 2024-09-14 |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-04-13 | 2026-06-30 | 2026-06-30 |
| NCT04233216 | Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) | COMPLETED | PHASE3 | 2020-03-18 | 2023-11-01 | 2022-11-21 |
| NCT04220866 | Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) | COMPLETED | PHASE2 | 2020-03-04 | 2022-09-30 | 2022-09-30 |
| NCT04233879 | Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) | COMPLETED | PHASE3 | 2020-02-28 | 2025-01-29 | 2022-11-17 |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-02-28 | 2027-02-01 | 2027-02-01 |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-02-27 | 2026-09-17 | 2024-04-15 |
| NCT04199689 | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-02-27 | 2028-08-31 | 2027-08-27 |
| NCT04223778 | Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) | COMPLETED | PHASE3 | 2020-02-18 | 2024-08-26 | 2021-09-08 |
| NCT04223791 | Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) | COMPLETED | PHASE3 | 2020-02-18 | 2025-02-27 | 2021-08-26 |
| NCT04250363 | Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model | COMPLETED | PHASE1 | 2020-02-17 | 2021-08-18 | 2021-08-18 |
| NCT04191096 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-02-12 | 2026-02-02 | 2022-10-31 |
| NCT04199104 | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) | COMPLETED | PHASE3 | 2020-02-05 | 2025-03-31 | 2023-05-30 |
| NCT04165096 | KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C) | COMPLETED | PHASE2 | 2020-01-21 | 2025-05-28 | 2025-04-30 |
| NCT04129398 | MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) | COMPLETED | PHASE3 | 2019-12-27 | 2022-10-06 | 2022-10-06 |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | RECRUITING | PHASE1, PHASE2 | 2019-12-19 | 2032-02-13 | 2032-02-13 |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-12-19 | 2025-11-18 | 2022-12-15 |
| NCT04153565 | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | COMPLETED | PHASE1 | 2019-12-09 | 2022-09-21 | 2022-09-21 |
| NCT04168190 | A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) | COMPLETED | PHASE1, PHASE2 | 2019-12-06 | 2021-07-12 | 2021-07-12 |
| NCT03979274 | A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers | COMPLETED | PHASE1 | 2019-12-06 | 2020-01-25 | 2020-01-13 |
| NCT04123366 | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | ACTIVE_NOT_RECRUITING | PHASE2 | 2019-11-18 | 2026-07-23 | 2026-07-23 |
| NCT04716933 | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study | COMPLETED | PHASE3 | 2019-11-05 | 2024-08-30 | 2023-08-11 |
| NCT03921424 | Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) | COMPLETED | PHASE3 | 2019-11-05 | 2021-05-03 | 2021-05-03 |
| NCT04135352 | A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | TERMINATED | PHASE1 | 2019-11-04 | 2022-08-24 | 2022-08-24 |
| NCT04086472 | Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) | COMPLETED | PHASE2 | 2019-10-28 | 2020-08-14 | 2020-03-22 |
| NCT04676412 | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study | COMPLETED | PHASE3 | 2019-10-23 | 2024-03-29 | 2021-05-19 |
| NCT04865289 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | COMPLETED | PHASE3 | 2019-10-22 | 2025-01-14 | 2023-10-02 |
| NCT04204902 | Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib | COMPLETED | PHASE1 | 2019-10-17 | 2019-12-16 | 2019-12-16 |
| NCT03969901 | Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021) | COMPLETED | PHASE2, PHASE3 | 2019-10-08 | 2024-05-07 | 2024-05-07 |
| NCT04029480 | Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) | COMPLETED | PHASE3 | 2019-10-08 | 2025-04-11 | 2025-04-11 |
| NCT03740178 | Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) | WITHDRAWN | PHASE1 | 2019-09-27 | 2020-02-28 | 2020-02-28 |
| NCT04003636 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | COMPLETED | PHASE3 | 2019-09-24 | 2025-04-01 | 2022-12-15 |
| NCT04132583 | Deflox Tablets Bioequivalence (BE) Trial | COMPLETED | PHASE1 | 2019-09-21 | 2019-10-27 | 2019-10-27 |
| NCT04003103 | Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) | COMPLETED | PHASE2 | 2019-09-19 | 2022-11-24 | 2022-03-18 |
| NCT04054193 | Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) | COMPLETED | PHASE4 | 2019-09-09 | 2021-02-11 | 2021-02-11 |
| NCT04031846 | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) | COMPLETED | PHASE3 | 2019-09-04 | 2021-08-05 | 2021-08-05 |
| NCT03845140 | L-PZQ ODT in Schistosoma Infected Children | COMPLETED | PHASE3 | 2019-09-02 | 2021-10-11 | 2021-10-11 |
| NCT04016714 | Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) | COMPLETED | PHASE3 | 2019-08-28 | 2021-10-29 | 2021-10-29 |
| NCT03940586 | Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) | COMPLETED | PHASE2 | 2019-08-08 | 2023-08-25 | 2023-01-04 |
| NCT03834493 | Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-07-28 | 2026-05-29 | 2022-12-12 |
| NCT03924895 | Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-07-24 | 2027-12-15 | 2025-06-06 |
| NCT03909165 | Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169) | COMPLETED | PHASE4 | 2019-07-23 | 2023-09-21 | 2023-09-21 |
| NCT03976323 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-28 | 2025-12-31 | 2024-02-07 |
| NCT03976362 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-28 | 2025-12-31 | 2023-09-21 |
| NCT03976375 | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | COMPLETED | PHASE3 | 2019-06-26 | 2024-08-22 | 2023-08-11 |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | TERMINATED | PHASE1 | 2019-06-26 | 2022-08-25 | 2022-08-25 |
| NCT03998254 | Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-26 | 2028-03-31 | 2028-03-31 |
| NCT03924869 | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | TERMINATED | PHASE3 | 2019-06-25 | 2025-01-20 | 2024-06-11 |
| NCT03885934 | Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) | COMPLETED | PHASE3 | 2019-06-25 | 2020-12-09 | 2020-12-09 |
| NCT04037748 | Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form | COMPLETED | PHASE1 | 2019-06-25 | 2019-09-11 | 2019-09-11 |
| NCT03930615 | Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) | COMPLETED | PHASE3 | 2019-06-21 | 2022-03-16 | 2021-10-27 |
| NCT03918278 | A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | COMPLETED | PHASE1 | 2019-06-19 | 2025-06-09 | 2025-06-09 |
| NCT03893448 | Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) | COMPLETED | PHASE3 | 2019-06-19 | 2021-05-24 | 2021-05-24 |
| NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-06-13 | 2026-09-01 | 2026-01-26 |
| NCT03950622 | Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) | COMPLETED | PHASE3 | 2019-06-13 | 2020-03-30 | 2020-03-30 |
| NCT03950856 | Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) | COMPLETED | PHASE3 | 2019-06-12 | 2020-04-03 | 2020-04-03 |
| NCT03858049 | Efficacy and Safety of Crinone Versus Combination Medication (ACCESS) | TERMINATED | PHASE4 | 2019-05-31 | 2021-10-27 | 2021-10-27 |
| NCT03867084 | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-05-28 | 2025-09-30 | 2025-03-20 |
| NCT04525885 | A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension | COMPLETED | PHASE3 | 2019-05-17 | 2022-09-15 | 2022-09-15 |
| NCT03943290 | Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) | TERMINATED | PHASE2 | 2019-05-10 | 2020-03-11 | 2020-03-11 |
| NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | COMPLETED | PHASE3 | 2019-05-06 | 2024-05-20 | 2021-07-26 |
| NCT03834506 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | COMPLETED | PHASE3 | 2019-05-02 | 2023-07-18 | 2022-06-20 |
| NCT03834519 | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | COMPLETED | PHASE3 | 2019-05-02 | 2024-01-27 | 2022-03-14 |
| NCT03873038 | Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004) | COMPLETED | PHASE1 | 2019-04-29 | 2021-12-20 | 2021-12-20 |
| NCT03903562 | Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | COMPLETED | PHASE3 | 2019-04-27 | 2025-02-28 | 2025-02-28 |
| NCT03859739 | Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) | COMPLETED | PHASE1 | 2019-04-26 | 2020-05-29 | 2020-05-29 |
| NCT03738150 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension | COMPLETED | PHASE2 | 2019-04-19 | 2022-03-22 | 2021-12-21 |
| NCT03872206 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | COMPLETED | PHASE1 | 2019-04-16 | 2023-01-04 | 2023-01-04 |
| NCT03934502 | Effect of Meal Composition and Timing on Evobrutinib Bioavailability | COMPLETED | PHASE1 | 2019-04-15 | 2019-06-12 | 2019-06-12 |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | COMPLETED | PHASE3 | 2019-04-11 | 2025-02-05 | 2023-10-02 |
| NCT03882801 | Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) | COMPLETED | PHASE1 | 2019-04-10 | 2019-10-22 | 2019-10-22 |
| NCT03848065 | Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) | COMPLETED | PHASE1 | 2019-04-02 | 2020-06-24 | 2020-06-24 |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-04-01 | 2025-12-22 | 2024-06-28 |
| NCT03829319 | Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) | COMPLETED | PHASE3 | 2019-03-25 | 2024-08-30 | 2023-08-11 |
| NCT03830333 | Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) | COMPLETED | PHASE3 | 2019-03-20 | 2020-10-14 | 2020-10-14 |
| NCT03833427 | Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) | TERMINATED | PHASE1 | 2019-03-18 | 2022-06-28 | 2022-06-28 |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | COMPLETED | PHASE1 | 2019-03-14 | 2023-12-18 | 2023-12-18 |
| NCT03829332 | Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) | COMPLETED | PHASE3 | 2019-03-13 | 2024-04-24 | 2021-05-19 |
| NCT03820986 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | COMPLETED | PHASE3 | 2019-03-12 | 2024-11-01 | 2023-01-18 |
| NCT03840174 | Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) | COMPLETED | PHASE1 | 2019-03-08 | 2019-11-07 | 2019-11-07 |
| NCT03843632 | Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) | COMPLETED | PHASE3 | 2019-03-01 | 2020-06-19 | 2020-06-19 |
| NCT03783078 | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | COMPLETED | PHASE3 | 2019-02-25 | 2024-02-15 | 2022-02-15 |
| NCT03745989 | Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | COMPLETED | PHASE1 | 2019-02-22 | 2021-03-19 | 2021-03-19 |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | COMPLETED | PHASE2 | 2019-02-12 | 2024-10-28 | 2024-10-28 |
| NCT03615183 | A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) | COMPLETED | PHASE1 | 2019-02-11 | 2019-09-26 | 2019-09-26 |
| NCT03217565 | A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014) | COMPLETED | PHASE1 | 2019-02-06 | 2023-04-06 | 2023-03-18 |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | COMPLETED | PHASE4 | 2019-01-31 | 2024-08-21 | 2024-08-21 |
| NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | COMPLETED | PHASE2 | 2019-01-30 | 2023-10-11 | 2023-10-11 |
| NCT03731182 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) | COMPLETED | PHASE3 | 2019-01-23 | 2020-06-08 | 2020-06-08 |
| NCT03881111 | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study | WITHDRAWN | PHASE3 | 2019-01-21 | 2022-05-11 | 2021-05-11 |
| NCT03176134 | A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) | COMPLETED | PHASE3 | 2019-01-20 | 2023-07-06 | 2023-07-06 |
| NCT03744637 | A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002) | COMPLETED | PHASE1 | 2019-01-18 | 2020-12-11 | 2020-12-11 |
| NCT03745144 | Effects of Cladribine Tablets on the PK of Microgynon® | COMPLETED | PHASE1 | 2019-01-17 | 2022-09-16 | 2022-09-02 |
| NCT03713593 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | COMPLETED | PHASE3 | 2018-12-31 | 2024-09-24 | 2022-06-21 |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-12-27 | 2031-01-24 | 2031-01-24 |
| NCT03711032 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-12-24 | 2034-11-20 | 2025-12-31 |
| NCT03740165 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-12-18 | 2026-05-29 | 2024-08-26 |
| NCT03739138 | Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | TERMINATED | PHASE1 | 2018-12-18 | 2021-03-02 | 2021-03-02 |
| NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-12-17 | 2026-09-10 | 2024-07-25 |
| NCT03692871 | A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) | COMPLETED | PHASE3 | 2018-12-14 | 2021-03-26 | 2021-03-26 |
| NCT03742895 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-12-12 | 2026-06-30 | 2026-06-30 |
| NCT03643952 | Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) | COMPLETED | PHASE2 | 2018-12-06 | 2020-04-07 | 2020-04-07 |
| NCT03665597 | Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | COMPLETED | PHASE1 | 2018-11-19 | 2023-12-04 | 2023-12-04 |
| NCT03675737 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | COMPLETED | PHASE3 | 2018-11-08 | 2025-03-03 | 2022-10-03 |
| NCT04859582 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | WITHDRAWN | PHASE3 | 2018-11-08 | 2024-11-29 | 2024-11-29 |
| NCT03696108 | A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) | COMPLETED | PHASE3 | 2018-10-31 | 2020-10-07 | 2020-10-07 |
| NCT03664024 | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) | COMPLETED | PHASE2 | 2018-10-30 | 2021-11-05 | 2021-11-05 |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | COMPLETED | PHASE2 | 2018-10-30 | 2021-05-27 | 2020-09-30 |
| NCT03725072 | Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib | COMPLETED | PHASE1 | 2018-10-30 | 2018-12-05 | 2018-12-05 |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | COMPLETED | PHASE3 | 2018-10-25 | 2024-06-04 | 2022-10-03 |
| NCT03631784 | A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) | COMPLETED | PHASE2 | 2018-10-19 | 2024-03-19 | 2021-10-18 |
| NCT03620162 | A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) | COMPLETED | PHASE3 | 2018-10-18 | 2020-12-14 | 2020-12-14 |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2018-10-17 | 2026-01-16 | 2026-01-16 |
| NCT03566810 | Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt) | COMPLETED | PHASE1 | 2018-10-11 | 2018-11-28 | 2018-11-28 |
| NCT03552536 | MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) | COMPLETED | PHASE1 | 2018-10-07 | 2019-03-11 | 2019-03-11 |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-10-05 | 2025-11-12 | 2024-03-20 |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | COMPLETED | PHASE2 | 2018-10-01 | 2025-06-13 | 2025-06-13 |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-09-27 | 2027-02-26 | 2027-02-26 |
| NCT03667547 | Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) | COMPLETED | PHASE4 | 2018-09-27 | 2018-10-23 | 2018-10-23 |
| NCT03631407 | Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | COMPLETED | PHASE2 | 2018-09-24 | 2021-06-08 | 2021-06-08 |
| NCT03524118 | Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) | COMPLETED | PHASE1, PHASE2 | 2018-09-20 | 2022-09-14 | 2022-09-14 |
| NCT03676322 | Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants | COMPLETED | PHASE1 | 2018-09-20 | 2019-07-26 | 2019-07-26 |
| NCT03583333 | Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) | COMPLETED | PHASE3 | 2018-09-18 | 2022-07-12 | 2022-07-12 |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | TERMINATED | PHASE3 | 2018-09-18 | 2018-11-20 | 2018-11-20 |
| NCT03615482 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) | COMPLETED | PHASE3 | 2018-09-14 | 2019-06-24 | 2019-06-24 |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-09-12 | 2033-10-12 | 2021-06-21 |
| NCT03565900 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) | COMPLETED | PHASE3 | 2018-09-12 | 2021-11-04 | 2021-11-04 |
| NCT03654326 | A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) | COMPLETED | PHASE2 | 2018-09-11 | 2020-06-30 | 2020-06-30 |
| NCT03493542 | A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) | COMPLETED | PHASE3 | 2018-08-31 | 2023-10-30 | 2023-10-30 |
| NCT03629223 | Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib | COMPLETED | PHASE1 | 2018-08-23 | 2019-01-25 | 2019-01-25 |
| NCT03583346 | Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA) | COMPLETED | PHASE1 | 2018-08-23 | 2019-07-31 | 2019-07-31 |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | RECRUITING | PHASE3 | 2018-08-21 | 2043-08-04 | 2043-08-04 |
| NCT03628339 | Effect of Tepotinib on PK of CYP3A Substrate Midazolam | COMPLETED | PHASE1 | 2018-08-20 | 2018-10-30 | 2018-10-25 |
| NCT03583385 | Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study | COMPLETED | PHASE1 | 2018-08-16 | 2018-10-05 | 2018-10-05 |
| NCT03515824 | Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) | TERMINATED | PHASE1 | 2018-08-13 | 2020-02-18 | 2020-02-18 |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | TERMINATED | PHASE1, PHASE2 | 2018-07-24 | 2023-02-27 | 2023-02-27 |
| NCT03547167 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) | COMPLETED | PHASE3 | 2018-07-16 | 2020-01-20 | 2020-01-20 |
| NCT03564691 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | COMPLETED | PHASE1 | 2018-07-11 | 2025-09-26 | 2025-09-26 |
| NCT03480802 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) | COMPLETED | PHASE3 | 2018-07-06 | 2020-01-17 | 2019-09-16 |
| NCT03569033 | Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013) | TERMINATED | PHASE2 | 2018-07-04 | 2018-11-19 | 2018-10-31 |
| NCT03515837 | Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | COMPLETED | PHASE3 | 2018-06-29 | 2023-10-02 | 2023-01-17 |
| NCT03546842 | Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | COMPLETED | PHASE3 | 2018-06-29 | 2019-01-29 | 2019-01-29 |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | TERMINATED | PHASE2 | 2018-06-28 | 2019-08-14 | 2019-08-14 |
| NCT03480763 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) | COMPLETED | PHASE3 | 2018-06-22 | 2019-12-23 | 2019-12-23 |
| NCT03369665 | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) | COMPLETED | PHASE4 | 2018-06-20 | 2021-11-12 | 2021-11-12 |
| NCT03565068 | A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) | COMPLETED | PHASE1 | 2018-06-20 | 2020-04-03 | 2020-04-03 |
| NCT03437447 | Praziquantel Bioequivalence Study | COMPLETED | PHASE1 | 2018-06-18 | 2018-07-06 | 2018-07-06 |
| NCT03496207 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE2 | 2018-06-13 | 2022-03-09 | 2022-03-09 |
| NCT03364036 | Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) | COMPLETED | PHASE4 | 2018-05-28 | 2022-02-21 | 2020-05-05 |
| NCT03492437 | Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | COMPLETED | PHASE1 | 2018-05-17 | 2018-08-27 | 2018-08-27 |
| NCT03531762 | Effect of a Proton Pump Inhibitor on the PK of Tepotinib | COMPLETED | PHASE1 | 2018-05-14 | 2018-07-02 | 2018-07-02 |
| NCT03443869 | Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) | COMPLETED | PHASE3 | 2018-05-03 | 2022-04-05 | 2022-04-05 |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-05-02 | 2026-03-29 | 2026-03-29 |
| NCT03486834 | V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002) | COMPLETED | PHASE2 | 2018-04-30 | 2021-06-30 | 2020-10-30 |
| NCT03230838 | MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) | COMPLETED | PHASE2 | 2018-04-26 | 2020-12-03 | 2020-12-03 |
| NCT03425643 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-04-24 | 2026-06-29 | 2023-07-10 |
| NCT03523390 | Phase I/Ib Multiple Ascending Dose Study in China | COMPLETED | PHASE1 | 2018-04-24 | 2021-02-08 | 2019-07-29 |
| NCT03164551 | TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment | TERMINATED | PHASE4 | 2018-04-16 | 2019-11-20 | 2019-11-20 |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | COMPLETED | PHASE2 | 2018-04-10 | 2021-05-19 | 2021-05-19 |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-04-09 | 2027-02-13 | 2027-02-13 |
| NCT03217136 | MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) | COMPLETED | PHASE2 | 2018-04-03 | 2020-03-16 | 2020-03-16 |
| NCT03182907 | Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) | COMPLETED | PHASE3 | 2018-03-27 | 2022-05-12 | 2022-05-12 |
| NCT03382600 | Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) | COMPLETED | PHASE2 | 2018-03-26 | 2021-05-30 | 2021-05-30 |
| NCT03387046 | A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) | TERMINATED | PHASE2 | 2018-03-26 | 2019-01-11 | 2019-01-11 |
| NCT03436394 | Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK) | COMPLETED | PHASE1 | 2018-03-21 | 2019-02-22 | 2019-02-22 |
| NCT03482713 | Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) | COMPLETED | PHASE2 | 2018-03-16 | 2018-06-07 | 2018-06-07 |
| NCT03449147 | A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030) | COMPLETED | PHASE3 | 2018-03-15 | 2020-10-30 | 2020-08-20 |
| NCT03449134 | A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027) | COMPLETED | PHASE3 | 2018-03-14 | 2020-08-17 | 2020-06-05 |
| NCT03467971 | A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants | COMPLETED | PHASE1 | 2018-03-06 | 2018-04-22 | 2018-04-22 |
| NCT03311841 | Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386) | COMPLETED | PHASE1 | 2018-03-01 | 2018-08-02 | 2018-08-02 |
| NCT03445169 | A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets | COMPLETED | PHASE1 | 2018-02-23 | 2018-05-26 | 2018-05-26 |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | COMPLETED | PHASE1 | 2018-02-18 | 2024-09-27 | 2024-09-27 |
| NCT03374254 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | COMPLETED | PHASE1 | 2018-02-16 | 2023-07-18 | 2021-09-08 |
| NCT03467945 | Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants | COMPLETED | PHASE1 | 2018-02-16 | 2018-04-29 | 2018-04-29 |
| NCT03478319 | A Study of ACE-2494 in Healthy Subjects | COMPLETED | PHASE1 | 2018-02-15 | 2019-06-17 | 2019-06-13 |
| NCT03351608 | Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) | COMPLETED | PHASE4 | 2018-02-12 | 2020-01-28 | 2020-01-28 |
| NCT03143998 | Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) | WITHDRAWN | PHASE4 | 2018-02-12 | 2019-01-12 | 2019-01-12 |
| NCT03379506 | Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) | COMPLETED | PHASE2 | 2018-01-25 | 2020-07-23 | 2019-10-28 |
| NCT03351699 | Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) | COMPLETED | PHASE1 | 2018-01-18 | 2018-11-02 | 2018-11-02 |
| NCT03387059 | Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle | TERMINATED | PHASE4 | 2018-01-12 | 2018-06-12 | 2018-06-12 |
| NCT03309150 | ATRi Transition Rollover Study | COMPLETED | PHASE1 | 2018-01-10 | 2024-01-26 | 2024-01-26 |
| NCT03393208 | Glucophage Immediate Release (GIR) China Bioequivalence Study | COMPLETED | PHASE1 | 2018-01-10 | 2018-01-29 | 2018-01-29 |
| NCT03346070 | Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146) | COMPLETED | PHASE4 | 2018-01-01 | 2019-01-29 | 2019-01-29 |
| NCT03346057 | Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) | COMPLETED | PHASE4 | 2017-12-20 | 2019-09-04 | 2019-09-04 |
| NCT03336502 | Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) | COMPLETED | PHASE1 | 2017-12-20 | 2018-11-26 | 2018-11-26 |
| NCT03295266 | Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006) | TERMINATED | PHASE1 | 2017-12-19 | 2018-03-15 | 2018-03-15 |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | COMPLETED | PHASE3 | 2017-12-14 | 2022-09-07 | 2020-09-01 |
| NCT03364049 | Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | COMPLETED | PHASE1 | 2017-12-06 | 2020-10-19 | 2020-10-19 |
| NCT03272347 | Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) | COMPLETED | PHASE2 | 2017-11-27 | 2022-03-09 | 2021-03-08 |
| NCT03326986 | Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) | COMPLETED | PHASE1 | 2017-11-10 | 2018-12-17 | 2018-12-17 |
| NCT03253796 | Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) | COMPLETED | PHASE4 | 2017-11-07 | 2021-03-17 | 2021-03-17 |
| NCT03230916 | A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020) | COMPLETED | PHASE1 | 2017-11-06 | 2020-08-11 | 2020-07-28 |
| NCT03284424 | Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) | COMPLETED | PHASE2 | 2017-10-26 | 2023-09-13 | 2020-07-29 |
| NCT03239873 | Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) | COMPLETED | PHASE3 | 2017-10-17 | 2019-04-02 | 2018-08-14 |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | COMPLETED | PHASE3 | 2017-10-09 | 2025-04-23 | 2024-02-16 |
| NCT03297983 | M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule | COMPLETED | PHASE1 | 2017-10-09 | 2017-12-06 | 2017-12-06 |
| NCT03293485 | Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) | COMPLETED | PHASE3 | 2017-10-04 | 2018-09-14 | 2018-09-14 |
| NCT03249792 | Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | TERMINATED | PHASE1 | 2017-09-20 | 2023-02-22 | 2023-02-22 |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | COMPLETED | PHASE3 | 2017-09-20 | 2018-11-19 | 2018-11-19 |
| NCT03261401 | First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants | COMPLETED | PHASE1 | 2017-09-15 | 2019-06-14 | 2019-06-14 |
| NCT03188523 | Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) | COMPLETED | PHASE1 | 2017-09-08 | 2018-06-04 | 2018-05-21 |
| NCT03224702 | First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers | COMPLETED | PHASE1 | 2017-09-04 | 2018-08-06 | 2018-08-06 |
| NCT03259087 | Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) | COMPLETED | PHASE1 | 2017-09-01 | 2018-02-09 | 2018-01-28 |
| NCT03170544 | Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) | COMPLETED | PHASE1 | 2017-08-16 | 2018-11-08 | 2018-11-08 |
| NCT03226275 | Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants | COMPLETED | PHASE1 | 2017-08-09 | 2017-09-09 | 2017-09-09 |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | WITHDRAWN | PHASE2 | 2017-08-01 | 2021-06-10 | 2019-03-20 |
| NCT03124459 | Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease | TERMINATED | PHASE2 | 2017-07-31 | 2020-03-11 | 2020-03-11 |
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | COMPLETED | PHASE3 | 2017-07-25 | 2023-07-10 | 2020-07-02 |
| NCT03136185 | Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | COMPLETED | PHASE1, PHASE2 | 2017-07-18 | 2022-03-08 | 2022-03-08 |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | COMPLETED | PHASE1, PHASE2 | 2017-07-02 | 2024-04-08 | 2024-04-08 |
| NCT03099161 | Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | TERMINATED | PHASE1 | 2017-06-27 | 2018-02-21 | 2017-11-24 |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2017-06-26 | 2026-09-18 | 2026-09-18 |
| NCT03111108 | Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) | COMPLETED | PHASE4 | 2017-06-20 | 2018-10-15 | 2018-10-15 |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-06-09 | 2025-12-28 | 2020-12-14 |
| NCT03094832 | Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) | TERMINATED | PHASE1, PHASE2 | 2017-05-16 | 2022-04-11 | 2022-04-11 |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | COMPLETED | PHASE3 | 2017-05-02 | 2021-09-21 | 2019-12-02 |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | COMPLETED | PHASE3 | 2017-04-27 | 2024-10-15 | 2021-06-30 |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | TERMINATED | PHASE1, PHASE2 | 2017-04-25 | 2018-05-18 | 2018-05-18 |
| NCT03108066 | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | COMPLETED | PHASE2 | 2017-04-24 | 2023-09-27 | 2023-08-30 |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | COMPLETED | PHASE3 | 2017-04-21 | 2023-09-14 | 2020-09-30 |
| NCT03108924 | The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) | COMPLETED | PHASE1 | 2017-04-14 | 2017-09-13 | 2017-09-03 |
| NCT03095651 | Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) | COMPLETED | PHASE1 | 2017-04-12 | 2018-01-30 | 2018-01-30 |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | COMPLETED | PHASE3 | 2017-04-05 | 2024-08-21 | 2022-05-31 |
| NCT03026088 | Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants | TERMINATED | PHASE4 | 2017-03-21 | 2018-12-26 | 2018-12-26 |
| NCT02987972 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) | COMPLETED | PHASE2 | 2017-03-21 | 2018-10-04 | 2018-10-04 |
| NCT03055338 | An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) | COMPLETED | PHASE2 | 2017-03-08 | 2018-01-09 | 2018-01-09 |
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-03-07 | 2025-10-14 | 2025-10-14 |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | TERMINATED | PHASE3 | 2017-02-16 | 2021-06-29 | 2021-06-29 |
| NCT03010176 | Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | COMPLETED | PHASE1 | 2017-02-03 | 2022-04-21 | 2022-04-21 |
| NCT02972034 | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | TERMINATED | PHASE1 | 2017-01-13 | 2022-12-02 | 2022-12-02 |
| NCT03933449 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | COMPLETED | PHASE3 | 2016-12-29 | 2022-03-14 | 2019-02-13 |
| NCT02964013 | Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) | COMPLETED | PHASE1 | 2016-12-13 | 2024-07-24 | 2024-07-24 |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2016-12-07 | 2027-04-14 | 2018-01-12 |
| NCT03010423 | Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants | TERMINATED | PHASE4 | 2016-11-30 | 2019-07-09 | 2019-07-09 |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | RECRUITING | PHASE1, PHASE2 | 2016-11-17 | 2027-10-22 | 2027-10-22 |
| NCT02956629 | Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) | TERMINATED | PHASE2 | 2016-11-16 | 2018-03-05 | 2017-12-22 |
| NCT02927080 | Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | PHASE2 | 2016-11 | 2019-10-09 | 2019-09-17 |
| NCT02906709 | Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) | COMPLETED | PHASE4 | 2016-10-17 | 2018-08-21 | 2018-08-21 |
| NCT02910739 | An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) | COMPLETED | PHASE1 | 2016-10-11 | 2017-04-12 | 2017-04-03 |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | COMPLETED | PHASE1, PHASE2 | 2016-10-06 | 2018-10-30 | 2018-10-30 |
| NCT02853344 | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | COMPLETED | PHASE2 | 2016-09-30 | 2022-04-01 | 2021-02-05 |
| NCT02861534 | A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) | COMPLETED | PHASE3 | 2016-09-20 | 2019-09-02 | 2019-06-18 |
| NCT02663622 | Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | COMPLETED | PHASE2 | 2016-09-19 | 2021-05-18 | 2020-06-08 |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-09-16 | 2025-12-31 | 2018-10-18 |
| NCT02853305 | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) | COMPLETED | PHASE3 | 2016-09-15 | 2022-09-15 | 2020-04-29 |
| NCT02864394 | Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | COMPLETED | PHASE3 | 2016-09-07 | 2022-10-14 | 2019-09-09 |
| NCT02862457 | Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | COMPLETED | PHASE1 | 2016-08-23 | 2020-11-20 | 2020-11-20 |
| NCT02835690 | Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | COMPLETED | PHASE1 | 2016-08-04 | 2021-12-31 | 2017-09-19 |
| NCT03850444 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study | COMPLETED | PHASE3 | 2016-08-01 | 2022-09-08 | 2018-09-04 |
| NCT02819518 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | COMPLETED | PHASE3 | 2016-07-27 | 2023-10-30 | 2021-06-15 |
| NCT02821000 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | COMPLETED | PHASE1 | 2016-07-08 | 2022-11-30 | 2017-12-27 |
| NCT02787005 | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | COMPLETED | PHASE2 | 2016-07-01 | 2022-02-28 | 2022-02-28 |
| NCT02761694 | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | TERMINATED | PHASE1 | 2016-06-26 | 2021-03-10 | 2021-03-10 |
| NCT02731742 | Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001) | TERMINATED | PHASE1 | 2016-06-22 | 2018-01-08 | 2018-01-08 |
| NCT02791490 | A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) | COMPLETED | PHASE3 | 2016-06-16 | 2018-02-01 | 2018-02-01 |
| NCT02806232 | An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) | COMPLETED | PHASE2 | 2016-06-12 | 2018-11-17 | 2018-10-30 |
| NCT02775435 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | COMPLETED | PHASE3 | 2016-06-09 | 2023-09-14 | 2018-04-03 |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | COMPLETED | PHASE2 | 2016-05-31 | 2023-09-29 | 2021-01-19 |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | COMPLETED | PHASE3 | 2016-05-26 | 2021-09-22 | 2019-01-02 |
| NCT02684292 | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-05-23 | 2026-01-12 | 2026-01-12 |
| NCT02750306 | Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) | COMPLETED | PHASE3 | 2016-05-23 | 2018-09-30 | 2018-09-30 |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) | TERMINATED | PHASE1 | 2016-05-19 | 2021-09-09 | 2018-01-18 |
| NCT02790840 | A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations | COMPLETED | PHASE1 | 2016-05-16 | 2016-06-21 | 2016-06-15 |
| NCT02720081 | Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) | COMPLETED | PHASE2 | 2016-05-11 | 2017-09-06 | 2017-08-16 |
| NCT02738879 | Randomized Sitagliptin Withdrawal Study (MK-0431-845) | COMPLETED | PHASE3 | 2016-05-09 | 2018-01-30 | 2018-01-22 |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | TERMINATED | PHASE1 | 2016-05-04 | 2017-04-26 | 2017-04-26 |
| NCT02759315 | Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) | TERMINATED | PHASE2 | 2016-05-03 | 2017-11-16 | 2017-07-27 |
| NCT02720068 | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | COMPLETED | PHASE1 | 2016-05-02 | 2024-03-15 | 2024-03-15 |
| NCT02750761 | A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) | COMPLETED | PHASE1 | 2016-05-02 | 2018-12-21 | 2018-12-16 |
| NCT02611960 | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | COMPLETED | PHASE3 | 2016-04-18 | 2022-09-30 | 2020-11-30 |
| NCT02728089 | Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) | COMPLETED | PHASE3 | 2016-04-14 | 2017-09-05 | 2017-09-05 |
| NCT02739997 | Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) | COMPLETED | PHASE3 | 2016-04-08 | 2017-07-28 | 2017-07-28 |
| NCT02684617 | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | TERMINATED | PHASE1 | 2016-03-29 | 2020-04-06 | 2020-04-06 |
| NCT02699515 | MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-03-11 | 2022-02-21 | 2022-02-21 |
| NCT02652260 | Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) | COMPLETED | PHASE2 | 2016-03-04 | 2024-02-07 | 2018-08-14 |
| NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | COMPLETED | PHASE2 | 2016-02-25 | 2021-03-18 | 2019-09-18 |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | COMPLETED | PHASE3 | 2016-02-22 | 2023-06-22 | 2019-05-20 |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) | ACTIVE_NOT_RECRUITING | PHASE2 | 2016-02-10 | 2025-10-31 | 2025-10-31 |
| NCT02501473 | Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) | TERMINATED | PHASE1, PHASE2 | 2016-02-03 | 2019-08-01 | 2019-08-01 |
| NCT03021642 | Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers | COMPLETED | PHASE1 | 2016-01-31 | 2016-03-31 | 2016-03-31 |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | COMPLETED | PHASE1 | 2016-01-27 | 2019-11-18 | 2018-05-31 |
| NCT02641067 | A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051) | COMPLETED | PHASE1 | 2016-01-26 | 2016-05-25 | 2016-05-14 |
| NCT02666352 | A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) | COMPLETED | PHASE1 | 2016-01-22 | 2017-01-16 | 2017-01-16 |
| NCT02661126 | Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) | COMPLETED | PHASE1 | 2016-01-19 | 2016-08-26 | 2016-08-26 |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | COMPLETED | PHASE3 | 2016-01-15 | 2023-06-22 | 2017-11-08 |
| NCT02629822 | Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) | COMPLETED | PHASE2 | 2016-01-14 | 2020-10-28 | 2018-11-28 |
| NCT02621606 | [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001) | COMPLETED | PHASE1 | 2016-01-08 | 2017-12-28 | 2017-12-28 |
| NCT02601573 | Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) | COMPLETED | PHASE2 | 2016-01-05 | 2017-01-06 | 2016-10-18 |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | ACTIVE_NOT_RECRUITING | PHASE2 | 2015-12-18 | 2027-05-04 | 2027-05-04 |
| NCT02612623 | An 8-Week Refractory Chronic Cough Study (MK-7264-021) | COMPLETED | PHASE2 | 2015-12-17 | 2016-05-18 | 2016-05-04 |
| NCT02630706 | A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012) | COMPLETED | PHASE3 | 2015-12-16 | 2017-12-27 | 2017-12-27 |
| NCT02612610 | A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) | COMPLETED | PHASE2 | 2015-12-15 | 2016-11-04 | 2016-10-31 |
| NCT02613403 | Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) | TERMINATED | PHASE2 | 2015-12-10 | 2017-03-27 | 2017-01-09 |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | COMPLETED | PHASE2 | 2015-12-02 | 2020-10-23 | 2019-05-28 |
| NCT02559687 | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | COMPLETED | PHASE2 | 2015-12-02 | 2021-10-29 | 2018-07-30 |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | COMPLETED | PHASE3 | 2015-12-01 | 2022-03-14 | 2018-10-15 |
| NCT02563002 | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | COMPLETED | PHASE3 | 2015-11-30 | 2023-07-17 | 2021-02-19 |
| NCT02493764 | Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) | COMPLETED | PHASE3 | 2015-11-24 | 2019-04-03 | 2019-04-03 |
| NCT02576054 | Safety and Tolerability Study of V501 in Japanese Boys (V501-200) | COMPLETED | PHASE3 | 2015-11-20 | 2018-08-08 | 2018-08-08 |
| NCT02553499 | Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | TERMINATED | PHASE1 | 2015-11-12 | 2018-10-17 | 2018-10-17 |
| NCT02577003 | Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) | COMPLETED | PHASE3 | 2015-11-09 | 2016-11-25 | 2016-11-25 |
| NCT02504372 | Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) | ACTIVE_NOT_RECRUITING | PHASE3 | 2015-11-06 | 2026-01-21 | 2023-01-24 |
| NCT02577016 | Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) | COMPLETED | PHASE3 | 2015-11-05 | 2016-11-18 | 2016-11-18 |
| NCT02573181 | Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) | COMPLETED | PHASE2 | 2015-10-30 | 2016-01-28 | 2016-01-28 |
| NCT02476890 | Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) | COMPLETED | PHASE2 | 2015-10-28 | 2016-10-20 | 2016-10-20 |
| NCT02564211 | Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) | COMPLETED | PHASE3 | 2015-10-26 | 2017-03-07 | 2017-03-07 |
| NCT02532855 | A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) | COMPLETED | PHASE3 | 2015-10-20 | 2017-10-10 | 2017-10-10 |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | TERMINATED | PHASE3 | 2015-10-19 | 2020-07-16 | 2018-07-09 |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | TERMINATED | PHASE3 | 2015-10-19 | 2020-07-13 | 2018-07-09 |
| NCT02562989 | [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001) | COMPLETED | PHASE1 | 2015-10-19 | 2016-12-27 | 2016-12-27 |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | COMPLETED | PHASE3 | 2015-10-13 | 2020-11-10 | 2019-04-11 |
| NCT02547649 | Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) | COMPLETED | PHASE2 | 2015-10-08 | 2016-01-20 | 2016-01-20 |
| NCT02652936 | A Pharmacokinetics Study of AF-130 in Healthy Subjects | COMPLETED | PHASE1 | 2015-10 | 2016-03 | 2016-03 |
| NCT02715700 | Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045) | COMPLETED | PHASE1 | 2015-09-28 | 2016-08-15 | 2016-06-13 |
| NCT02549040 | Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046) | COMPLETED | PHASE1 | 2015-09-21 | 2015-12-24 | 2015-12-24 |
| NCT02217904 | A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) | COMPLETED | PHASE1 | 2015-09-17 | 2017-05-11 | 2017-05-11 |
| NCT02531373 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) | COMPLETED | PHASE1, PHASE2 | 2015-09-15 | 2017-04-14 | 2017-04-14 |
| NCT02519842 | Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) | TERMINATED | PHASE3 | 2015-09-14 | 2017-02-24 | 2017-02-24 |
| NCT02519855 | Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) | COMPLETED | PHASE3 | 2015-09-11 | 2016-01-26 | 2016-01-26 |
| NCT02452034 | Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097) | COMPLETED | PHASE1 | 2015-09-07 | 2018-09-03 | 2018-06-26 |
| NCT02364752 | A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344) | WITHDRAWN | PHASE1 | 2015-09 | 2016-11 | 2016-03 |
| NCT02553356 | PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers | COMPLETED | PHASE1 | 2015-09 | 2015-12 | 2015-11 |
| NCT02502097 | A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | COMPLETED | PHASE2 | 2015-08-26 | 2016-07-14 | 2016-07-01 |
| NCT02460198 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | COMPLETED | PHASE2 | 2015-08-25 | 2021-02-19 | 2019-09-09 |
| NCT02452047 | Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) | COMPLETED | PHASE3 | 2015-08-21 | 2017-09-18 | 2017-09-18 |
| NCT02503202 | Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) | COMPLETED | PHASE3 | 2015-08-17 | 2017-09-29 | 2016-05-02 |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | COMPLETED | PHASE3 | 2015-07-31 | 2022-06-06 | 2019-03-26 |
| NCT02383966 | Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer | COMPLETED | PHASE3 | 2015-07-31 | 2021-12-20 | 2018-01-19 |
| NCT02492763 | A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) | TERMINATED | PHASE2 | 2015-07-27 | 2017-04-18 | 2017-04-18 |
| NCT02478398 | Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) | COMPLETED | PHASE3 | 2015-07-20 | 2018-11-19 | 2018-11-09 |
| NCT02477709 | A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2015-07-20 | 2015-08-21 | 2015-08-07 |
| NCT02362594 | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) | ACTIVE_NOT_RECRUITING | PHASE3 | 2015-07-16 | 2026-11-01 | 2018-01-08 |
| NCT02492776 | A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations | COMPLETED | PHASE1 | 2015-07-07 | 2015-08-11 | 2015-08-04 |
| NCT02410590 | Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104) | WITHDRAWN | PHASE4 | 2015-07 | 2016-10 | 2016-10 |
| NCT02417441 | TiLE (Time Lapse Eeva) Clinical Trial | COMPLETED | PHASE4 | 2015-06-29 | 2017-02-09 | 2017-02-09 |
| NCT02473367 | The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824) | COMPLETED | PHASE1 | 2015-06-23 | 2015-10-09 | 2015-08-29 |
| NCT02461563 | A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004) | COMPLETED | PHASE1 | 2015-06-23 | 2015-12-23 | 2015-12-23 |
| NCT02447003 | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | COMPLETED | PHASE2 | 2015-06-11 | 2020-01-31 | 2019-02-18 |
| NCT02453594 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | COMPLETED | PHASE2 | 2015-06-10 | 2023-09-18 | 2023-09-18 |
| NCT02397096 | Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) | COMPLETED | PHASE3 | 2015-06-09 | 2023-09-05 | 2018-02-22 |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | TERMINATED | PHASE1 | 2015-06-09 | 2019-05-07 | 2019-05-07 |
| NCT02403674 | Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) | COMPLETED | PHASE3 | 2015-06-05 | 2023-09-07 | 2017-03-20 |
| NCT02477514 | A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004) | COMPLETED | PHASE1 | 2015-06 | 2015-08 | 2015-08 |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | COMPLETED | PHASE3 | 2015-05-11 | 2021-06-10 | 2017-10-26 |
| NCT02387983 | Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) | COMPLETED | PHASE1 | 2015-05-06 | 2016-05-02 | 2016-05-02 |
| NCT02397460 | Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) | COMPLETED | PHASE2 | 2015-04-29 | 2016-05-16 | 2016-04-22 |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | TERMINATED | PHASE2 | 2015-04-29 | 2019-02-06 | 2019-02-06 |
| NCT02392494 | Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) | COMPLETED | PHASE1 | 2015-04-28 | 2015-08-10 | 2015-08-10 |
| NCT02315352 | Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years | COMPLETED | PHASE1 | 2015-04 | 2015-05 | 2015-05 |
| NCT02276482 | Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) | COMPLETED | PHASE3 | 2015-03-25 | 2018-09-17 | 2018-09-17 |
| NCT02358031 | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | COMPLETED | PHASE3 | 2015-03-19 | 2023-07-19 | 2019-02-25 |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | RECRUITING | PHASE1, PHASE2 | 2015-03-18 | 2027-10-25 | 2027-10-25 |
| NCT02336555 | The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012) | COMPLETED | PHASE1 | 2015-03-12 | 2016-02-29 | 2016-02-29 |
| NCT02349425 | A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) | COMPLETED | PHASE2 | 2015-03-09 | 2016-02-09 | 2016-02-01 |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | TERMINATED | PHASE1 | 2015-02-28 | 2019-03-29 | 2019-03-29 |
| NCT02318667 | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). | COMPLETED | PHASE4 | 2015-02-27 | 2017-09-05 | 2017-06-21 |
| NCT02358044 | Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) | COMPLETED | PHASE3 | 2015-02-27 | 2016-02-16 | 2015-11-26 |
| NCT02335424 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) | COMPLETED | PHASE2 | 2015-02-24 | 2022-02-18 | 2018-06-19 |
| NCT02387372 | Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) | COMPLETED | PHASE1 | 2015-02-05 | 2017-06-16 | 2017-06-15 |
| NCT02318693 | Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355) | COMPLETED | PHASE4 | 2015-02-04 | 2015-12-15 | 2015-12-15 |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | COMPLETED | PHASE2 | 2015-02-03 | 2021-07-23 | 2021-07-23 |
| NCT02317809 | Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects | COMPLETED | PHASE1 | 2015-01-31 | 2015-10-31 | 2015-10-31 |
| NCT02332720 | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) | COMPLETED | PHASE2 | 2015-01-28 | 2017-05-03 | 2016-09-19 |
| NCT02251990 | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) | COMPLETED | PHASE3 | 2015-01-28 | 2017-04-10 | 2016-09-27 |
| NCT02332707 | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) | COMPLETED | PHASE2 | 2015-01-22 | 2016-12-06 | 2016-09-16 |
| NCT02325713 | Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers | COMPLETED | PHASE1 | 2015-01 | 2015-03 | 2015-01 |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | WITHDRAWN | PHASE1, PHASE2 | 2015-01 | 2016-03 | 2016-03 |
| NCT02316197 | Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | COMPLETED | PHASE1 | 2014-12-31 | 2017-06-29 | 2017-06-29 |
| NCT02254304 | Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ | COMPLETED | PHASE4 | 2014-12-31 | 2016-08-20 | 2016-08-20 |
| NCT02341599 | Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) | COMPLETED | PHASE1 | 2014-12-11 | 2015-04-20 | 2015-04-13 |
| NCT02255110 | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | TERMINATED | PHASE2 | 2014-12-10 | 2016-01-12 | 2016-01-12 |
| NCT02314923 | Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) | COMPLETED | PHASE1 | 2014-12-05 | 2016-06-23 | 2016-06-23 |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | TERMINATED | PHASE1 | 2014-12-03 | 2019-07-05 | 2019-07-05 |
| NCT02275780 | Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) | COMPLETED | PHASE3 | 2014-12-01 | 2023-03-06 | 2016-09-29 |
| NCT02252965 | Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes | COMPLETED | PHASE4 | 2014-12 | 2016-04 | 2015-11 |
| NCT02269059 | Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) | COMPLETED | PHASE1 | 2014-12 | 2015-04 | 2015-02 |
| NCT02269735 | A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) | COMPLETED | PHASE1 | 2014-11-26 | 2016-07-29 | 2016-07-29 |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | ACTIVE_NOT_RECRUITING | PHASE1 | 2014-11-25 | 2026-11-30 | 2017-01-31 |
| NCT02252042 | Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | COMPLETED | PHASE3 | 2014-11-17 | 2022-08-15 | 2017-05-15 |
| NCT02204475 | Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) | WITHDRAWN | PHASE3 | 2014-11 | 2016-09 | 2016-06 |
| NCT02260882 | Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) | COMPLETED | PHASE4 | 2014-10-31 | 2015-04-09 | 2015-04-09 |
| NCT02271984 | Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers | COMPLETED | PHASE1 | 2014-10-31 | 2014-12-31 | 2014-12-31 |
| NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | COMPLETED | PHASE3 | 2014-10-30 | 2022-09-12 | 2018-09-04 |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | TERMINATED | PHASE2 | 2014-10-29 | 2015-10-20 | 2015-10-20 |
| NCT02411929 | A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020) | COMPLETED | PHASE1 | 2014-10-29 | 2015-02-09 | 2015-01-30 |
| NCT02255097 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | COMPLETED | PHASE2 | 2014-10-24 | 2021-06-18 | 2016-04-22 |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | COMPLETED | PHASE1 | 2014-10-23 | 2017-03-03 | 2017-03-03 |
| NCT02256436 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | COMPLETED | PHASE3 | 2014-10-22 | 2020-10-01 | 2016-09-07 |
| NCT02252016 | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) | COMPLETED | PHASE3 | 2014-10-22 | 2016-06-14 | 2015-12-07 |
| NCT02268409 | Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) | COMPLETED | PHASE2 | 2014-10-20 | 2020-06-18 | 2020-06-18 |
| NCT02269423 | Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) | COMPLETED | PHASE1 | 2014-10-13 | 2015-08-25 | 2015-08-25 |
| NCT02268383 | Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) | COMPLETED | PHASE2 | 2014-10-09 | 2020-03-19 | 2020-03-19 |
| NCT02280408 | Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) | COMPLETED | PHASE1 | 2014-10-07 | 2015-12-10 | 2015-12-10 |
| NCT02229877 | A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264) | COMPLETED | PHASE1 | 2014-10-06 | 2015-05-22 | 2015-05-14 |
| NCT02226003 | Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) | COMPLETED | PHASE3 | 2014-09-23 | 2016-02-23 | 2016-02-23 |
| NCT02115347 | Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) | COMPLETED | PHASE1 | 2014-09-19 | 2015-01-19 | 2015-01-10 |
| NCT02266706 | Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) | COMPLETED | PHASE1 | 2014-09-17 | 2017-06-15 | 2017-06-08 |
| NCT02174159 | Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) | COMPLETED | PHASE1 | 2014-09-15 | 2015-07-23 | 2015-07-16 |
| NCT02116660 | Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) | TERMINATED | PHASE2 | 2014-09-03 | 2017-07-10 | 2017-07-10 |
| NCT02070757 | Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) | COMPLETED | PHASE3 | 2014-09-02 | 2018-06-06 | 2018-05-15 |
| NCT02105688 | An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) | COMPLETED | PHASE3 | 2014-09-02 | 2018-12-04 | 2015-06-10 |
| NCT02257489 | Phase 1 Study of ACE-083 in Healthy Subjects | COMPLETED | PHASE1 | 2014-09 | 2016-04 | 2016-03 |
| NCT02225587 | Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) | COMPLETED | PHASE3 | 2014-08-28 | 2015-07-06 | 2015-07-06 |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | COMPLETED | PHASE3 | 2014-08-25 | 2021-05-27 | 2016-05-09 |
| NCT02155322 | A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) | COMPLETED | PHASE2 | 2014-08-19 | 2016-03-21 | 2016-03-21 |
| NCT02181803 | MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) | COMPLETED | PHASE1 | 2014-08-05 | 2015-04-23 | 2015-04-23 |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | COMPLETED | PHASE1, PHASE2 | 2014-08-04 | 2017-09-22 | 2017-07-05 |
| NCT02203149 | Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) | COMPLETED | PHASE2, PHASE3 | 2014-08-01 | 2016-05-16 | 2015-10-02 |
| NCT02156466 | Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects | COMPLETED | PHASE1 | 2014-08 | 2015-08 | 2015-08 |
| NCT02180165 | Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) | COMPLETED | PHASE3 | 2014-07-29 | 2018-01-24 | 2018-01-24 |
| NCT02180061 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | COMPLETED | PHASE1 | 2014-07-15 | 2017-08-31 | 2017-08-31 |
| NCT02155335 | Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) | COMPLETED | PHASE4 | 2014-07-01 | 2015-10-05 | 2015-10-05 |
| NCT02180295 | A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014) | WITHDRAWN | PHASE3 | 2014-07 | 2015-03 | 2015-03 |
| NCT02161510 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) | COMPLETED | PHASE1 | 2014-07 | 2015-04 | 2014-11 |
| NCT01626794 | A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062) | WITHDRAWN | PHASE3 | 2014-07 | 2015-10 | 2015-10 |
| NCT02132754 | Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | COMPLETED | PHASE1 | 2014-06-27 | 2019-07-31 | 2019-07-31 |
| NCT02133131 | Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) | COMPLETED | PHASE2 | 2014-06-13 | 2016-02-01 | 2015-11-02 |
| NCT02137772 | Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) | COMPLETED | PHASE3 | 2014-06-06 | 2016-11-21 | 2016-08-08 |
| NCT02105701 | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) | COMPLETED | PHASE3 | 2014-06-05 | 2015-06-19 | 2015-03-24 |
| NCT02105467 | Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) | COMPLETED | PHASE3 | 2014-06-05 | 2015-09-06 | 2015-02-26 |
| NCT02105662 | An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) | COMPLETED | PHASE3 | 2014-06-03 | 2015-05-22 | 2015-02-20 |
| NCT02650895 | Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001) | COMPLETED | PHASE1 | 2014-06-02 | 2015-01-15 | 2015-01-15 |
| NCT02064816 | A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis | COMPLETED | PHASE4 | 2014-05-31 | 2016-04-30 | 2016-04-30 |
| NCT02122861 | Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | COMPLETED | PHASE1 | 2014-05-30 | 2018-12-15 | 2018-11-14 |
| NCT02062385 | Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024) | COMPLETED | PHASE3 | 2014-05-30 | 2015-06-11 | 2015-06-11 |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | COMPLETED | PHASE1, PHASE2 | 2014-05-29 | 2021-07-14 | 2021-07-14 |
| NCT02131233 | Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) | COMPLETED | PHASE3 | 2014-05-23 | 2016-12-19 | 2015-12-21 |
| NCT01558674 | A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011) | TERMINATED | PHASE1 | 2014-05-23 | 2014-12-17 | 2014-12-17 |
| NCT02105454 | Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048) | COMPLETED | PHASE2 | 2014-05-23 | 2015-05-04 | 2015-05-04 |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | COMPLETED | PHASE1, PHASE2 | 2014-05-18 | 2018-02-14 | 2018-02-14 |
| NCT02115321 | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) | COMPLETED | PHASE2, PHASE3 | 2014-05-09 | 2015-06-16 | 2015-03-05 |
| NCT02092285 | Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) | COMPLETED | PHASE4 | 2014-05-09 | 2016-05-25 | 2016-05-25 |
| NCT02078557 | A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007) | TERMINATED | PHASE1 | 2014-05-09 | 2014-09-10 | 2014-08-15 |
| NCT01641666 | Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) | WITHDRAWN | PHASE3 | 2014-05 | 2016-09 | 2016-09 |
| NCT02064920 | Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) | COMPLETED | PHASE2 | 2014-04-22 | 2016-07-13 | 2016-07-13 |
| NCT02099110 | Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) | COMPLETED | PHASE3 | 2014-04-22 | 2016-05-26 | 2016-05-26 |
| NCT02076100 | Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) | COMPLETED | PHASE1 | 2014-03-27 | 2015-11-15 | 2015-11-15 |
| NCT02089659 | A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019) | COMPLETED | PHASE1 | 2014-03-26 | 2014-05-12 | 2014-05-12 |
| NCT02114385 | A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) | COMPLETED | PHASE3 | 2014-03-24 | 2015-04-22 | 2015-04-22 |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | COMPLETED | PHASE1, PHASE2 | 2014-03-17 | 2021-04-01 | 2021-04-01 |
| NCT02092350 | Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) | COMPLETED | PHASE2, PHASE3 | 2014-03-17 | 2015-09-02 | 2015-03-11 |
| NCT02036515 | Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) | COMPLETED | PHASE3 | 2014-03-12 | 2016-06-06 | 2016-06-06 |
| NCT02062502 | Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) | COMPLETED | PHASE3 | 2014-03-07 | 2015-10-13 | 2015-02-24 |
| NCT01977794 | Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension | COMPLETED | PHASE3 | 2014-03 | 2015-03 | 2015-03 |
| NCT02112942 | Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects | TERMINATED | PHASE1 | 2014-03 | 2014-06 | 2014-06 |
| NCT02007070 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | COMPLETED | PHASE1 | 2014-02-28 | 2017-03-31 | 2015-07-09 |
| NCT01973491 | ATX-MS-1467 in Multiple Sclerosis | COMPLETED | PHASE2 | 2014-02-28 | 2016-04-30 | 2016-04-30 |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | COMPLETED | PHASE1, PHASE2 | 2014-02-21 | 2021-10-18 | 2016-11-07 |
| NCT02054806 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | COMPLETED | PHASE1 | 2014-02-17 | 2021-04-30 | 2021-04-30 |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | TERMINATED | PHASE1 | 2014-02-14 | 2020-03-19 | 2020-03-19 |
| NCT02059187 | The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) | COMPLETED | PHASE3 | 2014-02-11 | 2015-03-11 | 2015-03-11 |
| NCT02059174 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) | COMPLETED | PHASE1 | 2014-02-10 | 2015-04-27 | 2015-03-30 |
| NCT02076230 | A Phase 1 TH-302 Mass Balance Trial | COMPLETED | PHASE1 | 2014-02 | 2016-03 | 2014-09 |
| NCT02047227 | Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) | COMPLETED | PHASE3 | 2014-01-31 | 2015-08-31 | 2015-08-31 |
| NCT02037984 | Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) | COMPLETED | PHASE1, PHASE2 | 2014-01-28 | 2016-07-01 | 2016-07-01 |
| NCT01945281 | Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) | TERMINATED | PHASE2 | 2014-01-15 | 2018-02-28 | 2018-01-02 |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | COMPLETED | PHASE1, PHASE2 | 2014-01-06 | 2020-12-03 | 2018-02-05 |
| NCT02019420 | Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) | COMPLETED | PHASE3 | 2014-01-06 | 2018-06-22 | 2018-06-22 |
| NCT02028065 | A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) | COMPLETED | PHASE1 | 2014-01-03 | 2014-07-01 | 2014-07-01 |
| NCT02035657 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | COMPLETED | PHASE1 | 2014-01 | 2018-03 | 2018-03 |
| NCT01770223 | A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) | WITHDRAWN | PHASE4 | 2014-01 | 2015-12 | 2015-12 |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | COMPLETED | PHASE1, PHASE2 | 2013-12-23 | 2021-10-14 | 2017-12-12 |
| NCT01993329 | A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009) | COMPLETED | PHASE2 | 2013-12-16 | 2014-02-28 | 2014-02-20 |
| NCT01999218 | Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) | COMPLETED | PHASE3 | 2013-12-16 | 2017-04-18 | 2017-04-18 |
| NCT02033889 | A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). | COMPLETED | PHASE3 | 2013-12-13 | 2017-08-03 | 2017-08-03 |
| NCT01984697 | A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) | COMPLETED | PHASE3 | 2013-12-12 | 2017-07-24 | 2015-06-19 |
| NCT02011490 | Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105) | COMPLETED | PHASE1 | 2013-12-11 | 2014-06-06 | 2014-06-06 |
| NCT01986855 | A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001) | COMPLETED | PHASE3 | 2013-12-02 | 2016-09-28 | 2016-09-28 |
| NCT01852825 | MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) | COMPLETED | PHASE1 | 2013-11-27 | 2015-08-03 | 2015-07-20 |
| NCT01986010 | Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) | COMPLETED | PHASE1 | 2013-11-25 | 2017-03-14 | 2016-04-19 |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | COMPLETED | PHASE1 | 2013-11-22 | 2020-06-26 | 2020-06-26 |
| NCT01934647 | Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) | TERMINATED | PHASE1 | 2013-11-22 | 2014-09-08 | 2014-09-08 |
| NCT01926509 | Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) | COMPLETED | PHASE1 | 2013-11-14 | 2014-09-08 | 2014-09-01 |
| NCT01982630 | Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) | COMPLETED | PHASE1 | 2013-11-07 | 2014-10-03 | 2014-10-03 |
| NCT01953601 | Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) | TERMINATED | PHASE3 | 2013-11-05 | 2018-04-17 | 2018-04-17 |
| NCT01986881 | Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) | COMPLETED | PHASE3 | 2013-11-04 | 2019-12-27 | 2019-12-27 |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | COMPLETED | PHASE1 | 2013-11 | 2017-03 | 2016-12 |
| NCT01979510 | Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164) | WITHDRAWN | PHASE3 | 2013-11 | 2014-05 | 2014-05 |
| NCT01963260 | Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) | COMPLETED | PHASE1 | 2013-10-31 | 2015-04-26 | 2015-04-26 |
| NCT01974687 | Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001) | COMPLETED | PHASE1, PHASE2 | 2013-10-31 | 2015-09-11 | 2015-09-02 |
| NCT01955473 | Japanese Phase 1 Trial of Sym004 in Solid Tumors | COMPLETED | PHASE1 | 2013-10-31 | 2015-10-31 | 2015-10-31 |
| NCT01852110 | Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) | TERMINATED | PHASE2 | 2013-10-22 | 2016-04-11 | 2016-04-11 |
| NCT01866306 | A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218) | COMPLETED | PHASE1 | 2013-10-22 | 2016-01-18 | 2015-12-25 |
| NCT02059161 | A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) | COMPLETED | PHASE3 | 2013-10-17 | 2015-11-12 | 2015-05-04 |
| NCT01971554 | Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003) | COMPLETED | PHASE1 | 2013-10-14 | 2014-04-26 | 2014-04-26 |
| NCT01945294 | Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) | COMPLETED | PHASE3 | 2013-10-10 | 2015-11-04 | 2015-08-05 |
| NCT01958671 | A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO) | COMPLETED | PHASE3 | 2013-10-09 | 2016-07-28 | 2016-07-28 |
| NCT01930058 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) | COMPLETED | PHASE1 | 2013-10-02 | 2014-05-05 | 2014-05-05 |
| NCT01932762 | Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) | COMPLETED | PHASE2 | 2013-10-01 | 2014-12-04 | 2014-12-04 |
| NCT01948986 | Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009) | COMPLETED | PHASE1 | 2013-10-01 | 2014-10-16 | 2014-10-06 |
| NCT01537900 | A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) | COMPLETED | PHASE1 | 2013-10-01 | 2014-07-31 | 2014-07-31 |
| NCT01930045 | A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) | COMPLETED | PHASE1 | 2013-10-01 | 2013-12-10 | 2013-12-10 |
| NCT01921452 | Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit | COMPLETED | PHASE4 | 2013-10 | 2014-02 | 2014-02 |
| NCT01782131 | A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) | COMPLETED | PHASE3 | 2013-09-25 | 2019-09-10 | 2019-07-10 |
| NCT01926015 | Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) | COMPLETED | PHASE4 | 2013-09-19 | 2014-06-06 | 2014-06-06 |
| NCT01922011 | Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) | COMPLETED | PHASE3 | 2013-09-13 | 2016-12-20 | 2016-06-14 |
| NCT01937975 | The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) | COMPLETED | PHASE1 | 2013-09-06 | 2013-12-17 | 2013-12-17 |
| NCT01943461 | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | COMPLETED | PHASE1 | 2013-09-02 | 2019-09-25 | 2015-01-07 |
| NCT01926002 | A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003) | WITHDRAWN | PHASE1 | 2013-09 | 2014-04 | 2014-04 |
| NCT02508740 | Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment | TERMINATED | PHASE1 | 2013-09 | 2013-12 | 2013-12 |
| NCT01866319 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | COMPLETED | PHASE3 | 2013-08-28 | 2019-06-03 | 2015-03-03 |
| NCT01905657 | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | COMPLETED | PHASE2, PHASE3 | 2013-08-09 | 2020-09-30 | 2015-09-30 |
| NCT01534351 | Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) | TERMINATED | PHASE3 | 2013-08-01 | 2013-11-18 | 2013-11-18 |
| NCT01919125 | Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) | COMPLETED | PHASE1 | 2013-08 | 2014-02 | 2014-02 |
| NCT01727271 | A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384) | WITHDRAWN | PHASE4 | 2013-08 | 2017-08 | 2017-08 |
| NCT01832103 | The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018) | WITHDRAWN | PHASE1 | 2013-08 | 2013-12 | 2013-12 |
| NCT01863667 | A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) | TERMINATED | PHASE3 | 2013-07-08 | 2014-04-03 | 2014-04-03 |
| NCT01901341 | The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | TERMINATED | PHASE3 | 2013-07-02 | 2014-02-13 | 2014-02-13 |
| NCT01871532 | Low-dose Gonal-f® in Ovulation Induction | TERMINATED | PHASE4 | 2013-07 | 2014-11 | 2014-03 |
| NCT01863680 | Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel | COMPLETED | PHASE3 | 2013-07 | 2014-10 | 2014-10 |
| NCT01862874 | Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) | COMPLETED | PHASE3 | 2013-06-27 | 2017-08-30 | 2017-08-30 |
| NCT01853982 | Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia | TERMINATED | PHASE3 | 2013-06-14 | 2013-12-08 | 2013-11-20 |
| NCT01841697 | Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) | COMPLETED | PHASE3 | 2013-06-13 | 2014-11-17 | 2014-11-17 |
| NCT01734239 | A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) | COMPLETED | PHASE3 | 2013-06-03 | 2013-10-22 | 2013-10-22 |
| NCT01806298 | An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) | COMPLETED | PHASE4 | 2013-06 | 2016-03 | 2016-03 |
| NCT01841684 | Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) | TERMINATED | PHASE3 | 2013-06 | 2014-06 | 2014-06 |
| NCT01901302 | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | TERMINATED | PHASE3 | 2013-05-20 | 2014-02-13 | 2014-02-13 |
| NCT01860729 | A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) | COMPLETED | PHASE3 | 2013-05-13 | 2015-08-20 | 2015-05-29 |
| NCT02055547 | A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002) | COMPLETED | PHASE1 | 2013-05-10 | 2013-09-17 | 2013-09-17 |
| NCT01848834 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | COMPLETED | PHASE1 | 2013-05-07 | 2020-06-30 | 2016-04-26 |
| NCT01814748 | A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) | COMPLETED | PHASE3 | 2013-05-03 | 2015-09-14 | 2015-09-14 |
| NCT01824238 | A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) | COMPLETED | PHASE3 | 2013-05 | 2014-05 | 2014-05 |
| NCT01907724 | Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) | COMPLETED | PHASE1 | 2013-05 | 2013-08 | 2013-08 |
| NCT01832506 | A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2013-04-30 | 2014-10-31 | 2014-03-31 |
| NCT01600092 | A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035) | COMPLETED | PHASE3 | 2013-04-29 | 2014-03-25 | 2014-03-25 |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | COMPLETED | PHASE1 | 2013-04-26 | 2020-02-28 | 2020-02-28 |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | COMPLETED | PHASE1 | 2013-04-18 | 2016-01-25 | 2015-08-31 |
| NCT01901328 | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | TERMINATED | PHASE3 | 2013-04-07 | 2014-02-13 | 2014-02-13 |
| NCT01798849 | A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) | COMPLETED | PHASE1 | 2013-03-15 | 2013-07-17 | 2013-07-17 |
| NCT01803607 | Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) | TERMINATED | PHASE3 | 2013-03-14 | 2014-11-11 | 2014-11-11 |
| NCT01760460 | A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) | COMPLETED | PHASE3 | 2013-03-14 | 2015-03-04 | 2015-03-04 |
| NCT01630616 | A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066) | TERMINATED | PHASE1 | 2013-03-12 | 2016-07-14 | 2016-07-14 |
| NCT01797536 | The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009) | COMPLETED | PHASE1 | 2013-03-06 | 2014-08-20 | 2014-08-20 |
| NCT01852604 | Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) | COMPLETED | PHASE2 | 2013-03 | 2015-04 | 2015-04 |
| NCT01749540 | Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) | COMPLETED | PHASE2 | 2013-02-28 | 2015-11-11 | 2015-11-11 |
| NCT01791244 | A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device | COMPLETED | PHASE4 | 2013-02-28 | 2016-02-29 | 2016-02-29 |
| NCT01732458 | A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) | COMPLETED | PHASE2 | 2013-02-12 | 2016-09-26 | 2016-09-26 |
| NCT01717326 | A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) | COMPLETED | PHASE2 | 2013-02-07 | 2015-05-06 | 2015-02-23 |
| NCT01756079 | A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) | COMPLETED | PHASE4 | 2013-02-06 | 2015-11-17 | 2015-11-17 |
| NCT01813552 | To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) | COMPLETED | PHASE1 | 2013-02 | 2013-03 | 2013-03 |
| NCT01590225 | Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) | WITHDRAWN | PHASE3 | 2013-01-28 | 2021-08-18 | 2021-08-18 |
| NCT01667107 | A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) | TERMINATED | PHASE4 | 2013-01-23 | 2014-01-16 | 2014-01-16 |
| NCT01749514 | Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) | COMPLETED | PHASE2 | 2013-01-21 | 2018-10-22 | 2018-10-22 |
| NCT01716156 | A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) | COMPLETED | PHASE2 | 2013-01-18 | 2014-03-12 | 2013-12-09 |
| NCT01767688 | A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031) | COMPLETED | PHASE1 | 2013-01-16 | 2013-03-07 | 2013-03-01 |
| NCT01737684 | A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) | COMPLETED | PHASE1 | 2013-01-15 | 2013-06-14 | 2013-06-14 |
| NCT01755156 | A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) | COMPLETED | PHASE3 | 2013-01-11 | 2016-03-16 | 2016-03-16 |
| NCT01606800 | Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) | TERMINATED | PHASE4 | 2013-01-01 | 2015-01-26 | 2015-01-26 |
| NCT01813513 | Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) | COMPLETED | PHASE1 | 2013-01 | 2013-07 | 2013-07 |
| NCT01500707 | Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235) | WITHDRAWN | PHASE1 | 2013-01 | 2013-07 | 2013-07 |
| NCT01636960 | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) | TERMINATED | PHASE1 | 2012-12-25 | 2015-11-04 | 2014-03-26 |
| NCT01732510 | A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) | TERMINATED | PHASE1 | 2012-12-21 | 2014-10-20 | 2014-10-20 |
| NCT01713582 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | COMPLETED | PHASE1 | 2012-12-14 | 2017-01-20 | 2017-01-20 |
| NCT01697579 | Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) | COMPLETED | PHASE2 | 2012-12-13 | 2016-11-21 | 2016-11-21 |
| NCT01636947 | A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) | COMPLETED | PHASE4 | 2012-12-12 | 2014-08-04 | 2014-08-04 |
| NCT01710501 | A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) | COMPLETED | PHASE2 | 2012-12-07 | 2014-01-29 | 2013-11-25 |
| NCT01702298 | A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312) | COMPLETED | PHASE3 | 2012-12-07 | 2013-05-29 | 2013-05-29 |
| NCT01717313 | A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) | COMPLETED | PHASE3 | 2012-12-05 | 2015-06-19 | 2015-06-19 |
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | TERMINATED | PHASE2 | 2012-12 | 2017-11 | 2017-06 |
| NCT01746862 | A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS) | COMPLETED | PHASE3 | 2012-12 | 2015-03 | 2014-08 |
| NCT01739348 | An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) | TERMINATED | PHASE2, PHASE3 | 2012-11-30 | 2017-04-14 | 2017-04-14 |
| NCT01713036 | Oral Bioavailability and Mass Balance Trial With Pimasertib | COMPLETED | PHASE1 | 2012-11-30 | 2014-07-31 | 2014-07-31 |
| NCT01728376 | Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) | COMPLETED | PHASE4 | 2012-11-29 | 2016-01-20 | 2016-01-20 |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | COMPLETED | PHASE2 | 2012-11-28 | 2018-04-30 | 2018-04-30 |
| NCT01728584 | A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) | COMPLETED | PHASE4 | 2012-11-28 | 2014-04-29 | 2014-04-29 |
| NCT01641926 | A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) | TERMINATED | PHASE3 | 2012-11-26 | 2016-01-21 | 2016-01-21 |
| NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | COMPLETED | PHASE2 | 2012-11-20 | 2019-01-31 | 2015-11-16 |
| NCT01717287 | A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) | COMPLETED | PHASE2 | 2012-11-16 | 2013-12-11 | 2013-12-11 |
| NCT01709305 | A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) | COMPLETED | PHASE4 | 2012-11-08 | 2015-04-17 | 2015-04-17 |
| NCT01717300 | A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) | COMPLETED | PHASE3 | 2012-11-06 | 2014-10-29 | 2014-10-29 |
| NCT01732471 | Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria | COMPLETED | PHASE3 | 2012-11 | 2013-10 | 2013-10 |
| NCT01527370 | Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) | COMPLETED | PHASE3 | 2012-10-31 | 2013-04-09 | 2013-04-09 |
| NCT01678131 | Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048) | COMPLETED | PHASE1 | 2012-10-30 | 2013-09-02 | 2013-08-27 |
| NCT01651949 | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | COMPLETED | PHASE3 | 2012-10-29 | 2014-08-04 | 2014-08-04 |
| NCT01703221 | Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) | COMPLETED | PHASE3 | 2012-10-24 | 2014-04-25 | 2014-04-25 |
| NCT01697592 | Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) | COMPLETED | PHASE3 | 2012-10-24 | 2014-05-08 | 2014-05-08 |
| NCT01704261 | Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) | COMPLETED | PHASE3 | 2012-10-18 | 2014-12-23 | 2014-12-23 |
| NCT01632345 | A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007) | COMPLETED | PHASE2 | 2012-10-12 | 2016-03-21 | 2014-12-03 |
| NCT01696643 | Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | TERMINATED | PHASE3 | 2012-10-12 | 2014-07-21 | 2014-07-21 |
| NCT01691248 | Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) | COMPLETED | PHASE3 | 2012-10-10 | 2015-04-16 | 2015-03-18 |
| NCT01678820 | A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) | TERMINATED | PHASE3 | 2012-10-10 | 2013-11-01 | 2013-11-01 |
| NCT01703208 | A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) | TERMINATED | PHASE3 | 2012-10-05 | 2017-03-22 | 2016-05-13 |
| NCT01698775 | A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) | COMPLETED | PHASE3 | 2012-10-02 | 2016-01-19 | 2016-01-19 |
| NCT01650727 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | COMPLETED | PHASE1 | 2012-10 | 2013-10 | 2013-10 |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | TERMINATED | PHASE1 | 2012-09-30 | 2015-05-31 | 2015-05-31 |
| NCT01594749 | Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) | COMPLETED | PHASE3 | 2012-09-24 | 2014-11-03 | 2014-11-03 |
| NCT01640873 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002) | COMPLETED | PHASE1 | 2012-09-19 | 2012-12-20 | 2012-12-20 |
| NCT01682759 | A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) | COMPLETED | PHASE3 | 2012-09-10 | 2015-01-26 | 2015-01-26 |
| NCT01668004 | The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) | COMPLETED | PHASE4 | 2012-09-03 | 2015-04-30 | 2015-04-30 |
| NCT01653743 | Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women | COMPLETED | PHASE3 | 2012-09 | 2014-12 | 2014-11 |
| NCT01651936 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010) | TERMINATED | PHASE2 | 2012-08-29 | 2013-10-08 | 2013-10-08 |
| NCT01656395 | A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012) | TERMINATED | PHASE2 | 2012-08-23 | 2014-07-08 | 2014-06-10 |
| NCT01624974 | Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011) | COMPLETED | PHASE2 | 2012-08-09 | 2014-05-05 | 2014-05-05 |
| NCT01656408 | A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002) | COMPLETED | PHASE1 | 2012-08-01 | 2013-05-23 | 2013-05-03 |
| NCT01580228 | A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) | COMPLETED | PHASE3 | 2012-08 | 2014-12 | 2014-12 |
| NCT01558687 | Cilengitide Imaging Trial in Glioblastoma | TERMINATED | PHASE1 | 2012-08 | 2013-02 | 2013-02 |
| NCT01477580 | Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) | COMPLETED | PHASE1 | 2012-07-23 | 2014-12-11 | 2014-01-23 |
| NCT01557504 | A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296) | COMPLETED | PHASE1 | 2012-07-18 | 2014-04-29 | 2014-04-29 |
| NCT01614769 | Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253) | COMPLETED | PHASE1 | 2012-07-18 | 2013-01-23 | 2013-01-09 |
| NCT01628042 | A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) | COMPLETED | PHASE1 | 2012-07-16 | 2013-01-25 | 2013-01-25 |
| NCT01590797 | A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254) | COMPLETED | PHASE3 | 2012-07-10 | 2014-06-25 | 2014-06-11 |
| NCT01590771 | A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) | COMPLETED | PHASE3 | 2012-07-09 | 2014-06-24 | 2014-06-10 |
| NCT01609231 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | TERMINATED | PHASE2 | 2012-07-06 | 2014-12-09 | 2014-12-09 |
| NCT01605396 | A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | COMPLETED | PHASE2 | 2012-07-04 | 2018-03-15 | 2014-02-19 |
| NCT01582308 | A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142) | COMPLETED | PHASE1 | 2012-06-21 | 2012-12-14 | 2012-12-04 |
| NCT01591863 | Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) | COMPLETED | PHASE2 | 2012-06-15 | 2014-03-07 | 2014-03-07 |
| NCT01536405 | Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) | COMPLETED | PHASE3 | 2012-06-05 | 2014-01-27 | 2013-07-02 |
| NCT01506271 | Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) | COMPLETED | PHASE2 | 2012-06-01 | 2014-08-12 | 2014-08-12 |
| NCT01622673 | A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) | COMPLETED | PHASE1 | 2012-06 | 2012-10 | 2012-10 |
| NCT01614782 | A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002) | TERMINATED | PHASE1 | 2012-06 | 2012-10 | 2012-10 |
| NCT01583647 | A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) | TERMINATED | PHASE1 | 2012-06 | 2012-12 | 2012-12 |
| NCT01510522 | Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets | WITHDRAWN | PHASE4 | 2012-06 | | 2012-06 |
| NCT01544920 | Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) | COMPLETED | PHASE3 | 2012-05-30 | 2015-05-19 | 2015-05-19 |
| NCT01569152 | Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) | TERMINATED | PHASE2 | 2012-05-22 | 2013-10-03 | 2013-10-03 |
| NCT01554176 | Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) | TERMINATED | PHASE2 | 2012-05-18 | 2013-09-03 | 2013-09-03 |
| NCT01623401 | A Phase 1, Open-Label, 10 Day Safety Study | COMPLETED | PHASE1 | 2012-05-17 | 2012-08-24 | 2012-08-24 |
| NCT01598311 | A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) | COMPLETED | PHASE3 | 2012-05-16 | 2015-08-25 | 2015-07-26 |
| NCT01597505 | Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) | COMPLETED | PHASE3 | 2012-05-16 | 2015-03-20 | 2015-03-20 |
| NCT01505634 | Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) | COMPLETED | PHASE2 | 2012-05-16 | 2015-07-28 | 2015-07-28 |
| NCT01590810 | A Single Rising Dose Study of MK-8150 (MK-8150-001) | COMPLETED | PHASE1 | 2012-05-07 | 2013-02-05 | 2013-01-24 |
| NCT01547312 | Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) | WITHDRAWN | PHASE1 | 2012-05 | 2012-11 | 2012-11 |
| NCT01497197 | A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique | TERMINATED | PHASE3 | 2012-05 | 2014-01 | 2014-01 |
| NCT01552122 | Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) | WITHDRAWN | PHASE3 | 2012-05 | 2015-02 | 2015-02 |
| NCT01593735 | A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) | COMPLETED | PHASE1 | 2012-05 | 2013-02 | 2013-02 |
| NCT01514370 | Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a | COMPLETED | PHASE2 | 2012-04-30 | 2016-03-31 | 2016-03-31 |
| NCT01577459 | A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response | COMPLETED | PHASE1 | 2012-04-23 | 2012-06-15 | 2012-06-15 |
| NCT01569438 | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) | TERMINATED | PHASE2 | 2012-04-13 | 2014-05-14 | 2014-05-01 |
| NCT01505647 | Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) | COMPLETED | PHASE3 | 2012-04 | 2012-11 | 2012-07 |
| NCT01556451 | ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) | COMPLETED | PHASE4 | 2012-04 | 2012-10 | 2012-10 |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | TERMINATED | PHASE1 | 2012-04 | 2012-11 | 2012-09 |
| NCT01554189 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002) | TERMINATED | PHASE1 | 2012-04 | 2013-04 | 2013-04 |
| NCT01554579 | A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee | COMPLETED | PHASE2 | 2012-03-29 | 2013-11-21 | 2013-11-11 |
| NCT01564459 | Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) | COMPLETED | PHASE2 | 2012-03-26 | 2013-04-18 | 2013-04-18 |
| NCT01513551 | The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) | COMPLETED | PHASE2 | 2012-03-13 | 2013-02-15 | 2013-02-15 |
| NCT01537757 | A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535]) | COMPLETED | PHASE1 | 2012-03 | 2012-05 | 2012-05 |
| NCT01500382 | A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) | TERMINATED | PHASE1 | 2012-02-27 | 2013-01-02 | 2013-01-02 |
| NCT01512693 | Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) | COMPLETED | PHASE1 | 2012-02-23 | 2012-04-24 | 2012-04-24 |
| NCT01545388 | Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136) | COMPLETED | PHASE3 | 2012-02-23 | 2013-03-12 | 2013-03-12 |
| NCT01527383 | A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) | COMPLETED | PHASE2 | 2012-02-21 | 2013-02-26 | 2013-02-26 |
| NCT01532973 | Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002) | COMPLETED | PHASE1 | 2012-02-16 | 2013-05-17 | 2013-05-17 |
| NCT01519778 | A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study | COMPLETED | PHASE2 | 2012-02-15 | 2012-08-27 | 2012-08-27 |
| NCT01453725 | Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) | COMPLETED | PHASE3 | 2012-02-13 | 2015-01-15 | 2014-03-11 |
| NCT01485614 | Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) | COMPLETED | PHASE3 | 2012-02-10 | 2019-10-09 | 2019-10-09 |
| NCT01513291 | A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) | COMPLETED | PHASE2 | 2012-02-06 | 2012-10-03 | 2012-10-03 |
| NCT01524289 | Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) | COMPLETED | PHASE3 | 2012-02-03 | 2018-11-13 | 2014-02-12 |
| NCT01513239 | A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) | COMPLETED | PHASE3 | 2012-02-01 | 2015-05-22 | 2015-05-22 |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer | COMPLETED | PHASE2 | 2012-02 | 2014-06 | 2014-06 |
| NCT01431547 | Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | COMPLETED | PHASE1 | 2012-02 | 2013-09 | 2013-09 |
| NCT01539473 | A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge | COMPLETED | PHASE1 | 2012-02 | 2012-05 | 2012-05 |
| NCT01724320 | A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors | UNKNOWN | PHASE1 | 2012-02 | 2013-05 | 2013-05 |
| NCT01431534 | A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) | TERMINATED | PHASE1 | 2012-01-30 | 2018-05-25 | 2013-08-20 |
| NCT01460719 | A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) | COMPLETED | PHASE1 | 2012-01-24 | 2012-09-25 | 2012-09-25 |
| NCT01512667 | Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067) | COMPLETED | PHASE1 | 2012-01-17 | 2012-08-22 | 2012-08-22 |
| NCT01496677 | Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects | COMPLETED | PHASE1 | 2012-01-17 | 2012-02-28 | 2012-02-28 |
| NCT01462266 | Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260) | COMPLETED | PHASE3 | 2012-01-13 | 2013-06-07 | 2013-06-06 |
| NCT01425190 | Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614) | TERMINATED | PHASE1 | 2012-01-04 | 2013-03-20 | 2013-03-20 |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | TERMINATED | NA | 2012-01 | 2015-08 | 2015-07 |
| NCT01508156 | Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) | COMPLETED | PHASE1, PHASE2 | 2012-01 | 2012-07 | 2012-07 |
| NCT01504165 | Pharmacokinetics in Subjects With Renal Impairment | COMPLETED | PHASE1 | 2012-01 | 2012-04 | 2012-04 |
| NCT01445678 | Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections | COMPLETED | PHASE3 | 2011-12-23 | 2013-10-15 | 2013-10-03 |
| NCT01463696 | Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) | TERMINATED | PHASE1 | 2011-12-21 | 2015-10-15 | 2014-09-15 |
| NCT01760447 | A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289) | COMPLETED | PHASE3 | 2011-12-07 | 2019-09-17 | 2019-09-17 |
| NCT01479764 | Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) | COMPLETED | PHASE3 | 2011-12-02 | 2012-11-05 | 2012-10-26 |
| NCT01254604 | Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) | COMPLETED | PHASE3 | 2011-12-01 | 2013-05-09 | 2013-05-09 |
| NCT01450319 | Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype | COMPLETED | PHASE2 | 2011-12 | 2014-12 | 2014-12 |
| NCT01496170 | A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1]) | COMPLETED | PHASE1 | 2011-12 | 2012-06 | 2012-06 |
| NCT01537120 | Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2) | COMPLETED | PHASE1 | 2011-12 | 2012-10 | 2012-10 |
| NCT02194608 | Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347) | COMPLETED | NA | 2011-12 | 2013-07 | 2013-07 |
| NCT01508325 | Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients | COMPLETED | PHASE4 | 2011-12 | 2014-04 | 2014-04 |
| NCT01463683 | Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) | COMPLETED | PHASE3 | 2011-11-29 | 2012-11-06 | 2012-11-06 |
| NCT01440595 | Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) | TERMINATED | PHASE2 | 2011-11-28 | 2012-05-01 | 2012-05-01 |
| NCT01461460 | A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects | COMPLETED | PHASE1 | 2011-11-28 | 2011-12-23 | 2011-12-23 |
| NCT01544478 | V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) | COMPLETED | PHASE4 | 2011-11-25 | 2016-08-27 | 2016-08-27 |
| NCT01425203 | The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) | COMPLETED | PHASE3 | 2011-11-23 | 2013-10-21 | 2013-10-21 |
| NCT01451437 | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) | TERMINATED | PHASE1 | 2011-11-18 | 2014-09-05 | 2014-09-05 |
| NCT01465412 | A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) | COMPLETED | PHASE1 | 2011-11-10 | 2012-06-14 | 2012-06-14 |
| NCT01358331 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | TERMINATED | PHASE1 | 2011-11-04 | 2014-05-20 | 2014-05-20 |
| NCT01473095 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | COMPLETED | PHASE1 | 2011-11 | 2017-08-07 | 2017-07-06 |
| NCT01432535 | Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655) | COMPLETED | PHASE1 | 2011-11 | 2012-08 | 2012-08 |
| NCT01451619 | A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155) | COMPLETED | PHASE1 | 2011-11 | 2012-04 | 2012-04 |
| NCT01431521 | Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008) | COMPLETED | PHASE1 | 2011-10-26 | 2012-10-01 | 2012-09-18 |
| NCT01446003 | A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1) | COMPLETED | PHASE1 | 2011-10-25 | 2012-03-03 | 2012-02-18 |
| NCT01405924 | Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) | TERMINATED | PHASE2 | 2011-10-25 | 2013-12-06 | 2013-12-06 |
| NCT01477853 | A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211) | TERMINATED | PHASE3 | 2011-10-24 | 2012-12-04 | 2012-12-04 |
| NCT01466985 | A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) | COMPLETED | PHASE1 | 2011-10-21 | 2012-04-10 | 2012-04-10 |
| NCT01390844 | Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) | COMPLETED | PHASE3 | 2011-10-21 | 2015-06-19 | 2015-06-19 |
| NCT01422304 | Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) | COMPLETED | PHASE3 | 2011-10-12 | 2012-09-26 | 2012-09-26 |
| NCT01241552 | A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) | COMPLETED | PHASE3 | 2011-10-10 | 2014-12-09 | 2014-12-09 |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | COMPLETED | PHASE2 | 2011-10 | 2015-09 | 2015-06 |
| NCT01452828 | A Pharmacokinetics and Safety Study in Subjects With Renal Impairment | COMPLETED | PHASE1 | 2011-10 | 2012-03 | 2012-03 |
| NCT01432730 | A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) | COMPLETED | PHASE2 | 2011-09-22 | 2013-02-21 | 2013-02-07 |
| NCT01421511 | TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections | COMPLETED | PHASE3 | 2011-09-15 | 2013-01-10 | 2013-01-10 |
| NCT01362530 | A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) | COMPLETED | PHASE3 | 2011-09-13 | 2013-08-16 | 2013-03-14 |
| NCT01419184 | Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA | COMPLETED | PHASE4 | 2011-09-09 | 2012-10-05 | 2012-09-01 |
| NCT01405560 | Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) | COMPLETED | PHASE3 | 2011-09-02 | 2013-03-29 | 2013-03-29 |
| NCT01370616 | Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061) | COMPLETED | PHASE3 | 2011-09-02 | 2013-12-18 | 2013-12-08 |
| NCT01396005 | A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) | COMPLETED | PHASE1 | 2011-09 | 2011-12 | 2011-12 |
| NCT01385566 | A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) | COMPLETED | PHASE1 | 2011-09 | 2013-05 | 2013-05 |
| NCT01396395 | Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina | COMPLETED | PHASE4 | 2011-09 | 2014-05 | 2014-05 |
| NCT01414166 | Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) | TERMINATED | PHASE3 | 2011-09 | 2013-02 | 2013-02 |
| NCT01419249 | First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study | COMPLETED | PHASE4 | 2011-09 | 2012-10 | 2012-10 |
| NCT01432717 | Study of ACE-536 in Healthy Postmenopausal Women | COMPLETED | PHASE1 | 2011-09 | 2012-10 | 2012-09 |
| NCT01405937 | Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) | COMPLETED | PHASE3 | 2011-08-29 | 2013-03-12 | 2013-02-26 |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | TERMINATED | PHASE1 | 2011-08-19 | 2014-12-01 | 2014-12-01 |
| NCT01385033 | [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002) | TERMINATED | PHASE1 | 2011-08-19 | 2012-05-15 | 2012-05-15 |
| NCT01405911 | Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) | COMPLETED | PHASE2 | 2011-08-16 | 2012-04-09 | 2012-04-09 |
| NCT01407276 | A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009) | COMPLETED | PHASE1 | 2011-08-08 | 2012-03-23 | 2012-03-23 |
| NCT01431833 | A PK and Safety Study in Subjects With Hepatic Impairment | COMPLETED | PHASE1 | 2011-08 | 2012-05 | 2012-05 |
| NCT01390428 | Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) | COMPLETED | PHASE1 | 2011-07-28 | 2014-09-12 | 2014-09-05 |
| NCT01357161 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | COMPLETED | PHASE2 | 2011-07-26 | 2016-08-08 | 2016-08-08 |
| NCT01377480 | A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) | COMPLETED | PHASE2 | 2011-07-06 | 2015-01-12 | 2014-07-22 |
| NCT01380184 | Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) | COMPLETED | PHASE1 | 2011-07-05 | 2012-04-05 | 2011-10-20 |
| NCT01395758 | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | COMPLETED | PHASE2 | 2011-07 | 2016-08 | 2016-08 |
| NCT01390441 | A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) | TERMINATED | PHASE1 | 2011-07 | 2014-04 | 2014-04 |
| NCT01371604 | Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) | COMPLETED | PHASE2 | 2011-07 | 2014-10 | 2013-03 |
| NCT01353911 | Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) | COMPLETED | PHASE2 | 2011-06-27 | 2015-03-10 | 2013-01-20 |
| NCT01370642 | Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) | COMPLETED | PHASE3 | 2011-06-27 | 2014-03-17 | 2013-07-31 |
| NCT01254630 | A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | COMPLETED | PHASE3 | 2011-06-24 | 2017-04-11 | 2017-04-11 |
| NCT01353898 | Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003) | TERMINATED | PHASE1 | 2011-06-21 | 2012-01-03 | 2012-01-03 |
| NCT01391546 | Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) | COMPLETED | PHASE3 | 2011-06-20 | 2012-10-15 | 2012-10-15 |
| NCT01345929 | Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis | COMPLETED | PHASE3 | 2011-06-20 | 2013-09-04 | 2013-08-11 |
| NCT01370655 | A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009) | COMPLETED | PHASE1 | 2011-06-15 | 2012-01-26 | 2011-12-19 |
| NCT01370317 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma | COMPLETED | PHASE1 | 2011-06-01 | 2011-12-27 | 2011-12-27 |
| NCT01318382 | Residual Curarization and Its Incidence at Tracheal Extubation (P08194) | COMPLETED | PHASE4 | 2011-06 | 2012-05 | 2012-05 |
| NCT01373450 | Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) | COMPLETED | PHASE1 | 2011-06 | 2011-07 | 2011-07 |
| NCT01388790 | Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer | COMPLETED | PHASE2 | 2011-06 | 2013-05 | 2012-08 |
| NCT01297465 | PERgoveriS In Stratified Treatment for Assisted Reproductive Technique | COMPLETED | PHASE3 | 2011-05-31 | 2012-10-31 | 2012-10-31 |
| NCT01340937 | A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) | COMPLETED | PHASE3 | 2011-05-10 | 2013-07-26 | 2012-12-18 |
| NCT01335997 | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) | TERMINATED | PHASE3 | 2011-05-01 | 2012-01-01 | 2012-01-01 |
| NCT01379300 | A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1) | COMPLETED | PHASE1 | 2011-05 | 2011-12 | 2011-12 |
| NCT01329913 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) | COMPLETED | PHASE1 | 2011-05 | 2012-04 | 2012-04 |
| NCT01652066 | Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults | COMPLETED | NA | 2011-05 | 2011-12 | 2011-07 |
| NCT01343407 | A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003) | COMPLETED | PHASE1 | 2011-04-19 | 2012-01-09 | 2012-01-09 |
| NCT01337167 | Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) | COMPLETED | PHASE3 | 2011-04-19 | 2013-05-09 | 2013-05-09 |
| NCT01337674 | Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010) | COMPLETED | PHASE1 | 2011-04-01 | 2011-11-01 | 2011-11-01 |
| NCT01245751 | Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) | COMPLETED | PHASE3 | 2011-04 | 2015-05 | 2012-07 |
| NCT01311882 | A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1) | COMPLETED | PHASE1 | 2011-04 | 2011-11 | 2011-11 |
| NCT01335607 | A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) | COMPLETED | PHASE1 | 2011-04 | 2011-05 | 2011-05 |
| NCT01364298 | Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management | COMPLETED | PHASE4 | 2011-04 | 2012-07 | 2012-07 |
| NCT01314872 | A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) | COMPLETED | PHASE2 | 2011-03-31 | 2013-10-10 | 2012-10-22 |
| NCT01323855 | A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512) | COMPLETED | PHASE1 | 2011-03-28 | 2011-11-29 | 2011-11-29 |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | TERMINATED | PHASE2 | 2011-03-25 | 2012-09-21 | 2012-09-21 |
| NCT01293006 | Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032) | COMPLETED | PHASE1 | 2011-03-25 | 2012-02-22 | 2012-01-20 |
| NCT01245764 | GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) | COMPLETED | PHASE3 | 2011-03-21 | 2013-04-15 | 2013-04-15 |
| NCT01300455 | Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036) | COMPLETED | PHASE1 | 2011-03-19 | 2011-08-11 | 2011-08-11 |
| NCT01296412 | Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) | COMPLETED | PHASE3 | 2011-03-11 | 2012-02-29 | 2012-02-29 |
| NCT01295827 | Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) | COMPLETED | PHASE1 | 2011-03-04 | 2018-12-11 | 2018-11-05 |
| NCT01274559 | Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) | TERMINATED | PHASE3 | 2011-03-01 | 2013-02-26 | 2013-02-26 |
| NCT01313520 | A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136) | COMPLETED | PHASE2 | 2011-03-01 | 2012-03-01 | 2012-03-01 |
| NCT01276847 | A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206) | COMPLETED | PHASE1 | 2011-03 | 2011-12 | 2011-12 |
| NCT01294800 | A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402) | COMPLETED | PHASE2 | 2011-02-25 | 2013-06-01 | 2013-06-01 |
| NCT01304498 | Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009) | COMPLETED | PHASE3 | 2011-02-23 | 2011-12-20 | 2011-12-20 |
| NCT01294683 | A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) | TERMINATED | PHASE3 | 2011-02-04 | 2012-01-17 | 2012-01-17 |
| NCT01285401 | Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment | COMPLETED | PHASE2 | 2011-02 | 2015-05 | 2015-04 |
| NCT00988728 | Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) | WITHDRAWN | PHASE2 | 2011-02 | 2012-07 | 2012-07 |
| NCT01295632 | Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) | COMPLETED | PHASE1 | 2011-02 | 2015-08 | 2013-12 |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | COMPLETED | PHASE1 | 2011-02 | 2012-05 | 2012-04 |
| NCT01275170 | A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005) | COMPLETED | PHASE1 | 2011-01-28 | 2012-03-05 | 2012-03-05 |
| NCT01177384 | Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130) | COMPLETED | PHASE3 | 2011-01-25 | 2013-03-25 | 2013-03-25 |
| NCT01299376 | MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) | COMPLETED | PHASE3 | 2011-01-24 | 2012-09-20 | 2011-11-16 |
| NCT01275755 | Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain | COMPLETED | PHASE2 | 2011-01-19 | 2011-07-15 | 2011-07-15 |
| NCT01254643 | A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | COMPLETED | PHASE3 | 2011-01-12 | 2013-08-10 | 2013-08-10 |
| NCT01302691 | MK-0954E Study in Participants With Hypertension (MK-0954E-357) | COMPLETED | PHASE3 | 2011-01-01 | 2012-04-01 | 2012-04-01 |
| NCT01327313 | A Study of EMD525797 in Solid Tumor Patients in Japan | COMPLETED | PHASE1 | 2011-01 | 2012-10 | 2012-07 |
| NCT01185015 | A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization | WITHDRAWN | PHASE4 | 2011-01 | | 2011-01 |
| NCT01271998 | Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg | COMPLETED | PHASE1 | 2010-12-08 | 2011-01-03 | 2011-01-03 |
| NCT01045798 | Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067) | TERMINATED | PHASE2 | 2010-12 | 2012-04 | 2012-04 |
| NCT01254344 | Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056) | COMPLETED | PHASE3 | 2010-12 | 2011-12 | 2011-12 |
| NCT01269658 | A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636) | TERMINATED | PHASE2 | 2010-12 | 2011-06 | 2011-06 |
| NCT01251276 | Hepatitis B Challenge Dose in Adults (V232-059-10) | COMPLETED | PHASE3 | 2010-11-30 | 2011-04-12 | 2011-04-12 |
| NCT01229267 | A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001) | COMPLETED | PHASE3 | 2010-11-30 | 2015-12-23 | 2015-12-23 |
| NCT01243762 | A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | TERMINATED | PHASE1 | 2010-11-22 | 2013-03-25 | 2012-12-04 |
| NCT01227265 | Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) | COMPLETED | PHASE3 | 2010-11-19 | 2013-04-16 | 2013-04-04 |
| NCT01215227 | An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) | TERMINATED | PHASE3 | 2010-11-18 | 2013-07-16 | 2013-07-16 |
| NCT01076088 | Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121) | COMPLETED | PHASE3 | 2010-11-15 | 2012-12-24 | 2012-12-24 |
| NCT01235728 | A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022) | COMPLETED | PHASE1 | 2010-11-01 | 2011-04-01 | 2011-04-01 |
| NCT01263314 | Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003) | COMPLETED | PHASE1 | 2010-11-01 | 2011-03-01 | 2011-02-01 |
| NCT01251146 | A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension | COMPLETED | PHASE4 | 2010-11 | 2012-02 | 2012-02 |
| NCT01244282 | A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180) | COMPLETED | PHASE1 | 2010-11 | 2011-04 | 2011-02 |
| NCT00895882 | Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) | WITHDRAWN | PHASE2 | 2010-11 | 2013-01 | 2013-01 |
| NCT01220258 | A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641) | TERMINATED | PHASE2 | 2010-11 | 2011-08 | 2011-08 |
| NCT01226901 | A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) | TERMINATED | PHASE1 | 2010-11 | 2011-11 | 2011-02 |
| NCT01225731 | A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) | COMPLETED | PHASE2 | 2010-10-25 | 2012-10-24 | 2011-11-04 |
| NCT01215188 | A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) | COMPLETED | PHASE2 | 2010-10-14 | 2012-07-31 | 2012-07-31 |
| NCT01207427 | Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain | COMPLETED | PHASE2 | 2010-10-14 | 2011-06-28 | 2011-04-18 |
| NCT01152255 | MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2) | TERMINATED | PHASE1 | 2010-10-10 | 2011-06-30 | 2011-06-30 |
| NCT01217073 | A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006) | COMPLETED | PHASE2 | 2010-10-08 | 2013-04-01 | 2012-01-03 |
| NCT01209728 | Effects of Insomnia on Simulated Driving (MK-0000-183-00) | COMPLETED | PHASE1 | 2010-10-01 | 2011-09-01 | 2011-09-01 |
| NCT01223339 | Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041) | COMPLETED | PHASE1 | 2010-10 | 2011-02 | 2011-02 |
| NCT01225536 | Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations | COMPLETED | PHASE1 | 2010-10 | 2013-03 | 2013-01 |
| NCT01239758 | Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | TERMINATED | PHASE2 | 2010-10 | 2011-05 | 2011-05 |
| NCT01234857 | A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | COMPLETED | PHASE2 | 2010-09-17 | 2013-10-15 | 2013-10-15 |
| NCT01228734 | A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients | COMPLETED | PHASE3 | 2010-09-09 | 2018-01-31 | 2016-01-25 |
| NCT01442831 | Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects | COMPLETED | PHASE1 | 2010-09-09 | 2010-09-22 | 2010-09-22 |
| NCT01220570 | The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) | COMPLETED | PHASE1 | 2010-09 | 2012-12 | 2012-12 |
| NCT01178411 | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | COMPLETED | PHASE1, PHASE2 | 2010-08-31 | 2019-01-14 | 2019-01-14 |
| NCT01244035 | Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008) | COMPLETED | PHASE1 | 2010-08-19 | 2010-12-23 | 2010-12-23 |
| NCT01189890 | Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251) | COMPLETED | PHASE3 | 2010-08-16 | 2012-10-31 | 2012-10-31 |
| NCT01170221 | TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. | COMPLETED | PHASE3 | 2010-08-15 | 2011-09-30 | 2011-09-30 |
| NCT01193049 | A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175) | COMPLETED | PHASE1 | 2010-08 | 2011-05 | 2011-05 |
| NCT01358344 | A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558) | COMPLETED | PHASE1 | 2010-08 | 2010-12 | 2010-12 |
| NCT01152242 | Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168) | COMPLETED | PHASE1 | 2010-08 | 2012-05 | 2012-05 |
| NCT01181622 | A Safety and Tolerability Study of Denufosol in 2-4 Year Olds | COMPLETED | PHASE2 | 2010-08 | 2010-10 | 2010-10 |
| NCT01360827 | EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck | TERMINATED | PHASE1 | 2010-08 | | 2011-04 |
| NCT01175707 | Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting | TERMINATED | PHASE4 | 2010-07-15 | 2011-11-17 | 2011-11-17 |
| NCT01155466 | A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938) | COMPLETED | PHASE3 | 2010-07-14 | 2012-12-20 | 2012-12-20 |
| NCT01155479 | A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664) | TERMINATED | PHASE3 | 2010-07-06 | 2013-07-16 | 2013-07-16 |
| NCT01165320 | A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) | COMPLETED | PHASE2 | 2010-07-06 | 2013-09-17 | 2013-09-17 |
| NCT01050283 | A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144) | TERMINATED | PHASE1 | 2010-07 | 2012-05 | 2012-05 |
| NCT01153958 | Colposeptine for the Treatment of Bacterial Vaginosis | TERMINATED | PHASE4 | 2010-07 | 2010-11 | 2010-11 |
| NCT01147640 | Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections | COMPLETED | PHASE2 | 2010-06-25 | 2011-03-25 | 2011-02-20 |
| NCT01340768 | Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) | COMPLETED | PHASE3 | 2010-06-22 | 2011-09-21 | 2011-09-21 |
| NCT01131182 | Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) | COMPLETED | PHASE4 | 2010-06-13 | 2010-11-04 | 2010-11-04 |
| NCT01120600 | A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053) | COMPLETED | PHASE3 | 2010-06-09 | 2013-07-22 | 2013-07-22 |
| NCT01076075 | A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229) | COMPLETED | PHASE3 | 2010-06-03 | 2012-01-19 | 2011-07-11 |
| NCT01156077 | Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients | COMPLETED | PHASE1 | 2010-06-02 | 2011-09-24 | 2011-09-24 |
| NCT01190644 | Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors | TERMINATED | PHASE2 | 2010-06-01 | 2012-10-29 | 2012-09-18 |
| NCT01125774 | Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) | COMPLETED | PHASE2, PHASE3 | 2010-06-01 | 2011-04-08 | 2011-04-08 |
| NCT01181804 | Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) | COMPLETED | PHASE1 | 2010-06 | 2010-12 | 2010-12 |
| NCT02508753 | Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects | COMPLETED | PHASE1 | 2010-06 | 2010-07 | 2010-07 |
| NCT01127308 | A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038) | COMPLETED | PHASE1 | 2010-06 | 2010-07 | 2010-07 |
| NCT01157104 | A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002) | COMPLETED | PHASE1 | 2010-06 | 2010-08 | 2010-07 |
| NCT01110616 | EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010) | COMPLETED | PHASE1 | 2010-06 | 2010-10 | 2010-10 |
| NCT01061333 | Early Airway Response to Allergen in Asthmatics (MK-0000-176) | COMPLETED | PHASE1 | 2010-06 | 2011-03 | 2011-02 |
| NCT01122667 | Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038) | COMPLETED | PHASE1 | 2010-06 | 2011-06 | 2011-06 |
| NCT01108588 | Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167) | COMPLETED | PHASE1 | 2010-06 | 2010-08 | 2010-08 |
| NCT01148901 | Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451) | WITHDRAWN | PHASE4 | 2010-06 | 2010-12 | 2010-12 |
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | TERMINATED | PHASE1, PHASE2 | 2010-05-31 | 2011-06-13 | 2011-06-13 |
| NCT01092780 | Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010) | COMPLETED | PHASE1 | 2010-05-26 | 2011-05-31 | 2011-05-31 |
| NCT01059851 | Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED) | COMPLETED | PHASE1 | 2010-05-24 | 2010-07-15 | 2010-07-15 |
| NCT01096667 | Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) | COMPLETED | PHASE2 | 2010-05-17 | 2011-02-25 | 2011-02-09 |
| NCT01097616 | Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028) | COMPLETED | PHASE3 | 2010-05-05 | 2011-12-07 | 2011-09-09 |
| NCT00993187 | Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) | COMPLETED | PHASE4 | 2010-05-04 | 2013-10-29 | 2013-10-29 |
| NCT01097629 | Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029) | COMPLETED | PHASE3 | 2010-05-03 | 2011-11-08 | 2011-11-08 |
| NCT01140061 | Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020) | COMPLETED | PHASE1 | 2010-05-01 | 2011-03-01 | 2011-03-01 |
| NCT01114568 | Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039) | COMPLETED | PHASE1 | 2010-05 | 2010-06 | 2010-06 |
| NCT01115712 | Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170) | COMPLETED | PHASE1 | 2010-05 | 2010-09 | 2010-09 |
| NCT01114490 | Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) | COMPLETED | PHASE1 | 2010-05 | 2010-07 | 2010-07 |
| NCT01130168 | The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED) | COMPLETED | PHASE1 | 2010-05 | 2010-11 | 2010-11 |
| NCT01293643 | A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) | COMPLETED | PHASE3 | 2010-05 | 2011-01 | 2011-01 |
| NCT01082328 | Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period | COMPLETED | PHASE4 | 2010-05 | 2012-05 | 2012-05 |
| NCT01073293 | A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) | COMPLETED | PHASE3 | 2010-04-22 | 2011-06-16 | 2011-06-16 |
| NCT01104662 | Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment | TERMINATED | PHASE4 | 2010-04-19 | 2012-06-12 | 2012-06-12 |
| NCT01015131 | 18F-FLT-PET in Breast Cancer (MK-0000-139) | COMPLETED | PHASE2 | 2010-04-08 | 2011-12-01 | 2011-05-24 |
| NCT01099761 | Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | TERMINATED | PHASE2 | 2010-04 | 2011-06 | 2011-06 |
| NCT01085591 | Study of CB-183,315 in Participants With Clostridium Difficile Infection | COMPLETED | PHASE2 | 2010-04-01 | 2011-05-13 | 2011-04-13 |
| NCT01093794 | Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122) | COMPLETED | PHASE1 | 2010-04 | 2010-06 | 2010-06 |
| NCT01055340 | A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED) | COMPLETED | PHASE1 | 2010-04 | 2010-06 | 2010-05 |
| NCT01111851 | Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) | COMPLETED | PHASE1 | 2010-04 | 2010-10 | 2010-10 |
| NCT01066039 | Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control | COMPLETED | PHASE4 | 2010-04 | 2013-04 | 2013-04 |
| NCT01096615 | Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens | COMPLETED | PHASE3 | 2010-04 | 2011-09 | 2011-09 |
| NCT01088711 | Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004) | COMPLETED | PHASE1 | 2010-03-11 | 2010-05-11 | 2010-05-11 |
| NCT01096160 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002) | COMPLETED | PHASE1 | 2010-03-01 | 2010-11-01 | 2010-11-01 |
| NCT01034111 | A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178) | COMPLETED | PHASE3 | 2010-03-01 | 2010-10-04 | 2010-10-04 |
| NCT01066871 | Sprifermin (AS902330) in Cartilage Injury Repair (CIR) | TERMINATED | PHASE2 | 2010-03 | 2013-04 | 2013-04 |
| NCT01071304 | Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) | COMPLETED | PHASE1 | 2010-03 | 2012-02 | 2010-09 |
| NCT01105624 | A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) | COMPLETED | PHASE4 | 2010-03 | 2010-11 | 2010-11 |
| NCT01047345 | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | COMPLETED | PHASE3 | 2010-02-24 | 2015-11-28 | 2011-06-10 |
| NCT01059825 | Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) | COMPLETED | PHASE2 | 2010-02-24 | 2011-01-20 | 2011-01-20 |
| NCT00998985 | A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004) | COMPLETED | PHASE1 | 2010-02-23 | 2012-11-08 | 2012-11-08 |
| NCT01075984 | Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520) | COMPLETED | PHASE1 | 2010-02-23 | 2012-11-20 | 2012-11-20 |
| NCT01043926 | Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017) | COMPLETED | PHASE1 | 2010-02-22 | 2010-04-14 | 2010-04-14 |
| NCT01054300 | Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) | COMPLETED | PHASE1 | 2010-02-17 | 2010-04-07 | 2010-04-07 |
| NCT01050543 | Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) | COMPLETED | PHASE3 | 2010-02-01 | 2010-08-20 | 2010-08-20 |
| NCT01071291 | Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069) | COMPLETED | PHASE1 | 2010-02 | 2010-09 | 2010-08 |
| NCT01071018 | A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) | COMPLETED | PHASE1 | 2010-02 | 2011-09 | 2011-09 |
| NCT01068145 | Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7) | TERMINATED | PHASE1 | 2010-02 | 2011-03 | 2011-03 |
| NCT01047007 | A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005 | TERMINATED | PHASE1 | 2010-01-18 | 2011-06-15 | 2011-06-15 |
| NCT01315847 | Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067) | COMPLETED | PHASE1 | 2010-01-14 | 2011-07-26 | 2011-07-26 |
| NCT00954993 | Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) | TERMINATED | PHASE1 | 2010-01-13 | 2011-03-04 | 2011-03-04 |
| NCT01026831 | Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED) | COMPLETED | PHASE3 | 2010-01-06 | 2010-09-17 | 2010-09-17 |
| NCT01019395 | Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics | COMPLETED | PHASE1 | 2010-01-05 | 2012-03-20 | 2012-03-20 |
| NCT00856960 | The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127) | COMPLETED | PHASE1 | 2010-01 | 2010-04 | 2010-03 |
| NCT00825812 | Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED) | COMPLETED | PHASE3 | 2010-01 | 2010-09 | 2010-09 |
| NCT00826176 | Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED) | COMPLETED | PHASE3 | 2010-01 | 2010-08 | 2010-08 |
| NCT01006161 | Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1) | WITHDRAWN | PHASE2 | 2010-01 | 2012-08 | 2012-08 |
| NCT01058642 | Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia | TERMINATED | PHASE2 | 2010-01 | 2010-12 | 2010-12 |
| NCT01043887 | Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) | COMPLETED | PHASE1 | 2010-01 | 2010-04 | 2010-04 |
| NCT01015677 | A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004) | TERMINATED | PHASE2 | 2009-12-17 | 2010-07-30 | 2010-07-30 |
| NCT01018823 | A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037) | COMPLETED | PHASE1 | 2009-12-14 | 2010-03-18 | 2010-03-18 |
| NCT01021813 | A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3) | COMPLETED | PHASE3 | 2009-12-10 | 2011-08-01 | 2011-05-17 |
| NCT01068262 | Safety and Tolerability of Odanacatib (0822-059) | COMPLETED | PHASE1 | 2009-12-08 | 2010-05-02 | 2010-04-26 |
| NCT01023035 | Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) | COMPLETED | PHASE3 | 2009-12-07 | 2011-10-26 | 2011-10-26 |
| NCT01025843 | Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001) | COMPLETED | PHASE1 | 2009-12-01 | 2010-05-01 | 2010-05-01 |
| NCT01190436 | A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes | COMPLETED | PHASE4 | 2009-12 | 2011-12 | 2011-12 |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | TERMINATED | PHASE3 | 2009-12 | 2015-06 | 2015-06 |
| NCT01003431 | A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) | WITHDRAWN | PHASE3 | 2009-12 | 2010-09 | 2010-08 |
| NCT01177956 | A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck | COMPLETED | PHASE3 | 2009-12 | 2012-11 | 2011-01 |
| NCT01079962 | An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION]) | COMPLETED | PHASE4 | 2009-12 | 2011-10 | 2011-10 |
| NCT01021852 | Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) | COMPLETED | PHASE2 | 2009-11-30 | 2011-02-01 | 2011-02-01 |
| NCT01021748 | A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) | COMPLETED | PHASE1 | 2009-11-23 | 2014-07-16 | 2012-11-26 |
| NCT01025791 | A Single Dose Study of MK-8266 (MK-8266-001) | COMPLETED | PHASE1 | 2009-11-18 | 2010-05-14 | 2010-05-14 |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | TERMINATED | PHASE1 | 2009-11-11 | 2010-12-22 | 2010-12-22 |
| NCT02549027 | A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003) | COMPLETED | PHASE1 | 2009-11-06 | 2010-04-06 | 2010-04-06 |
| NCT01198132 | A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly | COMPLETED | PHASE2 | 2009-11 | 2015-11 | 2015-03 |
| NCT00984568 | Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553) | TERMINATED | PHASE3 | 2009-11 | 2012-03 | 2012-03 |
| NCT00959699 | A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) | COMPLETED | PHASE2 | 2009-11 | 2012-10 | 2012-05 |
| NCT00996801 | MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) | COMPLETED | PHASE2 | 2009-11 | 2011-06 | 2011-06 |
| NCT01012219 | A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED) | COMPLETED | PHASE1 | 2009-11 | 2010-04 | 2010-03 |
| NCT00968617 | A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) | TERMINATED | PHASE2 | 2009-11 | 2010-05 | 2010-04 |
| NCT00990808 | The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3) | COMPLETED | PHASE1 | 2009-11 | 2011-07 | 2011-06 |
| NCT01011166 | Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) | COMPLETED | PHASE2 | 2009-11 | 2010-07 | 2010-07 |
| NCT01010672 | Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) | COMPLETED | PHASE2 | 2009-11 | 2013-01 | 2011-09 |
| NCT00943761 | A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) | COMPLETED | PHASE2 | 2009-10-23 | 2013-05-29 | 2013-05-29 |
| NCT00988884 | A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) | COMPLETED | PHASE3 | 2009-10-21 | 2011-02-22 | 2011-02-22 |
| NCT00989079 | A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) | COMPLETED | PHASE1 | 2009-10-16 | 2009-12-11 | 2009-12-11 |
| NCT00733122 | Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034) | WITHDRAWN | PHASE3 | 2009-10-01 | 2013-10-01 | 2013-10-01 |
| NCT01006616 | Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019) | TERMINATED | PHASE2 | 2009-10-01 | 2011-11-01 | 2011-03-01 |
| NCT00833053 | Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) | TERMINATED | PHASE3 | 2009-10 | 2011-04 | 2011-04 |
| NCT01106287 | Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027) | COMPLETED | PHASE1 | 2009-10 | 2010-03 | 2010-01 |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | COMPLETED | PHASE1, PHASE2 | 2009-10 | 2015-04 | 2015-04 |
| NCT00917696 | Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED) | COMPLETED | PHASE1 | 2009-10 | 2011-06 | 2011-06 |
| NCT00979953 | Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee | COMPLETED | PHASE2 | 2009-10 | 2010-06 | 2010-04 |
| NCT00960934 | A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001) | TERMINATED | PHASE2 | 2009-10 | 2010-12 | 2010-12 |
| NCT00961636 | A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) | COMPLETED | PHASE3 | 2009-10 | 2011-01 | 2011-01 |
| NCT01074307 | A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea | COMPLETED | PHASE4 | 2009-10 | 2012-08 | 2012-08 |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | COMPLETED | PHASE1 | 2009-10 | 2012-10 | 2012-06 |
| NCT01014078 | A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease | COMPLETED | PHASE4 | 2009-10 | 2010-03 | 2010-03 |
| NCT01215175 | Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) | COMPLETED | PHASE1 | 2009-09-25 | 2011-01-05 | 2010-04-16 |
| NCT00954512 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | TERMINATED | PHASE1, PHASE2 | 2009-09-25 | 2011-06-07 | 2011-06-07 |
| NCT00963547 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | TERMINATED | PHASE1 | 2009-09-15 | 2011-12-22 | 2011-08-09 |
| NCT00988065 | Sugammadex Hypersensitivity Study (Study P06042) | COMPLETED | PHASE1 | 2009-09-06 | 2010-04-13 | 2010-04-13 |
| NCT00975130 | Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) | COMPLETED | PHASE3 | 2009-09 | 2012-02 | 2011-08 |
| NCT00844805 | Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) | COMPLETED | PHASE3 | 2009-09 | 2011-09 | 2011-04 |
| NCT00983255 | Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) | COMPLETED | PHASE1 | 2009-09 | 2010-01 | 2010-01 |
| NCT00979459 | A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED) | COMPLETED | PHASE1 | 2009-09 | 2009-12 | 2009-11 |
| NCT00953056 | A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED) | COMPLETED | PHASE1 | 2009-09 | 2010-03 | 2010-03 |
| NCT00977288 | A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) | COMPLETED | PHASE2 | 2009-09 | 2014-04 | 2010-03 |
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | COMPLETED | PHASE1 | 2009-09 | 2011-10 | 2011-10 |
| NCT00827177 | Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2009-09 | 2013-05 | 2012-09 |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | COMPLETED | PHASE2 | 2009-09 | 2012-03 | 2011-10 |
| NCT00943722 | A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | COMPLETED | PHASE3 | 2009-08-27 | 2021-04-22 | 2011-04-30 |
| NCT00952341 | Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) | COMPLETED | PHASE3 | 2009-08-25 | 2010-05-05 | 2010-04-04 |
| NCT00972322 | Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012) | COMPLETED | PHASE1 | 2009-08-24 | 2010-01-26 | 2010-01-12 |
| NCT00954538 | Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001) | COMPLETED | PHASE1 | 2009-08 | 2011-05 | 2011-05 |
| NCT00896233 | Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED) | COMPLETED | PHASE1 | 2009-08 | 2010-01 | 2010-01 |
| NCT00825487 | Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies | COMPLETED | PHASE1 | 2009-08 | 2011-09 | 2011-05 |
| NCT00952887 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women | COMPLETED | PHASE1 | 2009-08 | 2011-02 | 2011-02 |
| NCT00907517 | Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | TERMINATED | PHASE1 | 2009-07-29 | 2011-06-13 | 2011-06-13 |
| NCT02549014 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001) | COMPLETED | PHASE1 | 2009-07-06 | 2009-09-29 | 2009-09-29 |
| NCT01010906 | A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005) | COMPLETED | PHASE1 | 2009-07-01 | 2010-06-21 | 2010-06-11 |
| NCT02835118 | A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009) | COMPLETED | PHASE1 | 2009-07 | 2009-10 | 2009-10 |
| NCT00935259 | Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED) | COMPLETED | PHASE1 | 2009-07 | 2009-10 | 2009-10 |
| NCT00934466 | Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) | COMPLETED | PHASE1 | 2009-07 | 2009-12 | 2009-12 |
| NCT00971932 | Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | COMPLETED | PHASE2 | 2009-07 | | 2011-03 |
| NCT00921024 | Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections | COMPLETED | PHASE2 | 2009-06-30 | 2010-03-11 | 2010-02-25 |
| NCT00941603 | Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675) | COMPLETED | PHASE2 | 2009-06-29 | 2010-02-22 | 2010-02-22 |
| NCT00910624 | Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) | COMPLETED | PHASE3 | 2009-06-22 | 2012-12-07 | 2012-12-07 |
| NCT00925015 | Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | COMPLETED | PHASE1 | 2009-06-17 | 2010-12-06 | 2010-07-28 |
| NCT00931606 | Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) | TERMINATED | PHASE2 | 2009-06-01 | 2010-11-18 | 2010-11-18 |
| NCT01777763 | Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615) | COMPLETED | PHASE1 | 2009-06 | 2012-02 | 2012-02 |
| NCT00924781 | A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) | TERMINATED | PHASE2 | 2009-06 | 2010-05 | 2010-04 |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | TERMINATED | PHASE1 | 2009-06 | 2010-06 | 2010-04 |
| NCT00888940 | Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery | COMPLETED | PHASE2 | 2009-06 | 2010-01 | 2009-12 |
| NCT01033643 | A Multiple Dose Study of MK-3614 (MK-3614-002) | COMPLETED | PHASE1 | 2009-05-27 | 2009-12-09 | 2009-12-09 |
| NCT00888238 | A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179) | COMPLETED | PHASE1 | 2009-05-12 | 2009-07-21 | 2009-06-10 |
| NCT00914212 | A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103) | COMPLETED | PHASE1 | 2009-05 | 2009-08 | 2009-08 |
| NCT00902161 | A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED) | COMPLETED | PHASE1 | 2009-05 | 2009-11 | 2009-10 |
| NCT00894530 | The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) | COMPLETED | PHASE2 | 2009-05 | 2009-12 | 2009-12 |
| NCT00882557 | Study to Evaluate Daptomycin Given During Dialysis and After Dialysis | COMPLETED | PHASE1 | 2009-04-29 | 2009-07-17 | 2009-07-17 |
| NCT00874731 | A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) | COMPLETED | PHASE1 | 2009-04-28 | 2010-04-30 | 2009-10-30 |
| NCT00832377 | COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED) | COMPLETED | PHASE2 | 2009-04-24 | 2010-03-26 | 2010-03-12 |
| NCT00845000 | Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) | COMPLETED | PHASE1 | 2009-04-21 | 2010-05-14 | 2010-04-30 |
| NCT00880763 | A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) | COMPLETED | PHASE2 | 2009-04-20 | 2012-02-23 | 2010-06-03 |
| NCT00875056 | Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) | COMPLETED | PHASE2 | 2009-04-15 | 2019-02-08 | 2011-09-06 |
| NCT00885352 | Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128) | COMPLETED | PHASE3 | 2009-04-15 | 2010-11-10 | 2010-11-10 |
| NCT00885170 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042) | COMPLETED | PHASE2 | 2009-04-13 | 2011-09-15 | 2011-09-15 |
| NCT00874939 | A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023) | TERMINATED | PHASE1 | 2009-04-06 | 2009-04-20 | 2009-04-20 |
| NCT00872001 | The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED) | TERMINATED | PHASE3 | 2009-04 | 2010-10 | 2010-10 |
| NCT00804843 | Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) | COMPLETED | PHASE2 | 2009-04 | 2010-10 | 2010-10 |
| NCT00837941 | A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115) | WITHDRAWN | PHASE2 | 2009-04 | 2009-09 | 2009-08 |
| NCT00828269 | Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123) | COMPLETED | PHASE1 | 2009-04 | 2010-03 | 2010-02 |
| NCT00880568 | Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED) | COMPLETED | PHASE1 | 2009-04 | 2011-01 | 2010-11 |
| NCT00879866 | EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE1 | 2009-04 | 2012-09 | 2011-02 |
| NCT00892970 | The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period | COMPLETED | PHASE2 | 2009-04 | 2010-01 | 2010-01 |
| NCT00704405 | Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) | COMPLETED | PHASE2 | 2009-03-27 | 2012-09-10 | 2012-03-26 |
| NCT00868790 | A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009) | TERMINATED | PHASE2 | 2009-03-24 | 2010-07-13 | 2010-07-12 |
| NCT00848718 | A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | COMPLETED | PHASE1 | 2009-03-17 | 2012-05-17 | 2011-05-19 |
| NCT00860392 | A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110) | COMPLETED | PHASE1 | 2009-03-02 | 2009-07-08 | 2009-07-08 |
| NCT00708201 | A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy | COMPLETED | PHASE4 | 2009-03 | 2012-01 | 2012-01 |
| NCT00886613 | A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003) | COMPLETED | PHASE1 | 2009-03 | 2009-12 | 2009-12 |
| NCT00827918 | A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) | COMPLETED | PHASE2 | 2009-03 | 2010-04 | 2010-04 |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | TERMINATED | PHASE2 | 2009-03 | 2010-12 | 2010-12 |
| NCT00869596 | Study of Biomarkers of Airway Inflammation (0000-128) | COMPLETED | PHASE1 | 2009-03 | 2009-09 | 2009-09 |
| NCT00816023 | A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume | COMPLETED | PHASE2 | 2009-03 | 2010-01 | 2009-12 |
| NCT00871871 | Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed) | COMPLETED | PHASE1 | 2009-03 | 2010-03 | 2010-02 |
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) | TERMINATED | PHASE2 | 2009-03 | 2012-08 | 2012-08 |
| NCT00865098 | Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | COMPLETED | PHASE2 | 2009-03 | 2010-06 | 2010-06 |
| NCT01081626 | Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction | COMPLETED | PHASE4 | 2009-03 | 2011-03 | 2011-03 |
| NCT00874042 | Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2009-03 | 2011-04 | 2011-02 |
| NCT00858234 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | COMPLETED | PHASE1 | 2009-02-13 | 2012-04-19 | 2010-06-11 |
| NCT00638157 | Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) | TERMINATED | PHASE4 | 2009-02-13 | 2011-11-09 | 2011-11-09 |
| NCT00764660 | Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) | TERMINATED | PHASE2 | 2009-02-13 | 2010-07-08 | 2010-05-28 |
| NCT00818259 | A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) | TERMINATED | PHASE1 | 2009-02-05 | 2014-01-20 | 2014-01-20 |
| NCT00837577 | MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104) | COMPLETED | PHASE3 | 2009-02-05 | 2010-08-11 | 2010-08-11 |
| NCT00828061 | A Study of the Effects of Single Dose Corticosteroids on Response to Allergens | COMPLETED | PHASE1 | 2009-02-04 | 2009-05-21 | 2009-05-07 |
| NCT00836927 | Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) | TERMINATED | PHASE2 | 2009-02-01 | 2018-02-04 | 2017-04-03 |
| NCT00845065 | Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED) | COMPLETED | PHASE3 | 2009-02 | 2010-10 | 2010-10 |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE2 | 2009-02 | 2013-07 | 2013-07 |
| NCT00876655 | Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate | COMPLETED | PHASE1 | 2009-02 | 2009-03 | 2009-03 |
| NCT00729742 | Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) | COMPLETED | PHASE1 | 2009-02 | 2011-05 | 2010-06 |
| NCT00848510 | EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases | COMPLETED | PHASE1 | 2009-02 | 2013-11 | 2013-11 |
| NCT00846781 | Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) | TERMINATED | PHASE3 | 2009-02 | 2011-02 | 2011-02 |
| NCT01012258 | Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects | COMPLETED | PHASE3 | 2009-02 | 2014-05 | 2010-09 |
| NCT00778830 | Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | COMPLETED | PHASE1, PHASE2 | 2009-02 | 2014-04 | 2014-04 |
| NCT00945321 | A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) | COMPLETED | PHASE1 | 2009-02 | 2009-03 | 2009-03 |
| NCT00819039 | A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) | COMPLETED | PHASE1 | 2009-01-26 | 2013-03-12 | 2013-03-12 |
| NCT00599755 | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | COMPLETED | PHASE1 | 2009-01-01 | 2011-04-13 | 2010-06-10 |
| NCT00822237 | Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) | COMPLETED | PHASE3 | 2009-01 | 2009-12 | 2009-10 |
| NCT02835105 | A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008) | COMPLETED | PHASE1 | 2009-01 | 2009-03 | 2009-03 |
| NCT00792935 | A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017) | COMPLETED | PHASE2 | 2009-01 | 2010-02 | 2010-02 |
| NCT00800865 | A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED) | COMPLETED | PHASE1 | 2009-01 | 2009-10 | 2009-10 |
| NCT00824616 | A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018) | COMPLETED | PHASE2 | 2009-01 | 2010-05 | 2010-05 |
| NCT00836498 | A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027) | TERMINATED | PHASE1 | 2009-01 | 2010-01 | 2010-01 |
| NCT00830791 | A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02) | TERMINATED | PHASE1 | 2009-01 | 2009-09 | 2009-09 |
| NCT00798213 | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | TERMINATED | PHASE2 | 2009-01 | 2010-04 | 2010-04 |
| NCT00831662 | The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637) | COMPLETED | PHASE3 | 2009-01 | 2009-12 | 2009-12 |
| NCT00820755 | Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE3 | 2009-01 | 2013-06 | 2011-12 |
| NCT00802555 | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | COMPLETED | PHASE1 | 2009-01 | 2011-12 | 2011-12 |
| NCT00834106 | Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) | COMPLETED | PHASE3 | 2008-12-31 | 2016-09-30 | 2012-05-11 |
| NCT00696709 | A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED) | COMPLETED | PHASE1 | 2008-12-12 | 2009-11-16 | 2009-11-16 |
| NCT00790205 | Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) | COMPLETED | PHASE3 | 2008-12-10 | 2015-03-30 | 2015-03-30 |
| NCT00813995 | A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074) | COMPLETED | PHASE3 | 2008-12-09 | 2010-08-09 | 2010-08-09 |
| NCT00758836 | A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) | COMPLETED | PHASE2 | 2008-12-03 | 2009-08-24 | 2009-08-24 |
| NCT00830076 | A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110) | COMPLETED | PHASE1 | 2008-12-02 | 2009-05-14 | 2009-04-30 |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | COMPLETED | PHASE3 | 2008-12-01 | 2015-06-30 | 2011-09-08 |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | COMPLETED | PHASE2 | 2008-12-01 | 2012-04-09 | 2011-05-16 |
| NCT00771316 | Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054) | TERMINATED | PHASE3 | 2008-12 | 2009-06 | 2009-06 |
| NCT00813709 | Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) | COMPLETED | PHASE3 | 2008-12 | 2013-09 | 2011-08 |
| NCT00807001 | Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects | COMPLETED | PHASE1, PHASE2 | 2008-12 | 2009-07 | 2009-07 |
| NCT00803894 | A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor | COMPLETED | PHASE1 | 2008-12 | 2009-01 | 2009-01 |
| NCT00846391 | A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2) | TERMINATED | PHASE2 | 2008-12 | 2009-08 | 2009-08 |
| NCT00820664 | A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women | COMPLETED | PHASE1 | 2008-12 | 2009-05 | 2009-05 |
| NCT00806585 | Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007) | TERMINATED | PHASE2 | 2008-12 | 2010-06 | 2010-03 |
| NCT00960115 | Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | COMPLETED | PHASE1, PHASE2 | 2008-12 | 2015-06 | 2014-05 |
| NCT00777608 | A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED) | COMPLETED | PHASE1 | 2008-12 | 2010-04 | 2009-10 |
| NCT00873821 | A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED) | COMPLETED | PHASE1 | 2008-12 | 2009-05 | 2009-05 |
| NCT01104558 | Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients. | COMPLETED | PHASE4 | 2008-12 | 2010-07 | 2010-07 |
| NCT00832624 | The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118) | TERMINATED | PHASE4 | 2008-11-26 | 2009-09-02 | 2009-09-02 |
| NCT00797667 | MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) | TERMINATED | PHASE2 | 2008-11-12 | 2009-05-20 | 2009-05-20 |
| NCT00792298 | Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) | COMPLETED | PHASE2 | 2008-11-05 | 2009-12-26 | 2009-12-26 |
| NCT01104545 | A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED) | COMPLETED | PHASE1 | 2008-11-01 | 2009-05-01 | 2009-05-01 |
| NCT00811642 | Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) | COMPLETED | PHASE3 | 2008-11 | 2010-03 | 2010-03 |
| NCT00752622 | Treatment With Infliximab in a Medical Setting (Study P05587) | TERMINATED | PHASE4 | 2008-11 | 2010-06 | 2010-06 |
| NCT00811928 | Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED) | COMPLETED | PHASE3 | 2008-11 | 2010-05 | 2010-05 |
| NCT00791661 | MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) | COMPLETED | PHASE1 | 2008-11 | 2009-03 | 2009-03 |
| NCT00729222 | Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503) | COMPLETED | PHASE2 | 2008-11 | 2009-03 | 2009-03 |
| NCT00751179 | Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED) | COMPLETED | PHASE3 | 2008-11 | 2009-12 | 2009-12 |
| NCT00797745 | A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) | COMPLETED | PHASE2 | 2008-11 | 2010-09 | 2009-07 |
| NCT01075815 | A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age | TERMINATED | PHASE2 | 2008-11 | 2010-10 | 2010-10 |
| NCT01185704 | Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) | COMPLETED | PHASE3 | 2008-11 | 2012-02 | 2011-10 |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | COMPLETED | PHASE1 | 2008-10-17 | 2011-05-28 | 2011-05-28 |
| NCT00750919 | Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) | TERMINATED | PHASE3 | 2008-10-07 | 2010-03-10 | 2010-03-10 |
| NCT00729183 | Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) | COMPLETED | PHASE3 | 2008-10-02 | 2011-03-21 | 2010-03-23 |
| NCT00638963 | Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) | TERMINATED | PHASE2 | 2008-10-02 | 2010-06-30 | 2010-06-30 |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | COMPLETED | PHASE1 | 2008-10 | 2011-03 | 2010-09 |
| NCT00764946 | A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) | COMPLETED | PHASE3 | 2008-10 | 2011-02 | 2011-02 |
| NCT00790556 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED) | COMPLETED | PHASE1 | 2008-10 | 2009-09 | 2009-09 |
| NCT00848484 | Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED) | COMPLETED | PHASE2 | 2008-10 | 2009-06 | 2009-06 |
| NCT00777959 | Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | COMPLETED | PHASE2 | 2008-10 | 2011-06 | 2011-05 |
| NCT00758485 | Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) | COMPLETED | PHASE3 | 2008-10 | 2009-06 | 2009-05 |
| NCT00912002 | A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED) | COMPLETED | PHASE1 | 2008-10 | 2009-01 | 2008-11 |
| NCT00767000 | Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED) | TERMINATED | PHASE2 | 2008-10 | 2010-06 | 2010-04 |
| NCT00781846 | Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | COMPLETED | PHASE1 | 2008-10 | 2010-02 | 2010-02 |
| NCT01033994 | A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery | COMPLETED | PHASE1 | 2008-10 | 2010-12 | 2010-10 |
| NCT00705016 | Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | COMPLETED | PHASE1, PHASE2 | 2008-10 | 2013-06 | 2011-09 |
| NCT00759785 | A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) | COMPLETED | PHASE1 | 2008-09-30 | 2010-02-17 | 2010-02-17 |
| NCT00702715 | Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769) | COMPLETED | PHASE3 | 2008-09-24 | 2010-03-15 | 2010-03-15 |
| NCT00761215 | Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections | COMPLETED | PHASE2 | 2008-09-17 | 2009-02-24 | 2009-02-24 |
| NCT00695903 | Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia | TERMINATED | PHASE2 | 2008-09-17 | 2010-10-01 | 2010-08-24 |
| NCT00722371 | MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) | COMPLETED | PHASE3 | 2008-09-05 | 2011-03-25 | 2010-10-26 |
| NCT00768521 | A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) | COMPLETED | PHASE1 | 2008-09-03 | 2009-01-19 | 2009-01-19 |
| NCT00770341 | A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) | COMPLETED | PHASE3 | 2008-09 | 2010-02 | 2010-02 |
| NCT00745823 | A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071) | TERMINATED | PHASE3 | 2008-09 | 2011-05 | 2010-10 |
| NCT00782418 | A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED) | COMPLETED | PHASE1 | 2008-09 | 2009-03 | 2009-02 |
| NCT00692458 | A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029) | WITHDRAWN | PHASE3 | 2008-09 | 2008-09 | 2008-09 |
| NCT00691899 | A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) | WITHDRAWN | PHASE3 | 2008-09 | 2008-09 | 2008-09 |
| NCT00767793 | A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650) | COMPLETED | PHASE1 | 2008-09 | 2009-05 | 2009-05 |
| NCT00757939 | A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED) | COMPLETED | PHASE1 | 2008-09 | 2010-10 | 2010-10 |
| NCT00768170 | MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028) | COMPLETED | PHASE1 | 2008-09 | 2009-05 | 2009-05 |
| NCT00746512 | A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088) | COMPLETED | PHASE1 | 2008-09 | 2009-09 | 2009-09 |
| NCT00664287 | Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) | WITHDRAWN | PHASE3 | 2008-09 | | 2009-11 |
| NCT00754130 | MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). | COMPLETED | PHASE1 | 2008-09 | 2008-10 | 2008-10 |
| NCT00972543 | Raptiva in Palm and Sole Psoriasis | TERMINATED | PHASE4 | 2008-09 | | 2009-05 |
| NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | COMPLETED | PHASE2 | 2008-09 | 2011-08 | 2011-05 |
| NCT00755638 | A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers | COMPLETED | PHASE1 | 2008-09 | 2009-07 | 2009-07 |
| NCT00483704 | Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) | COMPLETED | PHASE3 | 2008-08-14 | 2009-03-25 | 2009-03-25 |
| NCT00694356 | Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) | COMPLETED | PHASE1 | 2008-08-04 | 2009-04-28 | 2009-03-18 |
| NCT00708500 | Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) | COMPLETED | PHASE3 | 2008-08 | 2010-04 | 2010-04 |
| NCT00705432 | Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) | COMPLETED | PHASE3 | 2008-08 | 2010-05 | 2010-05 |
| NCT00718237 | Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED) | COMPLETED | PHASE3 | 2008-08 | 2009-08 | 2009-08 |
| NCT00717860 | A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) | COMPLETED | PHASE3 | 2008-08 | 2010-07 | 2010-07 |
| NCT00758680 | A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED) | TERMINATED | PHASE1 | 2008-08 | 2010-03 | 2010-03 |
| NCT00703261 | Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED) | COMPLETED | PHASE1 | 2008-08 | 2009-12 | 2009-12 |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | COMPLETED | PHASE2 | 2008-08 | 2012-07 | 2011-02 |
| NCT00751413 | Plasma Levels of MK0633 in Children Ages 6-12 (0633-023) | COMPLETED | PHASE1 | 2008-08 | 2009-01 | 2009-01 |
| NCT00771472 | Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | COMPLETED | PHASE1 | 2008-08 | 2011-07 | 2011-07 |
| NCT00572910 | A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) | COMPLETED | PHASE2 | 2008-08 | 2010-01 | 2010-01 |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | COMPLETED | PHASE1 | 2008-08 | 2011-04 | 2011-04 |
| NCT00829244 | CONSORT Randomized Controlled Trial in Assisted Reproductive Technology | COMPLETED | PHASE4 | 2008-08 | 2010-01 | 2010-01 |
| NCT01210144 | EXpression PRofile Endometrium Samples Study | TERMINATED | PHASE4 | 2008-08 | 2010-08 | 2010-08 |
| NCT00704184 | Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) | COMPLETED | PHASE2 | 2008-07-25 | 2010-04-14 | 2008-12-12 |
| NCT00725725 | Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) | TERMINATED | PHASE2 | 2008-07-23 | 2010-04-23 | 2010-04-23 |
| NCT00711802 | Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections | COMPLETED | PHASE4 | 2008-07-23 | 2013-10-11 | 2013-10-11 |
| NCT00496626 | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | COMPLETED | PHASE3 | 2008-07-20 | 2009-02-28 | 2009-02-28 |
| NCT00730275 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081) | COMPLETED | PHASE1 | 2008-07-18 | 2011-02-14 | 2010-12-30 |
| NCT00724932 | Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699) | COMPLETED | PHASE3 | 2008-07-16 | 2009-05-03 | 2009-04-01 |
| NCT00617123 | Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) | COMPLETED | PHASE3 | 2008-07-01 | 2010-10-01 | 2010-10-01 |
| NCT00732810 | SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | COMPLETED | PHASE2 | 2008-07 | 2011-06 | 2011-06 |
| NCT00789321 | A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED) | COMPLETED | PHASE1 | 2008-07 | 2009-03 | 2009-02 |
| NCT00736970 | Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | COMPLETED | PHASE2 | 2008-07 | 2011-05 | 2011-01 |
| NCT00730431 | Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) | COMPLETED | PHASE1 | 2008-07 | 2008-10 | 2008-10 |
| NCT00730379 | A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) | COMPLETED | PHASE1 | 2008-07 | 2010-11 | 2010-11 |
| NCT00712725 | MK3207 for Treatment of Acute Migraines (3207-005) | COMPLETED | PHASE2 | 2008-07 | 2009-01 | 2009-01 |
| NCT00686725 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | COMPLETED | PHASE4 | 2008-06-24 | 2011-09-28 | 2011-09-28 |
| NCT00687271 | A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006) | COMPLETED | PHASE2 | 2008-06-14 | 2009-01-08 | 2009-01-08 |
| NCT00694083 | Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) | COMPLETED | PHASE1 | 2008-06-10 | 2009-09-06 | 2009-09-06 |
| NCT00642993 | Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED) | COMPLETED | PHASE2 | 2008-06-09 | 2009-01-30 | 2009-01-30 |
| NCT00679835 | PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections | COMPLETED | PHASE1 | 2008-06-03 | 2008-11-20 | 2008-11-20 |
| NCT00688467 | Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363) | COMPLETED | PHASE2 | 2008-06-01 | 2009-03-01 | 2009-03-01 |
| NCT00730912 | Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539) | COMPLETED | PHASE4 | 2008-06 | 2008-12 | 2008-12 |
| NCT01000818 | A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) | COMPLETED | PHASE1 | 2008-06 | 2009-03 | 2009-03 |
| NCT00847197 | A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) | COMPLETED | PHASE2 | 2008-06 | 2009-09 | 2009-09 |
| NCT00772967 | A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED) | COMPLETED | PHASE1 | 2008-06 | 2008-11 | 2008-11 |
| NCT00692614 | A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001) | TERMINATED | PHASE2 | 2008-06 | 2008-11 | 2008-11 |
| NCT00678535 | Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer | COMPLETED | PHASE3 | 2008-06 | 2013-02 | 2012-03 |
| NCT00681031 | Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) | COMPLETED | PHASE4 | 2008-05-14 | 2008-06-25 | 2008-06-25 |
| NCT00632502 | Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED) | COMPLETED | PHASE2 | 2008-05-01 | 2009-02-01 | 2009-02-01 |
| NCT00652509 | Journey for Control of Diabetes Study (0431-111) | COMPLETED | NA | 2008-05-01 | 2011-07-01 | 2010-03-01 |
| NCT00496054 | Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021) | COMPLETED | PHASE3 | 2008-05 | 2008-10 | 2008-10 |
| NCT00701090 | A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED) | COMPLETED | PHASE3 | 2008-05 | 2009-10 | 2009-10 |
| NCT00799708 | A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED) | COMPLETED | PHASE1 | 2008-05 | 2008-10 | 2008-10 |
| NCT00673062 | Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED) | COMPLETED | PHASE2 | 2008-05 | 2008-07 | 2008-07 |
| NCT00646789 | A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019) | COMPLETED | PHASE1 | 2008-05 | 2008-07 | 2008-07 |
| NCT00675792 | Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) | COMPLETED | PHASE3 | 2008-05 | 2008-09 | 2008-09 |
| NCT00673465 | Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED) | COMPLETED | PHASE1 | 2008-04-17 | 2008-12-11 | 2008-12-11 |
| NCT01716234 | A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579) | TERMINATED | PHASE1 | 2008-04-17 | 2015-04-01 | 2015-04-01 |
| NCT00670488 | Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) | COMPLETED | PHASE1 | 2008-04-15 | 2011-07-11 | 2011-07-11 |
| NCT00666601 | Microdialysis and Pharmacokinetic Study of TR-701 | COMPLETED | PHASE1 | 2008-04-04 | 2008-08-12 | 2008-08-12 |
| NCT00610441 | Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003) | COMPLETED | PHASE2 | 2008-04-01 | 2009-03-09 | 2009-03-02 |
| NCT01014013 | Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055) | COMPLETED | PHASE3 | 2008-04 | 2009-02 | 2009-02 |
| NCT00757601 | A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED) | COMPLETED | PHASE1 | 2008-04 | 2008-12 | 2008-12 |
| NCT00656799 | Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) | COMPLETED | PHASE3 | 2008-04 | 2009-07 | 2009-07 |
| NCT00739882 | TRUST Study: Raptiva ® in Hand & Foot Psoriasis | TERMINATED | PHASE4 | 2008-04 | 2009-06 | 2009-06 |
| NCT01012102 | EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2008-04 | 2011-09 | 2009-10 |
| NCT00656539 | Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis | COMPLETED | PHASE4 | 2008-04 | | 2008-11 |
| NCT00658554 | Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers | COMPLETED | PHASE1 | 2008-04 | 2008-06 | 2008-05 |
| NCT00543387 | Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001) | COMPLETED | PHASE1 | 2008-03-27 | 2011-04-04 | 2011-04-04 |
| NCT00685776 | Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) | COMPLETED | PHASE3 | 2008-03-24 | 2017-11-23 | 2009-07-02 |
| NCT00654420 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | COMPLETED | PHASE2 | 2008-03-19 | 2012-02-13 | 2009-11-25 |
| NCT00662818 | Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) | COMPLETED | PHASE3 | 2008-03-17 | 2009-09-02 | 2009-09-02 |
| NCT00671359 | Food Effects of Single Oral Dose of 600mg TR-701 | COMPLETED | PHASE1 | 2008-03-10 | 2008-05-15 | 2008-05-15 |
| NCT00631657 | A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002) | COMPLETED | PHASE3 | 2008-03-04 | 2009-11-19 | 2009-11-19 |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | TERMINATED | PHASE2 | 2008-03-04 | 2011-01-07 | 2011-01-06 |
| NCT00833027 | ALPHA Sitagliptin Add on to Metformin (0431-103) | COMPLETED | PHASE4 | 2008-03-01 | 2009-10-30 | 2009-10-30 |
| NCT00835380 | A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069) | COMPLETED | PHASE3 | 2008-03 | 2008-10 | 2008-10 |
| NCT00664521 | Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III) | COMPLETED | PHASE2 | 2008-03 | 2010-10 | 2010-10 |
| NCT00735839 | V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED) | COMPLETED | PHASE1 | 2008-03 | 2008-06 | 2008-06 |
| NCT00635830 | An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035) | COMPLETED | PHASE1 | 2008-03 | 2008-04 | 2008-04 |
| NCT00966030 | Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042) | COMPLETED | PHASE1 | 2008-03 | 2008-05 | 2008-05 |
| NCT01104519 | A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093) | COMPLETED | PHASE1 | 2008-03 | 2008-07 | 2008-07 |
| NCT00965887 | Bioequivalence of Two Tablet Forms of MK0974 (0974-045) | COMPLETED | PHASE1 | 2008-03 | 2008-05 | 2008-05 |
| NCT00632073 | Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241) | COMPLETED | PHASE1 | 2008-03 | 2010-03 | 2009-07 |
| NCT00642798 | An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED) | COMPLETED | PHASE1 | 2008-03 | 2008-03 | 2008-03 |
| NCT00629590 | Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis | COMPLETED | PHASE4 | 2008-03 | | 2008-07 |
| NCT00575367 | Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers | COMPLETED | PHASE4 | 2008-03 | | 2008-10 |
| NCT00629941 | Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis | COMPLETED | PHASE4 | 2008-03 | | 2008-08 |
| NCT00651638 | A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype | COMPLETED | PHASE1 | 2008-03 | 2008-06 | 2008-05 |
| NCT00648648 | A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001) | COMPLETED | PHASE1 | 2008-02-25 | 2014-01-06 | 2014-01-06 |
| NCT00604188 | A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) | COMPLETED | PHASE4 | 2008-02-22 | 2009-12-10 | 2009-12-10 |
| NCT00635804 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002) | COMPLETED | PHASE1 | 2008-02-19 | 2009-12-22 | 2009-12-22 |
| NCT00642954 | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | COMPLETED | PHASE1 | 2008-02-13 | 2013-08-20 | 2012-09-03 |
| NCT01294709 | A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) | COMPLETED | PHASE1 | 2008-02-12 | 2009-03-13 | 2009-02-28 |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | TERMINATED | PHASE2 | 2008-02-01 | 2013-08-31 | 2011-08-31 |
| NCT00839917 | A Study of ProQuad™ in Healthy Children in Korea (V221-023) | TERMINATED | PHASE3 | 2008-02 | 2008-05 | 2008-05 |
| NCT00619359 | Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) | COMPLETED | PHASE3 | 2008-02 | 2009-06 | 2009-06 |
| NCT00631488 | A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015) | COMPLETED | PHASE2 | 2008-02 | 2009-01 | 2009-01 |
| NCT00625612 | Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease | COMPLETED | PHASE3 | 2008-02 | 2010-10 | 2010-10 |
| NCT00620659 | Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) | TERMINATED | PHASE2 | 2008-02 | 2009-02 | 2009-02 |
| NCT01021527 | A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED) | COMPLETED | PHASE1 | 2008-02 | 2008-04 | 2008-03 |
| NCT01263132 | Neuropathic Pain Management | COMPLETED | PHASE3 | 2008-02 | 2010-02 | 2010-02 |
| NCT00612703 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2008-02 | | 2010-09 |
| NCT00629980 | Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis | COMPLETED | PHASE4 | 2008-02 | | 2008-09 |
| NCT00532935 | MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) | COMPLETED | PHASE3 | 2008-01-26 | 2009-10-23 | 2009-10-23 |
| NCT00541450 | A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED) | COMPLETED | PHASE3 | 2008-01-15 | 2010-01-16 | 2010-01-08 |
| NCT00561574 | A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) | COMPLETED | PHASE3 | 2008-01-09 | 2010-02-14 | 2010-02-14 |
| NCT00671814 | Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults | COMPLETED | PHASE1 | 2008-01-06 | 2008-06-06 | 2008-06-06 |
| NCT00709540 | A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women | COMPLETED | PHASE1 | 2008-01 | 2008-11 | 2008-11 |
| NCT00686777 | Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) | COMPLETED | PHASE4 | 2008-01 | 2010-12 | 2010-12 |
| NCT00635648 | A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066) | COMPLETED | PHASE3 | 2008-01 | 2011-05 | 2011-05 |
| NCT00686894 | Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440) | TERMINATED | PHASE4 | 2008-01 | 2008-11 | 2008-11 |
| NCT00938366 | Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects | COMPLETED | PHASE1 | 2008-01 | 2009-01 | 2009-01 |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | COMPLETED | PHASE2 | 2008-01 | 2012-03 | 2011-02 |
| NCT00404313 | The Effect of MK0633 in Patients With Chronic Asthma (0633-007) | TERMINATED | PHASE2 | 2008-01 | 2009-06 | 2009-06 |
| NCT00418613 | A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED) | COMPLETED | PHASE2 | 2008-01 | 2009-03 | 2009-03 |
| NCT00929201 | Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080) | COMPLETED | PHASE1 | 2008-01 | 2008-05 | 2008-03 |
| NCT00623714 | Induced Sputum Study (0000-065) | COMPLETED | PHASE1 | 2008-01 | 2009-03 | 2009-02 |
| NCT00704054 | A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) | COMPLETED | PHASE1 | 2008-01 | 2010-06 | 2010-06 |
| NCT00816712 | A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064) | COMPLETED | PHASE1 | 2008-01 | 2008-12 | 2008-12 |
| NCT00600288 | Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634) | COMPLETED | PHASE3 | 2008-01 | 2008-05 | 2008-05 |
| NCT00697593 | ChangE From Any Systemic psoriasiS therapY to Raptiva | TERMINATED | PHASE4 | 2008-01 | 2009-04 | 2009-04 |
| NCT00982865 | Trial of MSC1936369B in Subjects With Solid Tumors | COMPLETED | PHASE1 | 2007-12-31 | 2016-04-30 | 2013-03-31 |
| NCT00614393 | Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | COMPLETED | PHASE2 | 2007-12-24 | 2012-03-07 | 2010-06-01 |
| NCT00564421 | Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648) | COMPLETED | PHASE3 | 2007-12-18 | 2008-02-14 | 2008-02-14 |
| NCT00559182 | A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001) | COMPLETED | PHASE1 | 2007-12-05 | 2010-07-09 | 2010-06-10 |
| NCT00620113 | Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) | COMPLETED | PHASE2 | 2007-12-03 | 2009-05-29 | 2009-05-29 |
| NCT00527943 | Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) | TERMINATED | PHASE3 | 2007-12-01 | 2011-07-01 | 2011-07-01 |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | COMPLETED | PHASE4 | 2007-12 | 2009-04 | 2009-04 |
| NCT00686686 | Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED) | COMPLETED | PHASE3 | 2007-12 | 2009-04 | 2009-02 |
| NCT00550732 | A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2) | COMPLETED | PHASE2 | 2007-12 | 2012-11 | 2012-11 |
| NCT00518687 | Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2) | TERMINATED | PHASE2, PHASE3 | 2007-12 | 2011-08 | 2011-08 |
| NCT00506077 | MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) | COMPLETED | PHASE2 | 2007-12 | 2008-10 | 2008-10 |
| NCT00570310 | Neuropathic Pain Syndrome Patient Study (MK-0000-072) | COMPLETED | PHASE1 | 2007-12 | 2008-09 | 2008-09 |
| NCT00551018 | Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875) | COMPLETED | PHASE2 | 2007-12 | 2010-10 | 2010-05 |
| NCT00553514 | AS900672-Enriched in Ovulation Induction | TERMINATED | PHASE2 | 2007-12 | 2009-03 | 2009-03 |
| NCT00933686 | Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome | COMPLETED | PHASE3 | 2007-12 | 2010-07 | 2010-07 |
| NCT00564447 | Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers | COMPLETED | PHASE4 | 2007-12 | | 2007-12 |
| NCT00575380 | Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery | COMPLETED | PHASE4 | 2007-12 | | 2008-06 |
| NCT00566527 | Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) | COMPLETED | PHASE3 | 2007-11-29 | 2008-12-29 | 2008-12-29 |
| NCT00537017 | Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175) | COMPLETED | PHASE2 | 2007-11-23 | 2009-11-19 | 2009-11-19 |
| NCT00551213 | A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | COMPLETED | PHASE2 | 2007-11-21 | 2009-06-04 | 2009-06-04 |
| NCT00701389 | Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) | COMPLETED | PHASE1 | 2007-11-20 | 2008-04-10 | 2008-04-10 |
| NCT00561821 | Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709) | COMPLETED | PHASE3 | 2007-11-20 | 2009-12-21 | 2009-12-21 |
| NCT00535236 | A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002) | COMPLETED | PHASE1 | 2007-11-02 | 2010-01-26 | 2010-01-25 |
| NCT00603265 | Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | COMPLETED | PHASE2 | 2007-11 | 2008-08 | 2008-08 |
| NCT00567112 | Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009) | COMPLETED | PHASE1 | 2007-11 | 2008-04 | 2008-02 |
| NCT00812396 | Biomarkers of Muscle Anabolism (MK-0000-082) | COMPLETED | PHASE1 | 2007-11 | 2008-02 | 2008-02 |
| NCT00911469 | Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement | COMPLETED | PHASE1 | 2007-11 | 2010-06 | 2010-04 |
| NCT01079949 | A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age | TERMINATED | PHASE2 | 2007-11 | 2010-10 | 2010-10 |
| NCT00558207 | A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma | COMPLETED | PHASE2 | 2007-11 | 2008-04 | 2008-04 |
| NCT00561080 | Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043) | COMPLETED | PHASE3 | 2007-10-26 | 2009-06-03 | 2009-06-03 |
| NCT00560755 | Safety Study of ProQuad® rHA in Infants (V221-037) | COMPLETED | PHASE3 | 2007-10-24 | 2008-11-24 | 2008-11-24 |
| NCT00509236 | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) | COMPLETED | PHASE3 | 2007-10-19 | 2011-03-14 | 2011-03-14 |
| NCT00509262 | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) | COMPLETED | PHASE3 | 2007-10-09 | 2011-03-16 | 2011-03-16 |
| NCT00686595 | A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) | COMPLETED | PHASE4 | 2007-10-01 | 2009-10-01 | 2009-10-01 |
| NCT00534248 | Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) | COMPLETED | PHASE3 | 2007-10 | 2010-01 | 2010-01 |
| NCT00546819 | ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED) | COMPLETED | PHASE2 | 2007-10 | 2010-08 | 2010-08 |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | COMPLETED | PHASE2 | 2007-10 | 2011-05 | 2011-05 |
| NCT00543413 | A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006) | COMPLETED | PHASE2 | 2007-10 | 2008-06 | 2008-06 |
| NCT00798395 | A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED) | COMPLETED | PHASE1 | 2007-10 | 2008-09 | 2008-09 |
| NCT01209741 | Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED) | COMPLETED | PHASE1 | 2007-10 | 2007-11 | 2007-11 |
| NCT00961480 | A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095) | COMPLETED | PHASE1 | 2007-10 | 2007-11 | 2007-11 |
| NCT00626275 | Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis | COMPLETED | PHASE2 | 2007-10 | 2008-09 | 2008-09 |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | COMPLETED | PHASE2 | 2007-10 | 2009-05 | 2009-05 |
| NCT00534794 | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis | COMPLETED | PHASE4 | 2007-10 | | 2008-01 |
| NCT00538239 | Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) | COMPLETED | PHASE3 | 2007-10 | 2012-12 | 2010-10 |
| NCT00529659 | A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005) | COMPLETED | PHASE2 | 2007-10 | 2009-10 | 2009-10 |
| NCT00500006 | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | TERMINATED | PHASE1 | 2007-10 | 2007-11 | 2007-11 |
| NCT00539721 | A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED) | COMPLETED | PHASE2 | 2007-10 | 2008-07 | 2008-07 |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | COMPLETED | PHASE2 | 2007-10 | 2011-02 | 2010-12 |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | COMPLETED | PHASE3 | 2007-09-24 | 2016-07-07 | 2013-04-10 |
| NCT00610649 | Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001) | COMPLETED | PHASE2 | 2007-09-20 | 2008-12-10 | 2008-11-18 |
| NCT00529373 | A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) | TERMINATED | PHASE3 | 2007-09-13 | 2017-02-01 | 2012-11-14 |
| NCT01033318 | A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED) | COMPLETED | PHASE1 | 2007-09-11 | 2008-06-19 | 2008-06-19 |
| NCT00526474 | Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) | COMPLETED | PHASE3 | 2007-09-01 | 2011-12-01 | 2011-12-01 |
| NCT01028391 | 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064) | COMPLETED | PHASE3 | 2007-09-01 | 2009-01-01 | 2009-01-01 |
| NCT00550745 | ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) | COMPLETED | PHASE4 | 2007-09 | 2009-01 | 2009-01 |
| NCT00536263 | PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) | COMPLETED | PHASE3 | 2007-09 | 2009-11 | 2009-11 |
| NCT00551330 | Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) | COMPLETED | PHASE2 | 2007-09 | 2010-05 | 2010-02 |
| NCT00482430 | MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) | COMPLETED | PHASE2 | 2007-09 | 2008-10 | 2008-10 |
| NCT00535496 | Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) | COMPLETED | PHASE3 | 2007-09 | 2008-02 | 2008-01 |
| NCT00541229 | Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED) | COMPLETED | PHASE1 | 2007-08-24 | 2008-07-01 | 2008-06-17 |
| NCT00693472 | Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) | TERMINATED | PHASE2 | 2007-08-15 | 2009-01-09 | 2008-12-12 |
| NCT00490737 | Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021) | COMPLETED | PHASE1 | 2007-08-12 | 2008-05-12 | 2008-05-12 |
| NCT00769132 | A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) | COMPLETED | PHASE1 | 2007-08-03 | 2007-11-06 | 2007-10-13 |
| NCT00822757 | Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004) | COMPLETED | PHASE1 | 2007-08 | 2007-12 | 2007-10 |
| NCT00618995 | A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED) | COMPLETED | PHASE1 | 2007-08 | 2007-12 | 2007-12 |
| NCT00943371 | A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002) | TERMINATED | PHASE1 | 2007-08 | 2009-05 | 2007-09 |
| NCT01021462 | A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078) | COMPLETED | PHASE1 | 2007-08 | 2007-09 | 2007-08 |
| NCT00887601 | BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) | COMPLETED | PHASE1 | 2007-08 | 2008-05 | 2008-05 |
| NCT00425165 | Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease | TERMINATED | PHASE2 | 2007-08 | 2008-05 | 2008-05 |
| NCT00647114 | A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED) | COMPLETED | PHASE1 | 2007-08 | 2009-04 | 2008-09 |
| NCT00548353 | A Study of Gastric Delay in Migraine Patients (3207-003) | COMPLETED | PHASE1 | 2007-08 | 2010-02 | 2008-04 |
| NCT00524524 | An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2007-08 | 2008-08 | 2008-08 |
| NCT00443690 | Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy | COMPLETED | PHASE3 | 2007-08 | 2009-01 | 2009-01 |
| NCT00687323 | Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) | COMPLETED | PHASE2 | 2007-07-30 | 2012-12-23 | 2011-05-09 |
| NCT00550771 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | COMPLETED | PHASE2 | 2007-07-16 | 2010-08-23 | 2010-08-23 |
| NCT00511108 | Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061) | COMPLETED | PHASE1 | 2007-07-11 | 2009-02-24 | 2009-02-24 |
| NCT00537316 | Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807) | TERMINATED | PHASE3 | 2007-07 | 2010-02 | 2010-02 |
| NCT00761735 | 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) | COMPLETED | PHASE3 | 2007-07 | 2013-01 | 2013-01 |
| NCT00560950 | Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) | COMPLETED | PHASE3 | 2007-07 | 2008-05 | 2008-05 |
| NCT00485758 | Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) | COMPLETED | PHASE3 | 2007-07 | 2008-08 | 2008-08 |
| NCT00782951 | A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800) | TERMINATED | PHASE2 | 2007-07 | 2007-08 | 2007-08 |
| NCT00523211 | Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5) | COMPLETED | PHASE3 | 2007-07 | 2011-03 | 2009-06 |
| NCT00479466 | Dose-Range Finding Study for MK0893 (0893-008) | TERMINATED | PHASE2 | 2007-07 | 2008-05 | 2008-05 |
| NCT00518622 | Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) | COMPLETED | PHASE1 | 2007-07 | 2008-09 | 2008-09 |
| NCT00401310 | The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018) | TERMINATED | PHASE2 | 2007-07 | 2009-01 | 2009-01 |
| NCT00632931 | A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) | COMPLETED | PHASE1 | 2007-07 | 2009-04 | 2008-05 |
| NCT00475735 | A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) | COMPLETED | PHASE2 | 2007-07 | 2008-04 | 2008-04 |
| NCT00511472 | An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006) | COMPLETED | PHASE1 | 2007-07 | 2008-04 | 2008-04 |
| NCT00943124 | MK0524B Bioequivalence Study (0524B-070) | COMPLETED | PHASE1 | 2007-07 | 2007-08 | 2007-08 |
| NCT00601458 | Bunionectomy Study (0000-063) | COMPLETED | PHASE1 | 2007-07 | 2008-01 | 2008-01 |
| NCT01081158 | Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) | COMPLETED | PHASE1 | 2007-07 | 2008-08 | 2008-08 |
| NCT00479388 | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) | COMPLETED | PHASE3 | 2007-07 | 2008-10 | 2008-07 |
| NCT00619307 | Transition to Rebif New Formulation | COMPLETED | PHASE3 | 2007-07 | 2008-04 | 2008-04 |
| NCT00428844 | Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci | COMPLETED | PHASE2 | 2007-06-26 | 2010-06-23 | 2010-03-26 |
| NCT00482729 | MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED) | COMPLETED | PHASE3 | 2007-06-19 | 2009-04-27 | 2008-11-03 |
| NCT00479882 | MK-0524B Lipid Study (MK-0524B-063) | COMPLETED | PHASE3 | 2007-06-15 | 2008-06-16 | 2008-06-16 |
| NCT00506389 | A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707) | COMPLETED | PHASE3 | 2007-06-06 | 2008-02-13 | 2008-02-13 |
| NCT00684593 | A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009) | COMPLETED | PHASE2 | 2007-06-01 | 2007-10-01 | 2007-10-01 |
| NCT00521924 | Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED) | TERMINATED | PHASE3 | 2007-06 | 2008-04 | 2008-04 |
| NCT00535730 | ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) | COMPLETED | PHASE3 | 2007-06 | 2008-02 | 2008-02 |
| NCT00491764 | A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) | COMPLETED | PHASE2 | 2007-06 | 2008-12 | 2008-12 |
| NCT00687219 | Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) | COMPLETED | PHASE3 | 2007-06 | 2010-10 | 2010-10 |
| NCT01017458 | Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) | COMPLETED | PHASE1 | 2007-06 | 2008-08 | 2008-08 |
| NCT01181310 | Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) | COMPLETED | PHASE1 | 2007-06 | 2007-10 | 2007-10 |
| NCT00479232 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | COMPLETED | PHASE1 | 2007-06 | 2012-03 | 2010-04 |
| NCT00486720 | Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) | TERMINATED | PHASE2 | 2007-06 | 2009-07 | 2009-07 |
| NCT00496353 | MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) | COMPLETED | PHASE1, PHASE2 | 2007-06 | 2008-11 | 2008-10 |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | TERMINATED | PHASE1, PHASE2 | 2007-06 | 2009-12 | 2009-12 |
| NCT01097512 | AS703569 and Gemcitabine Combination in Advanced Malignancies | COMPLETED | PHASE1 | 2007-06 | 2011-02 | 2010-07 |
| NCT00463788 | Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer | COMPLETED | PHASE2 | 2007-06 | 2011-02 | 2009-07 |
| NCT00993863 | Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction | COMPLETED | PHASE2 | 2007-06 | | 2007-09 |
| NCT00545064 | Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) | COMPLETED | PHASE4 | 2007-05-23 | 2008-09-15 | 2008-09-15 |
| NCT00474370 | Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED) | COMPLETED | PHASE3 | 2007-05-15 | 2010-10-26 | 2009-08-24 |
| NCT00380367 | Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | COMPLETED | PHASE3 | 2007-05-03 | 2008-02-04 | 2008-02-04 |
| NCT00448864 | Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement | TERMINATED | PHASE2 | 2007-05-01 | 2008-08-01 | 2008-07-01 |
| NCT00423267 | POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) | COMPLETED | PHASE3 | 2007-05 | 2009-05 | 2009-05 |
| NCT00443703 | MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) | TERMINATED | PHASE3 | 2007-05 | 2009-04 | 2009-04 |
| NCT00443729 | MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED) | TERMINATED | PHASE3 | 2007-05 | 2009-04 | 2008-10 |
| NCT00511667 | A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005) | COMPLETED | PHASE1 | 2007-05 | 2008-04 | 2008-04 |
| NCT00473889 | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | TERMINATED | PHASE2, PHASE3 | 2007-05 | 2008-12 | 2008-12 |
| NCT00202891 | Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460) | WITHDRAWN | PHASE4 | 2007-05 | 2007-09 | |
| NCT00505843 | A Study of MK0657 in Parkinson's Disease Patients (0657-006) | COMPLETED | PHASE1 | 2007-05 | 2008-02 | 2008-02 |
| NCT00684463 | Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) | COMPLETED | PHASE4 | 2007-04-11 | 2008-02-22 | 2008-02-22 |
| NCT00725075 | Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) | COMPLETED | PHASE2 | 2007-04-10 | 2008-10-24 | 2008-10-24 |
| NCT00545584 | Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078) | COMPLETED | PHASE3 | 2007-04-01 | 2009-11-19 | 2009-11-19 |
| NCT00493805 | Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) | TERMINATED | PHASE4 | 2007-04 | 2009-10 | 2009-10 |
| NCT00533611 | Effect of MK0524A on Flushing Caused by Niacin (0524A-056) | COMPLETED | PHASE3 | 2007-04 | 2007-08 | 2007-08 |
| NCT00536510 | Effect of MK0524A on Cholesterol Levels (0524A-048) | COMPLETED | PHASE3 | 2007-04 | 2008-03 | 2008-03 |
| NCT00612209 | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2007-04 | 2010-02 | 2010-01 |
| NCT00679055 | A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED) | TERMINATED | PHASE1 | 2007-03-31 | 2008-08-26 | 2008-08-26 |
| NCT00326183 | Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) | COMPLETED | PHASE4 | 2007-03-26 | 2008-01-15 | 2008-01-15 |
| NCT00449956 | MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED) | COMPLETED | PHASE3 | 2007-03-12 | 2008-02-16 | 2008-02-16 |
| NCT00449930 | Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049) | COMPLETED | PHASE3 | 2007-03-01 | 2008-07-25 | 2008-07-25 |
| NCT00362648 | Developing World Study for RotaTeq™ (V260-015)(COMPLETED) | COMPLETED | PHASE3 | 2007-03 | 2009-03 | 2009-03 |
| NCT00423449 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | COMPLETED | PHASE1 | 2007-03 | 2010-04 | 2010-04 |
| NCT00464334 | A Study of V950 in People With Alzheimer Disease (V950-001 AM7) | COMPLETED | PHASE1 | 2007-03 | 2012-01 | 2012-01 |
| NCT00444860 | ZOSTAVAX(R) Local Registration Trial (V211-019) | COMPLETED | PHASE3 | 2007-03 | 2007-05 | 2007-05 |
| NCT00432237 | Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) | COMPLETED | PHASE3 | 2007-03 | 2007-12 | 2007-12 |
| NCT00565084 | Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057) | COMPLETED | PHASE1 | 2007-03 | 2007-12 | 2007-12 |
| NCT00443924 | Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma | COMPLETED | PHASE1 | 2007-03 | 2009-04 | 2009-04 |
| NCT01187550 | Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® | COMPLETED | PHASE4 | 2007-03 | 2009-04 | 2008-09 |
| NCT00443209 | Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) | COMPLETED | PHASE3 | 2007-02-21 | 2009-01-22 | 2009-01-22 |
| NCT00689390 | Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) | TERMINATED | PHASE2, PHASE3 | 2007-02-20 | 2014-10-13 | 2014-10-13 |
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | COMPLETED | PHASE1 | 2007-02-20 | 2012-07-11 | 2008-05-27 |
| NCT00442936 | Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) | COMPLETED | PHASE3 | 2007-02-15 | 2007-10-02 | 2007-10-02 |
| NCT00704132 | Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059) | COMPLETED | PHASE1 | 2007-02-14 | 2010-04-28 | 2010-04-28 |
| NCT00832390 | Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158) | COMPLETED | PHASE4 | 2007-02-14 | 2008-07-11 | 2008-07-11 |
| NCT00443846 | RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) | COMPLETED | PHASE3 | 2007-02-13 | 2007-10-23 | 2007-09-04 |
| NCT00604968 | Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059) | TERMINATED | PHASE4 | 2007-02-07 | 2009-10-16 | 2009-10-16 |
| NCT00875394 | Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189) | COMPLETED | PHASE3 | 2007-02-01 | 2008-06-27 | 2008-06-27 |
| NCT00518739 | MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) | COMPLETED | PHASE1 | 2007-02 | 2008-12 | 2008-12 |
| NCT00439517 | Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. | COMPLETED | PHASE2 | 2007-02 | 2012-05 | 2009-06 |
| NCT01185782 | SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women | COMPLETED | PHASE3 | 2007-02 | 2007-12 | 2007-12 |
| NCT00423150 | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) | TERMINATED | PHASE2 | 2007-01-26 | 2009-06-11 | 2009-06-11 |
| NCT00432042 | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) | COMPLETED | PHASE3 | 2007-01-12 | 2008-03-27 | 2008-03-27 |
| NCT00337727 | Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) | COMPLETED | PHASE3 | 2007-01-01 | 2008-11-19 | 2008-10-28 |
| NCT00423670 | Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) | COMPLETED | PHASE2 | 2007-01 | 2008-11 | 2008-08 |
| NCT00411554 | A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED) | COMPLETED | PHASE3 | 2007-01 | 2007-08 | 2007-08 |
| NCT00506987 | Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887) | COMPLETED | PHASE2 | 2007-01 | 2007-11 | 2007-11 |
| NCT00424775 | A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) | TERMINATED | PHASE1 | 2007-01 | 2007-03 | 2007-03 |
| NCT00505752 | Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART) | COMPLETED | PHASE2 | 2007-01 | 2008-09 | 2008-09 |
| NCT00506545 | Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888) | COMPLETED | PHASE2 | 2007-01 | 2007-10 | 2007-10 |
| NCT00426933 | Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections | COMPLETED | PHASE2 | 2007-01 | 2007-09 | 2007-09 |
| NCT00397631 | Initial Combination With Pioglitazone Study (0431-064) | COMPLETED | PHASE3 | 2006-12-19 | 2008-06-28 | 2008-06-28 |
| NCT00395343 | Sitagliptin Added-on to Insulin Study (0431-051) | COMPLETED | PHASE3 | 2006-12-11 | 2008-10-13 | 2008-10-13 |
| NCT00411749 | V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) | COMPLETED | PHASE2 | 2006-12-11 | 2009-09-18 | 2009-09-18 |
| NCT00559468 | Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) | COMPLETED | PHASE3 | 2006-12-07 | 2007-03-02 | 2007-03-02 |
| NCT00482612 | Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) | COMPLETED | PHASE3 | 2006-12-07 | 2008-08-11 | 2008-08-11 |
| NCT00610675 | Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708) | COMPLETED | PHASE3 | 2006-12-07 | 2009-08-17 | 2009-08-17 |
| NCT00441701 | Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012) | TERMINATED | PHASE2 | 2006-12-01 | 2008-10-01 | 2008-10-01 |
| NCT00686881 | Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) | TERMINATED | PHASE3 | 2006-12 | 2011-02 | 2011-02 |
| NCT00423800 | Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) | TERMINATED | PHASE3 | 2006-12 | 2009-10 | 2009-10 |
| NCT00440297 | Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) | COMPLETED | PHASE3 | 2006-12 | 2008-05 | 2008-05 |
| NCT00684203 | Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) | COMPLETED | PHASE2 | 2006-12-01 | 2007-10-01 | 2007-10-01 |
| NCT00359671 | Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) | TERMINATED | PHASE1 | 2006-12 | 2007-07 | 2007-07 |
| NCT00387036 | Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036) | TERMINATED | PHASE2 | 2006-12 | 2009-07 | 2009-07 |
| NCT00407927 | A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis | COMPLETED | PHASE2 | 2006-12 | 2007-03 | 2007-03 |
| NCT00441012 | Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) | COMPLETED | PHASE3 | 2006-12 | 2008-06 | 2008-06 |
| NCT00405054 | A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) | TERMINATED | PHASE2 | 2006-12 | 2009-06 | 2009-06 |
| NCT00441103 | A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE3 | 2006-12 | 2009-02 | 2008-11 |
| NCT00622063 | An Extension Study for Patients Previously Treated With ARQ 501 | COMPLETED | PHASE1, PHASE2 | 2006-12 | | 2008-09 |
| NCT01032681 | EMD 521873 in Advanced Solid Tumors, MTD Finding | COMPLETED | PHASE1 | 2006-12 | 2012-01 | 2011-02 |
| NCT00448422 | Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers | COMPLETED | PHASE3 | 2006-12 | 2008-08 | 2008-08 |
| NCT00406029 | Dyskinesia in Parkinson's Disease (Study P04501) | COMPLETED | PHASE2 | 2006-11-20 | 2008-11-03 | 2008-10-05 |
| NCT00399802 | A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) | COMPLETED | PHASE2 | 2006-11-16 | 2007-12-05 | 2007-12-05 |
| NCT00398840 | A Study of ARQ 171 in Patients With Advanced Solid Tumors | TERMINATED | PHASE1 | 2006-11 | 2008-09 | 2008-09 |
| NCT00440531 | Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) | COMPLETED | PHASE3 | 2006-11 | 2007-11 | 2007-11 |
| NCT00445094 | A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) | COMPLETED | PHASE4 | 2006-11 | 2007-01 | 2007-01 |
| NCT00362024 | MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) | TERMINATED | PHASE2 | 2006-11 | 2007-11 | 2007-11 |
| NCT00421278 | The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED) | COMPLETED | PHASE2 | 2006-11 | 2007-01 | 2006-12 |
| NCT00430742 | An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED) | TERMINATED | PHASE3 | 2006-11 | 2008-11 | 2008-01 |
| NCT00420420 | MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) | COMPLETED | PHASE2 | 2006-11 | 2008-08 | 2008-08 |
| NCT00404352 | REbif FLEXible Dosing in Early Multiple Sclerosis (MS) | COMPLETED | PHASE3 | 2006-11 | 2011-07 | 2010-08 |
| NCT00871910 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | COMPLETED | PHASE1 | 2006-10-11 | 2010-02-22 | 2010-02-22 |
| NCT00687011 | Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594) | COMPLETED | PHASE4 | 2006-10-10 | 2008-10-27 | 2008-10-27 |
| NCT00402831 | ProQuad® Intramuscular vs Subcutaneous | COMPLETED | PHASE3 | 2006-10-06 | 2007-05-11 | 2007-05-11 |
| NCT00414050 | A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) | COMPLETED | PHASE3 | 2006-10-06 | 2007-10-24 | 2007-10-22 |
| NCT00468728 | PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | COMPLETED | PHASE3 | 2006-10-04 | 2009-12-11 | 2009-12-11 |
| NCT00397683 | A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011) | TERMINATED | PHASE2 | 2006-10 | 2007-04 | 2007-04 |
| NCT00387140 | A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005) | COMPLETED | PHASE2 | 2006-10 | 2007-05 | 2007-05 |
| NCT00350623 | Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED) | TERMINATED | PHASE2 | 2006-10 | 2008-05 | 2008-05 |
| NCT00365443 | Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | WITHDRAWN | PHASE2 | 2006-10 | | |
| NCT00944645 | MK0524A Bioequivalence Study (0524A-059) | COMPLETED | PHASE1 | 2006-10 | 2007-01 | 2007-01 |
| NCT00384605 | An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED) | TERMINATED | PHASE3 | 2006-10 | 2008-12 | 2008-01 |
| NCT00851266 | A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults | COMPLETED | PHASE1 | 2006-10 | 2009-01 | 2007-08 |
| NCT00420589 | A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED) | TERMINATED | PHASE3 | 2006-10 | 2008-11 | 2008-02 |
| NCT00395421 | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin | COMPLETED | PHASE2 | 2006-10 | 2008-08 | 2008-06 |
| NCT00354458 | PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | COMPLETED | PHASE3 | 2006-10 | 2009-07 | 2009-07 |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | COMPLETED | PHASE2 | 2006-09-26 | 2011-02-16 | 2010-01-11 |
| NCT00684515 | Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) | COMPLETED | PHASE2 | 2006-09-21 | 2007-11-08 | 2007-11-08 |
| NCT00393523 | Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) | COMPLETED | PHASE3 | 2006-09 | 2008-06 | 2008-06 |
| NCT00371761 | PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) | COMPLETED | PHASE3 | 2006-09 | 2009-02 | 2009-02 |
| NCT01382654 | Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis | COMPLETED | PHASE2 | 2006-09 | 2006-10 | 2006-10 |
| NCT00384293 | Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) | TERMINATED | PHASE3 | 2006-09 | 2008-08 | 2008-08 |
| NCT01324440 | Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) | COMPLETED | PHASE1 | 2006-09 | 2007-10 | 2007-10 |
| NCT00536588 | A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) | COMPLETED | PHASE1 | 2006-09 | 2009-08 | 2009-08 |
| NCT00381017 | Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) | WITHDRAWN | PHASE3 | 2006-09 | | |
| NCT00372060 | MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) | COMPLETED | PHASE3 | 2006-08-21 | 2008-02-05 | 2008-02-05 |
| NCT02004886 | A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005) | COMPLETED | PHASE2 | 2006-08-11 | 2007-02-07 | 2007-02-07 |
| NCT00635778 | A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) | COMPLETED | PHASE1 | 2006-08-07 | 2008-11-05 | 2008-11-05 |
| NCT00732875 | A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED) | COMPLETED | PHASE3 | 2006-08 | 2008-05 | 2008-05 |
| NCT00369941 | A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) | COMPLETED | PHASE3 | 2006-08 | 2012-02 | 2009-05 |
| NCT00945750 | A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144) | COMPLETED | PHASE1 | 2006-08 | 2006-09 | 2006-09 |
| NCT00424424 | A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002) | TERMINATED | PHASE2 | 2006-08 | 2007-01 | 2007-01 |
| NCT00394914 | Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295) | COMPLETED | PHASE2 | 2006-08 | 2007-04 | 2007-04 |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | COMPLETED | PHASE1 | 2006-08 | 2012-10 | 2012-10 |
| NCT00392574 | Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea | COMPLETED | PHASE3 | 2006-08 | 2008-03 | 2008-02 |
| NCT00328692 | PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | COMPLETED | PHASE3 | 2006-08 | 2009-07 | 2009-07 |
| NCT00686699 | Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) | TERMINATED | PHASE2 | 2006-07-10 | 2008-03-06 | 2008-03-06 |
| NCT00376584 | Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) | COMPLETED | PHASE3 | 2006-07 | 2007-01 | 2007-01 |
| NCT00378833 | Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) | COMPLETED | PHASE3 | 2006-07 | 2007-03 | 2007-03 |
| NCT00357279 | Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease | COMPLETED | PHASE3 | 2006-07 | 2008-09 | 2008-09 |
| NCT00373490 | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) | COMPLETED | PHASE1 | 2006-07 | 2007-10 | 2007-10 |
| NCT00565006 | A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED) | COMPLETED | PHASE1 | 2006-07 | 2006-09 | 2006-09 |
| NCT00565292 | A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED) | COMPLETED | PHASE1 | 2006-07 | 2006-08 | 2006-08 |
| NCT00358930 | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | COMPLETED | PHASE2 | 2006-07 | 2007-08 | 2007-08 |
| NCT00753883 | Ezetrol Post-Marketing Study | COMPLETED | PHASE4 | 2006-07 | | 2008-05 |
| NCT00350779 | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | COMPLETED | PHASE3 | 2006-06-12 | 2008-06-11 | 2007-09-25 |
| NCT00378560 | V501 Efficacy Study in Women Aged 18 to 26 (V501-027) | COMPLETED | PHASE2 | 2006-06-12 | 2009-09-16 | 2009-09-16 |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | COMPLETED | PHASE2 | 2006-06-09 | 2009-09-15 | 2009-09-15 |
| NCT00354991 | Hyzaar Asia HEAALTH (0954A-950) | COMPLETED | PHASE3 | 2006-06-01 | 2007-04-01 | 2007-04-01 |
| NCT00687401 | A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) | COMPLETED | PHASE3 | 2006-06 | 2009-05 | 2009-05 |
| NCT00337610 | Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2006-06 | 2007-08 | 2007-05 |
| NCT00541775 | Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801) | COMPLETED | PHASE3 | 2006-06 | 2007-03 | 2007-03 |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | TERMINATED | PHASE2 | 2006-06 | 2007-05 | 2007-05 |
| NCT00543959 | Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005) | TERMINATED | PHASE2 | 2006-06 | 2007-08 | 2007-08 |
| NCT00325455 | MK0859 Dose-Ranging Study (0859-003) | TERMINATED | PHASE2 | 2006-06 | 2007-03 | 2007-02 |
| NCT00546286 | A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153) | COMPLETED | PHASE3 | 2006-05-31 | 2007-08-23 | 2007-08-23 |
| NCT00687362 | A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528) | COMPLETED | PHASE2 | 2006-05-30 | 2008-11-11 | 2008-11-11 |
| NCT00314951 | Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) | COMPLETED | PHASE3 | 2006-05-02 | 2008-08-21 | 2008-07-23 |
| NCT00378599 | Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) | COMPLETED | PHASE3 | 2006-05 | 2009-07 | 2009-07 |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | COMPLETED | PHASE2 | 2006-05 | 2007-07 | 2007-07 |
| NCT00367237 | Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) | COMPLETED | PHASE3 | 2006-05 | 2008-03 | 2008-03 |
| NCT00358670 | Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) | TERMINATED | PHASE3 | 2006-05 | 2009-01 | 2009-01 |
| NCT00330395 | Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058) | COMPLETED | PHASE2 | 2006-05 | 2006-10 | 2006-10 |
| NCT00337428 | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) | COMPLETED | PHASE3 | 2006-05 | 2007-05 | 2007-05 |
| NCT00971724 | Biomarkers of Prednisolone Treatment (P05888) | COMPLETED | NA | 2006-05 | 2008-03 | 2006-10 |
| NCT00337415 | MK0354 Clinical Efficacy and Tolerability Study (0354-004) | TERMINATED | PHASE2 | 2006-05 | 2006-08 | 2006-08 |
| NCT00322231 | A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014) | COMPLETED | PHASE3 | 2006-05 | 2007-07 | 2007-07 |
| NCT00289913 | Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) | COMPLETED | PHASE4 | 2006-04 | 2010-06 | 2010-06 |
| NCT00312858 | Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) | COMPLETED | PHASE4 | 2006-04 | 2008-03 | 2008-03 |
| NCT00316212 | Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass | TERMINATED | PHASE2 | 2006-04 | | 2006-08 |
| NCT00851643 | Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) | COMPLETED | PHASE1 | 2006-04 | 2009-11 | 2007-12 |
| NCT00325130 | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) | COMPLETED | PHASE3 | 2006-04 | 2007-04 | 2007-04 |
| NCT00331045 | Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid | TERMINATED | PHASE2 | 2006-04 | 2006-12 | 2006-10 |
| NCT01111019 | Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children | COMPLETED | PHASE2 | 2006-03-21 | 2017-01-17 | 2017-01-17 |
| NCT00305604 | Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED) | COMPLETED | PHASE3 | 2006-03-08 | 2008-03-12 | 2008-03-12 |
| NCT00109343 | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) | COMPLETED | PHASE3 | 2006-03 | 2007-09 | 2007-09 |
| NCT00394589 | Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) | TERMINATED | PHASE3 | 2006-03 | 2008-10 | 2008-10 |
| NCT00548080 | Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055) | COMPLETED | PHASE3 | 2006-03 | 2006-11 | 2006-11 |
| NCT00289848 | MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040) | COMPLETED | PHASE3 | 2006-03 | 2007-03 | 2007-03 |
| NCT00302471 | MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) | COMPLETED | PHASE1 | 2006-03 | 2007-10 | 2007-10 |
| NCT00450190 | Saizen® E-Device User Trial | COMPLETED | PHASE3 | 2006-02-28 | 2006-09-30 | 2006-09-30 |
| NCT00295178 | Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas | COMPLETED | PHASE4 | 2006-02-20 | 2006-08-09 | 2006-08-09 |
| NCT00474253 | Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026) | COMPLETED | PHASE3 | 2006-02-10 | 2006-09-09 | 2006-08-22 |
| NCT00293254 | A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019) | COMPLETED | PHASE3 | 2006-02 | 2011-05 | 2007-10 |
| NCT00258154 | V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010) | COMPLETED | PHASE3 | 2006-02 | 2006-11 | 2006-11 |
| NCT00293267 | A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2) | COMPLETED | PHASE3 | 2006-02 | 2011-05 | 2007-08 |
| NCT00288431 | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | COMPLETED | PHASE1 | 2006-02 | 2008-07 | 2008-07 |
| NCT00779285 | Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED) | TERMINATED | PHASE4 | 2006-02 | 2006-08 | 2006-08 |
| NCT01134627 | Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] | TERMINATED | PHASE2 | 2006-02 | 2011-04 | 2011-04 |
| NCT00310518 | Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma | COMPLETED | PHASE2 | 2006-02 | 2007-07 | 2007-07 |
| NCT00289900 | Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) | COMPLETED | PHASE3 | 2006-01-24 | 2010-08-06 | 2010-08-06 |
| NCT00266799 | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | COMPLETED | PHASE3 | 2006-01-13 | 2010-10-18 | 2010-09-29 |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | COMPLETED | PHASE1 | 2006-01-12 | 2009-12-01 | 2009-12-01 |
| NCT00591409 | A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956) | COMPLETED | PHASE2 | 2006-01-03 | 2006-12-18 | 2006-09-22 |
| NCT00269217 | Lipid Efficacy Study (0524B-022)(COMPLETED) | COMPLETED | PHASE3 | 2006-01 | 2007-01 | 2007-01 |
| NCT00250432 | A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED) | COMPLETED | PHASE3 | 2006-01 | 2008-03 | 2008-01 |
| NCT00975052 | A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED) | COMPLETED | PHASE1 | 2006-01 | 2006-03 | 2006-03 |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | TERMINATED | PHASE1, PHASE2 | 2006-01 | 2007-10 | 2007-10 |
| NCT00302172 | ARQ 197 in Subjects With Metastatic Solid Tumors | COMPLETED | PHASE1 | 2006-01 | | |
| NCT00474617 | Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029) | COMPLETED | PHASE3 | 2005-12-29 | 2006-10-20 | 2006-10-20 |
| NCT01112358 | Lutropin Alfa in Women at Risk of Poor Response | COMPLETED | PHASE2 | 2005-12-07 | 2007-01-30 | 2007-01-30 |
| NCT00591786 | A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957) | COMPLETED | PHASE2 | 2005-12-05 | 2006-10-19 | 2006-08-31 |
| NCT00961857 | A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048) | COMPLETED | PHASE1 | 2005-12-01 | 2006-01-01 | 2005-12-01 |
| NCT00687544 | Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) | TERMINATED | PHASE4 | 2005-12 | 2008-09 | 2008-09 |
| NCT00686790 | Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) | COMPLETED | PHASE3 | 2005-12 | 2009-05 | 2009-05 |
| NCT00282763 | A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) | TERMINATED | PHASE2 | 2005-12 | 2006-08 | 2006-08 |
| NCT00269204 | Lipid Efficacy/Tolerability Study (0524A-020) | COMPLETED | PHASE3 | 2005-12 | 2006-12 | 2006-12 |
| NCT00260039 | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | COMPLETED | PHASE2 | 2005-12 | 2007-08 | 2007-08 |
| NCT01142466 | A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone | COMPLETED | PHASE4 | 2005-12 | 2010-01 | 2009-12 |
| NCT00400530 | Upper GI Handling of Branded vs. Generic Alendronate | COMPLETED | PHASE3 | 2005-12 | | |
| NCT00473694 | Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) | COMPLETED | PHASE3 | 2005-11-28 | 2007-01-29 | 2006-11-06 |
| NCT00451217 | Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) | COMPLETED | PHASE3 | 2005-11-17 | 2006-03-06 | 2006-03-06 |
| NCT00451100 | Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931) | COMPLETED | PHASE3 | 2005-11-10 | 2006-08-29 | 2006-05-22 |
| NCT00420680 | Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934) | COMPLETED | PHASE3 | 2005-11-07 | 2006-08-01 | 2006-08-01 |
| NCT01011725 | Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003) | COMPLETED | PHASE1 | 2005-11 | 2009-03 | 2006-04 |
| NCT00246337 | A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004) | COMPLETED | PHASE2 | 2005-11 | 2006-05 | 2006-05 |
| NCT00274716 | Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED) | COMPLETED | PHASE2 | 2005-11 | 2007-01 | 2007-01 |
| NCT00303069 | V710 First-In-Man (FIM) Study (V710-001) | COMPLETED | PHASE1 | 2005-11 | 2006-07 | 2006-07 |
| NCT00245544 | Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004) | TERMINATED | PHASE2 | 2005-11 | 2007-01 | 2007-01 |
| NCT00475215 | Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) | COMPLETED | PHASE3 | 2005-10-27 | 2006-09-09 | 2006-08-21 |
| NCT00298831 | Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) | COMPLETED | PHASE3 | 2005-10-27 | 2006-05-22 | 2006-05-22 |
| NCT00552929 | A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974) | COMPLETED | PHASE2 | 2005-10-04 | 2006-09-15 | 2006-09-15 |
| NCT00496093 | Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) | COMPLETED | PHASE3 | 2005-10 | 2006-01 | 2006-01 |
| NCT00157950 | Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) | COMPLETED | PHASE3 | 2005-10 | 2006-06 | 2006-06 |
| NCT00230230 | Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED) | COMPLETED | PHASE2 | 2005-10 | 2007-04 | 2007-04 |
| NCT00130832 | Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) | COMPLETED | PHASE3 | 2005-10 | 2006-07 | 2006-07 |
| NCT00287079 | A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome | COMPLETED | PHASE3 | 2005-10 | 2008-11 | 2008-11 |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | COMPLETED | PHASE2 | 2005-09-27 | 2007-10-31 | 2007-10-31 |
| NCT00552617 | A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) | COMPLETED | PHASE2 | 2005-09-20 | 2006-08-31 | 2006-08-31 |
| NCT00243230 | Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) | COMPLETED | PHASE2 | 2005-09-19 | 2011-03-17 | 2007-10-19 |
| NCT00243568 | Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 | WITHDRAWN | PHASE3 | 2005-09-01 | | |
| NCT00251641 | The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED) | COMPLETED | PHASE3 | 2005-09-01 | 2008-06-01 | 2008-06-01 |
| NCT00139932 | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | COMPLETED | PHASE4 | 2005-09-01 | 2006-11-21 | 2006-11-21 |
| NCT00114062 | Study to Treat Uveitis Associated Macular Edema | TERMINATED | PHASE2 | 2005-09 | 2006-12 | 2006-12 |
| NCT00130806 | An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065) | TERMINATED | PHASE3 | 2005-09 | 2005-11 | 2005-11 |
| NCT00128115 | Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032) | TERMINATED | PHASE2 | 2005-09 | 2007-08 | 2007-08 |
| NCT00160251 | Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED) | COMPLETED | PHASE2 | 2005-09 | 2007-07 | 2007-07 |
| NCT00231816 | A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011) | COMPLETED | PHASE3 | 2005-09 | 2006-03 | 2006-03 |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | COMPLETED | PHASE1 | 2005-09 | 2011-05 | 2009-12 |
| NCT00242476 | A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009) | COMPLETED | PHASE2 | 2005-09 | 2006-07 | 2006-07 |
| NCT00127101 | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | TERMINATED | PHASE1 | 2005-09 | 2008-10 | 2008-10 |
| NCT00250419 | V930 First in Man (FIM) Study (V930-002)(COMPLETED) | COMPLETED | PHASE1 | 2005-09 | 2008-09 | 2008-09 |
| NCT00131404 | A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED) | TERMINATED | PHASE3 | 2005-09 | 2008-12 | 2007-02 |
| NCT00844922 | Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) | COMPLETED | PHASE2 | 2005-09 | 2006-06 | 2006-06 |
| NCT00296569 | A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006) | COMPLETED | PHASE2 | 2005-09 | 2006-05 | 2006-05 |
| NCT00159614 | Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment | COMPLETED | PHASE2 | 2005-09 | | |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | COMPLETED | PHASE2 | 2005-08-31 | 2008-08-31 | 2008-07-31 |
| NCT00132912 | Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573) | COMPLETED | PHASE2 | 2005-08-30 | 2007-01-28 | 2007-01-28 |
| NCT00136292 | Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics | COMPLETED | PHASE1 | 2005-08-24 | 2006-08-09 | 2006-08-01 |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | COMPLETED | PHASE3 | 2005-08-01 | 2007-02-01 | 2007-02-01 |
| NCT00131430 | An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED) | COMPLETED | PHASE2, PHASE3 | 2005-08 | 2007-05 | 2007-05 |
| NCT00231790 | A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) | COMPLETED | PHASE2 | 2005-08 | 2006-10 | 2006-09 |
| NCT00254982 | Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED) | COMPLETED | PHASE3 | 2005-08 | 2006-09 | 2006-09 |
| NCT00778869 | Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED) | COMPLETED | PHASE4 | 2005-08 | 2005-08 | 2005-08 |
| NCT00907738 | A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | COMPLETED | PHASE2 | 2005-08 | 2010-06 | 2010-06 |
| NCT00166517 | V260 Registration Study (V260-013)(COMPLETED) | COMPLETED | PHASE3 | 2005-08 | 2006-07 | 2006-07 |
| NCT00122343 | AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | COMPLETED | PHASE2 | 2005-08 | 2008-01 | 2008-01 |
| NCT00130793 | A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED) | COMPLETED | PHASE3 | 2005-08 | 2005-11 | 2005-11 |
| NCT00135655 | A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema | WITHDRAWN | PHASE2 | 2005-08 | | |
| NCT00130182 | A Study in Pediatric Patients With Cystic Fibrosis Lung Disease | COMPLETED | PHASE2 | 2005-08 | | 2006-09 |
| NCT00256932 | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | COMPLETED | PHASE3 | 2005-08 | 2006-05 | |
| NCT00259922 | Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | COMPLETED | PHASE3 | 2005-08 | | 2006-06 |
| NCT00106626 | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | COMPLETED | PHASE1 | 2005-08 | 2007-12 | 2007-12 |
| NCT00118768 | A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C | COMPLETED | PHASE2 | 2005-08 | | |
| NCT00237484 | Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) | COMPLETED | PHASE3 | 2005-07-18 | 2011-06-30 | 2011-06-30 |
| NCT00687440 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | COMPLETED | PHASE2 | 2005-07-15 | 2008-10-24 | 2008-10-24 |
| NCT00758069 | Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045) | COMPLETED | PHASE2 | 2005-07-03 | 2006-02-13 | 2006-02-13 |
| NCT00441584 | The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) | TERMINATED | PHASE3 | 2005-07 | 2008-06 | 2008-06 |
| NCT00398099 | To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052) | COMPLETED | PHASE3 | 2005-07 | 2006-01 | 2006-01 |
| NCT00254553 | A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815) | TERMINATED | PHASE2 | 2005-07 | 2007-01 | 2007-01 |
| NCT00231777 | A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015) | COMPLETED | PHASE3 | 2005-07 | 2005-11 | 2005-11 |
| NCT02012166 | A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) | COMPLETED | PHASE1 | 2005-07 | 2005-12 | 2005-12 |
| NCT00721461 | A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001) | COMPLETED | PHASE1 | 2005-07 | 2005-10 | 2005-10 |
| NCT00127192 | A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) | COMPLETED | PHASE2 | 2005-07 | 2006-03 | 2006-03 |
| NCT00482196 | To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED) | COMPLETED | PHASE2 | 2005-07 | 2006-03 | 2006-03 |
| NCT00131391 | A Study of MK0364 in Obese Patients (0364-014) | TERMINATED | PHASE3 | 2005-07 | 2008-12 | 2008-02 |
| NCT00125034 | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) | COMPLETED | PHASE2 | 2005-07 | 2010-11 | 2007-03 |
| NCT00686829 | Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100) | COMPLETED | PHASE2 | 2005-06-30 | 2010-10-21 | 2010-10-21 |
| NCT00128102 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | COMPLETED | PHASE3 | 2005-06-30 | 2011-11-21 | 2011-07-15 |
| NCT00112437 | A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004) | COMPLETED | PHASE2 | 2005-06-24 | 2016-01-20 | 2007-12-26 |
| NCT00496327 | Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) | COMPLETED | PHASE3 | 2005-06-22 | 2005-10-06 | 2005-10-06 |
| NCT00127127 | A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | COMPLETED | PHASE1 | 2005-06-10 | 2009-08-21 | 2009-08-21 |
| NCT00482599 | Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED) | COMPLETED | PHASE3 | 2005-06-01 | 2006-04-13 | 2006-04-13 |
| NCT00787371 | Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) | COMPLETED | PHASE2 | 2005-06 | 2006-07 | 2006-07 |
| NCT00202852 | A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED) | COMPLETED | PHASE3 | 2005-06-01 | 2006-03-01 | 2006-03-01 |
| NCT00489099 | A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) | COMPLETED | PHASE3 | 2005-06 | 2006-05 | 2006-05 |
| NCT00111891 | An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) | COMPLETED | PHASE2 | 2005-06 | 2005-08 | 2005-08 |
| NCT00379964 | A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) | COMPLETED | PHASE3 | 2005-06 | 2006-05 | 2006-05 |
| NCT00379951 | A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) | COMPLETED | PHASE3 | 2005-06 | 2006-05 | 2006-05 |
| NCT00127140 | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | COMPLETED | PHASE1 | 2005-06 | 2012-04 | 2012-04 |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | COMPLETED | PHASE1 | 2005-06 | 2008-05 | 2008-05 |
| NCT00256126 | Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® | COMPLETED | PHASE4 | 2005-05-31 | 2007-09-30 | 2007-09-30 |
| NCT00421148 | Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961) | COMPLETED | PHASE3 | 2005-05-30 | 2006-06-02 | 2006-05-31 |
| NCT00097929 | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) | COMPLETED | PHASE2 | 2005-05-01 | 2006-07-31 | 2006-07-31 |
| NCT00202865 | Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) | COMPLETED | PHASE3 | 2005-05-01 | 2007-05-01 | 2007-05-01 |
| NCT00110188 | Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) | COMPLETED | PHASE2 | 2005-05 | 2007-08 | 2007-04 |
| NCT02532868 | A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002) | TERMINATED | PHASE1 | 2005-05 | 2008-01 | 2008-01 |
| NCT00109538 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | TERMINATED | PHASE3 | 2005-05 | 2008-08 | 2008-08 |
| NCT00112372 | Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) | COMPLETED | PHASE1 | 2005-05 | 2009-03 | 2008-12 |
| NCT00104364 | A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED) | COMPLETED | PHASE1 | 2005-05 | 2008-01 | 2008-01 |
| NCT00533312 | MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) | COMPLETED | PHASE2 | 2005-04 | 2007-01 | 2005-07 |
| NCT00850616 | Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED) | COMPLETED | PHASE1 | 2005-04 | 2011-03 | 2006-08 |
| NCT01381731 | A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK) | TERMINATED | PHASE2 | 2005-04 | 2005-06 | 2005-06 |
| NCT00157196 | Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease | COMPLETED | PHASE2 | 2005-04 | 2012-04 | 2007-09 |
| NCT00108017 | Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) | COMPLETED | PHASE3 | 2005-04 | 2006-07 | 2006-07 |
| NCT00106145 | A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) | COMPLETED | PHASE1 | 2005-04 | 2011-08 | 2011-08 |
| NCT00103857 | MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) | COMPLETED | PHASE3 | 2005-03-17 | 2008-02-21 | 2006-07-25 |
| NCT00266812 | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED) | TERMINATED | PHASE2 | 2005-03-08 | 2008-01-16 | 2008-01-16 |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | COMPLETED | PHASE3 | 2005-03-02 | 2006-02-23 | 2006-02-23 |
| NCT00255008 | Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) | TERMINATED | PHASE4 | 2005-03 | 2007-12 | 2007-12 |
| NCT00202839 | Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) | COMPLETED | PHASE4 | 2005-03 | 2008-07 | 2008-07 |
| NCT00105157 | Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED) | COMPLETED | PHASE2 | 2005-03 | 2009-07 | 2006-10 |
| NCT00106704 | Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035) | COMPLETED | PHASE3 | 2005-03 | 2007-01 | 2006-06 |
| NCT00127153 | A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) | COMPLETED | PHASE3 | 2005-03 | 2005-05 | 2005-05 |
| NCT01071200 | Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | TERMINATED | PHASE3 | 2005-03 | 2009-04 | 2009-04 |
| NCT00617877 | Antihypertensive Response to Losartan and Genetic Polymorphisms | COMPLETED | NA | 2005-03 | 2009-06 | 2009-06 |
| NCT00249821 | Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age | COMPLETED | PHASE3 | 2005-02-28 | 2007-09-30 | 2007-09-30 |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | COMPLETED | PHASE2 | 2005-02-03 | 2006-03-13 | 2005-11-23 |
| NCT00255034 | Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) | TERMINATED | PHASE4 | 2005-02 | 2008-06 | 2008-06 |
| NCT00104052 | Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) | COMPLETED | PHASE3 | 2005-02 | 2007-11 | 2007-11 |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | TERMINATED | PHASE1 | 2005-02 | 2006-10 | 2006-09 |
| NCT00432523 | Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) | COMPLETED | PHASE3 | 2005-01-20 | 2005-09-05 | 2005-09-05 |
| NCT01110707 | A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve | COMPLETED | PHASE2 | 2005-01-10 | 2006-11-15 | 2006-11-15 |
| NCT00102947 | Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections | TERMINATED | PHASE4 | 2005-01 | 2006-11 | 2006-11 |
| NCT00103714 | Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease | COMPLETED | PHASE2 | 2005-01 | 2005-08 | 2005-08 |
| NCT00109135 | A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007) | COMPLETED | PHASE2 | 2005-01 | 2005-06 | 2005-06 |
| NCT00100048 | A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) | COMPLETED | PHASE2 | 2005-01 | 2010-07 | 2006-10 |
| NCT00990821 | A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) | COMPLETED | PHASE1 | 2005-01 | 2006-01 | 2005-12 |
| NCT00132769 | A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED) | COMPLETED | PHASE2 | 2005-01 | 2005-11 | 2005-11 |
| NCT00099346 | MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) | TERMINATED | PHASE1 | 2005-01 | 2007-04 | 2007-04 |
| NCT01201343 | Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients | COMPLETED | PHASE4 | 2005-01 | 2010-07 | 2010-07 |
| NCT00120861 | Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy | COMPLETED | PHASE2 | 2005-01 | | |
| NCT00102700 | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | COMPLETED | PHASE2 | 2005-01 | 2007-01 | 2007-01 |
| NCT00249808 | A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies | COMPLETED | PHASE4 | 2004-12-13 | 2007-01-25 | 2007-01-25 |
| NCT00126451 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) | TERMINATED | PHASE2 | 2004-12-01 | 2005-10-11 | 2005-10-11 |
| NCT00432731 | Safety Study of a Refrigerator-stable Formulation of VARIVAX® | COMPLETED | PHASE4 | 2004-12 | 2005-09 | 2005-09 |
| NCT00265395 | Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) | COMPLETED | PHASE3 | 2004-12 | 2008-05 | 2008-05 |
| NCT00124722 | A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia | COMPLETED | PHASE3 | 2004-12 | 2007-07 | 2007-07 |
| NCT00099450 | Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers | COMPLETED | PHASE1 | 2004-12 | 2005-03 | 2005-03 |
| NCT00122460 | Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) | COMPLETED | PHASE3 | 2004-12 | 2011-01 | 2007-03 |
| NCT00099190 | ARQ 501 in Combination With Docetaxel in Patients With Cancer | COMPLETED | PHASE1 | 2004-12 | 2006-11 | 2006-11 |
| NCT00652782 | Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients | COMPLETED | PHASE2 | 2004-12 | | 2005-08 |
| NCT00727961 | A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) | COMPLETED | PHASE4 | 2004-11-09 | 2008-01-10 | 2008-01-10 |
| NCT00750178 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) | COMPLETED | PHASE1 | 2004-11-01 | 2005-11-01 | 2005-08-01 |
| NCT00097422 | OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD) | COMPLETED | PHASE2 | 2004-11-01 | 2005-04-01 | 2005-04-01 |
| NCT00770159 | A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED) | COMPLETED | PHASE1 | 2004-11 | 2005-11 | 2005-06 |
| NCT00095576 | Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) | TERMINATED | PHASE2 | 2004-11 | 2009-09 | 2007-09 |
| NCT00863525 | A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) | COMPLETED | PHASE1 | 2004-11 | 2006-06 | 2004-12 |
| NCT01075763 | A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease | COMPLETED | PHASE2 | 2004-11 | 2008-05 | 2008-05 |
| NCT00287118 | A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE4 | 2004-10-27 | 2006-05-30 | 2006-05-30 |
| NCT00091572 | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | COMPLETED | PHASE3 | 2004-10-20 | 2007-12-31 | 2007-12-31 |
| NCT00560833 | Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) | COMPLETED | PHASE3 | 2004-10-15 | 2006-01-15 | 2006-01-15 |
| NCT00094757 | An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023) | COMPLETED | PHASE3 | 2004-10-06 | 2006-04-28 | 2005-08-17 |
| NCT00779935 | Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) | COMPLETED | PHASE4 | 2004-10-01 | 2007-02-01 | 2005-10-01 |
| NCT00779012 | A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) | COMPLETED | PHASE4 | 2004-10-01 | 2007-06-01 | 2007-06-01 |
| NCT00109278 | A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) | COMPLETED | PHASE2 | 2004-10 | 2005-05 | 2005-05 |
| NCT00124735 | A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) | COMPLETED | PHASE3 | 2004-10 | 2007-09 | 2007-08 |
| NCT00783601 | MK0524 Asthma POC Study (0524-008)(COMPLETED) | COMPLETED | PHASE2 | 2004-10 | 2005-05 | 2005-05 |
| NCT00095056 | An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) | COMPLETED | PHASE3 | 2004-10 | 2006-07 | 2006-07 |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | COMPLETED | PHASE2 | 2004-10 | 2008-11 | 2008-11 |
| NCT00969163 | A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED). | COMPLETED | PHASE1 | 2004-10 | 2005-06 | 2005-04 |
| NCT00148798 | Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) | COMPLETED | PHASE3 | 2004-10 | 2012-05 | 2007-07 |
| NCT00249834 | Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF) | COMPLETED | PHASE4 | 2004-09-22 | 2006-01-16 | 2006-01-16 |
| NCT00535288 | Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) | COMPLETED | PHASE3 | 2004-09-15 | 2006-01-15 | 2006-01-15 |
| NCT00090285 | An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) | COMPLETED | PHASE3 | 2004-09-03 | 2017-04-03 | 2009-07-31 |
| NCT00094770 | An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) | COMPLETED | PHASE3 | 2004-09 | 2007-05 | 2006-05 |
| NCT00139438 | Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038) | COMPLETED | NA | 2004-09 | 2005-06 | 2005-06 |
| NCT00397956 | To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053) | COMPLETED | PHASE3 | 2004-09 | 2005-12 | 2005-12 |
| NCT00769418 | Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002) | COMPLETED | PHASE1 | 2004-09 | 2006-09 | 2004-12 |
| NCT00135577 | Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects | COMPLETED | PHASE2 | 2004-09 | 2007-04 | 2007-04 |
| NCT00146640 | Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis | COMPLETED | PHASE3 | 2004-08-31 | 2007-01-31 | 2007-01-31 |
| NCT03519867 | Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042) | COMPLETED | PHASE2 | 2004-08-01 | 2005-05-26 | 2005-05-26 |
| NCT00533676 | Endpoint Validation Study (0524A-015) | COMPLETED | PHASE2 | 2004-08 | 2006-12 | 2006-12 |
| NCT00239655 | A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) | TERMINATED | PHASE2 | 2004-08 | 2006-01 | 2005-12 |
| NCT00944450 | Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027) | COMPLETED | PHASE1 | 2004-08 | 2004-11 | 2004-09 |
| NCT00536237 | MK0524A Phase IIb Study (0524A-011)(COMPLETED) | COMPLETED | PHASE2 | 2004-08 | 2006-12 | 2005-02 |
| NCT00543465 | 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003) | TERMINATED | PHASE2 | 2004-08 | 2004-11 | 2004-11 |
| NCT00543595 | MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005) | COMPLETED | PHASE2 | 2004-08 | 2005-05 | 2005-05 |
| NCT00211601 | Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) | COMPLETED | NA | 2004-08 | 2005-12 | 2005-12 |
| NCT00159627 | Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). | COMPLETED | PHASE2 | 2004-08 | | |
| NCT00212797 | A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) | COMPLETED | PHASE2 | 2004-07 | 2006-07 | 2006-07 |
| NCT00145080 | Comparison of Osteoporosis Disease Management Strategies (0000-039) | COMPLETED | NA | 2004-07 | 2006-01 | 2006-01 |
| NCT00109148 | An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006) | COMPLETED | PHASE2 | 2004-07 | 2005-02 | 2005-01 |
| NCT00087451 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | COMPLETED | PHASE1 | 2004-07 | 2005-11 | 2005-11 |
| NCT00533403 | MK0686 in Postsurgery Dental Pain (0686-002) | COMPLETED | PHASE2 | 2004-07 | 2004-11 | 2004-11 |
| NCT00105469 | Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) | COMPLETED | PHASE3 | 2004-07 | 2005-10 | 2005-10 |
| NCT00105534 | Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) | COMPLETED | PHASE3 | 2004-07 | 2006-01 | 2006-01 |
| NCT00120835 | Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C | COMPLETED | PHASE1, PHASE2 | 2004-07 | | |
| NCT00086515 | Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) | COMPLETED | PHASE3 | 2004-06-30 | 2007-02-02 | 2005-07-20 |
| NCT00090220 | A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) | COMPLETED | PHASE3 | 2004-06-16 | 2015-11-12 | 2009-05-21 |
| NCT00132730 | An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005) | TERMINATED | PHASE2 | 2004-06-01 | 2005-08-17 | 2005-08-17 |
| NCT00651131 | Cubicin(R) for Complicated Post-surgical Wound Infections | TERMINATED | PHASE4 | 2004-06-01 | 2005-03-01 | 2005-03-01 |
| NCT00371007 | MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043) | COMPLETED | PHASE2 | 2004-06-01 | 2005-04-25 | 2005-04-25 |
| NCT00086502 | Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 | 2004-06 | 2005-11 | 2005-11 |
| NCT00403975 | Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease | COMPLETED | PHASE3 | 2004-06 | 2004-11 | 2004-11 |
| NCT00205842 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | COMPLETED | PHASE3 | 2004-06 | 2005-12 | 2005-12 |
| NCT00542022 | Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) | COMPLETED | PHASE2 | 2004-06 | 2005-05 | 2005-05 |
| NCT00863590 | A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers | COMPLETED | PHASE1 | 2004-06 | 2008-08 | 2005-02 |
| NCT00972595 | Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) | COMPLETED | PHASE1 | 2004-06 | 2004-09 | 2004-08 |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | COMPLETED | PHASE2 | 2004-06 | 2006-06 | 2006-06 |
| NCT00543868 | MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) | COMPLETED | PHASE2 | 2004-06 | 2004-08 | 2004-08 |
| NCT00087516 | Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) | COMPLETED | PHASE3 | 2004-06 | 2007-02 | 2005-07 |
| NCT00083967 | Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment | TERMINATED | PHASE2 | 2004-06 | 2006-04 | 2006-04 |
| NCT00140920 | A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259) | TERMINATED | PHASE4 | 2004-05-25 | 2004-09-27 | 2004-09-27 |
| NCT00090246 | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) | COMPLETED | PHASE3 | 2004-05-13 | 2005-04-20 | 2005-04-06 |
| NCT00482638 | Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED) | COMPLETED | PHASE2 | 2004-05-12 | 2004-10-29 | 2004-10-29 |
| NCT01183143 | Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization | COMPLETED | PHASE3 | 2004-05-11 | 2006-03-02 | 2006-03-02 |
| NCT00083343 | Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) | COMPLETED | PHASE2 | 2004-05 | 2006-02 | 2006-02 |
| NCT00292071 | Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042) | COMPLETED | PHASE2 | 2004-05 | 2006-07 | 2006-07 |
| NCT00154102 | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) | COMPLETED | PHASE3 | 2004-05 | 2011-03 | 2006-12 |
| NCT00857311 | MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) | COMPLETED | PHASE1 | 2004-05 | 2010-05 | 2006-01 |
| NCT00367484 | Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis | COMPLETED | PHASE4 | 2004-05 | 2006-01 | 2006-01 |
| NCT01081652 | A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET) | COMPLETED | PHASE3 | 2004-05 | 2005-05 | |
| NCT00082524 | Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) | COMPLETED | PHASE2 | 2004-04 | 2007-07 | 2007-07 |
| NCT00082537 | MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) | COMPLETED | PHASE2 | 2004-04 | 2006-10 | 2006-10 |
| NCT00696826 | A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED) | COMPLETED | PHASE1 | 2004-04 | 2004-05 | 2004-05 |
| NCT00080444 | Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) | COMPLETED | PHASE3 | 2004-04 | 2007-03 | 2006-09 |
| NCT00076856 | Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) | COMPLETED | PHASE2 | 2004-03-31 | 2006-03-31 | 2006-03-31 |
| NCT00535743 | Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) | COMPLETED | PHASE2 | 2004-03-04 | 2004-07-20 | 2004-07-20 |
| NCT00081770 | Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) | COMPLETED | PHASE3 | 2004-03 | 2007-11 | 2007-11 |
| NCT00533481 | Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED) | COMPLETED | PHASE2 | 2004-02 | 2004-12 | 2004-12 |
| NCT01079988 | Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence | COMPLETED | PHASE4 | 2004-02 | 2005-04 | 2004-12 |
| NCT01084265 | A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism | COMPLETED | PHASE3 | 2004-02 | 2005-12 | 2005-12 |
| NCT01067352 | A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA) | TERMINATED | PHASE3 | 2004-02 | 2009-07 | 2009-07 |
| NCT00090207 | Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) | COMPLETED | PHASE4 | 2004-01-13 | 2004-09-30 | 2004-09-30 |
| NCT00157872 | A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231) | COMPLETED | PHASE4 | 2004-01-07 | 2004-09-19 | 2004-07-05 |
| NCT00157898 | A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) | COMPLETED | PHASE4 | 2004-01 | 2004-09 | 2004-08 |
| NCT00092079 | A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) | COMPLETED | PHASE3 | 2004-01 | 2004-11 | 2004-11 |
| NCT01060488 | Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency | COMPLETED | PHASE3 | 2004-01 | | 2005-11 |
| NCT00442650 | Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis | COMPLETED | PHASE3 | 2004-01 | 2005-12 | 2005-12 |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) | TERMINATED | PHASE1 | 2003-12-01 | 2006-02-14 | 2006-02-14 |
| NCT00686517 | Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137) | COMPLETED | PHASE3 | 2003-12 | 2010-12 | 2010-12 |
| NCT00081510 | Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) | COMPLETED | PHASE2 | 2003-12 | 2009-05 | 2009-05 |
| NCT01081756 | A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET) | COMPLETED | PHASE3 | 2003-12 | 2004-09 | |
| NCT00379613 | Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) | COMPLETED | PHASE2 | 2003-11-07 | 2004-07-14 | 2004-07-14 |
| NCT00796250 | Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732) | TERMINATED | PHASE3 | 2003-11-01 | 2005-01-01 | 2005-01-01 |
| NCT00971633 | A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) | COMPLETED | PHASE1 | 2003-11 | 2004-01 | 2003-12 |
| NCT00145067 | Osteoporosis Disease Management Demonstration Project (0000-040) | COMPLETED | NA | 2003-11 | 2006-06 | 2006-06 |
| NCT00092872 | A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED) | COMPLETED | PHASE3 | 2003-11 | 2005-02 | 2005-02 |
| NCT01081639 | To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen | COMPLETED | PHASE3 | 2003-11 | 2004-09 | 2004-09 |
| NCT00092547 | A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) | COMPLETED | PHASE3 | 2003-10-08 | 2015-06-01 | 2005-11-03 |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication | COMPLETED | PHASE2 | 2003-10-01 | 2006-05-01 | 2006-05-01 |
| NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | COMPLETED | PHASE2 | 2003-10-01 | 2007-09-06 | 2007-09-06 |
| NCT00092417 | Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009) | COMPLETED | PHASE3 | 2003-10 | 2004-06 | 2004-06 |
| NCT00074529 | Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) | COMPLETED | PHASE2 | 2003-10 | 2006-01 | 2006-01 |
| NCT00090155 | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) | COMPLETED | PHASE3 | 2003-09-26 | 2004-11-24 | 2004-11-24 |
| NCT00092378 | A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED) | COMPLETED | PHASE3 | 2003-09-01 | 2003-12-01 | 2003-12-01 |
| NCT00963573 | Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428) | COMPLETED | PHASE4 | 2003-09 | 2006-11 | 2006-11 |
| NCT00073450 | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) | TERMINATED | PHASE2 | 2003-09 | 2004-06 | 2004-06 |
| NCT01157793 | A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood | COMPLETED | PHASE4 | 2003-09 | 2005-02 | 2005-02 |
| NCT00075933 | ARQ 501 in Subjects With Cancer | COMPLETED | PHASE1 | 2003-09 | 2007-01 | 2007-01 |
| NCT00481663 | A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014) | COMPLETED | PHASE2 | 2003-08-19 | 2006-05-14 | 2004-07-21 |
| NCT00302081 | Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) | COMPLETED | PHASE3 | 2003-08 | 2008-04 | 2008-04 |
| NCT00092859 | A 2-Year Study of an Investigational Drug in Obese Patients (0557-011) | COMPLETED | PHASE3 | 2003-08 | 2005-06 | 2005-06 |
| NCT00543816 | MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030) | TERMINATED | PHASE3 | 2003-08 | 2003-11 | 2003-11 |
| NCT00794898 | Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027) | COMPLETED | PHASE4 | 2003-07-01 | 2004-04-01 | 2004-04-01 |
| NCT00533208 | MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED) | COMPLETED | PHASE2 | 2003-07 | 2003-10 | 2003-10 |
| NCT00547274 | Dyslipidemia in Type 2 Diabetes (0767-034) | TERMINATED | PHASE3 | 2003-07 | 2003-11 | 2003-11 |
| NCT00543738 | MK0767 and Metformin Combination Study (0767-028) | TERMINATED | PHASE3 | 2003-06 | 2003-12 | 2003-12 |
| NCT00984633 | Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED) | COMPLETED | PHASE3 | 2003-06 | 2003-12 | 2003-12 |
| NCT00849732 | A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018) | COMPLETED | PHASE1 | 2003-06 | 2011-02 | 2006-10 |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | COMPLETED | PHASE2 | 2003-05-27 | 2005-06-17 | 2005-06-17 |
| NCT00482079 | A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) | COMPLETED | PHASE2 | 2003-05-13 | 2006-06-15 | 2004-08-25 |
| NCT00139425 | Osteoporosis Disease Management Demonstration Project (0000-037) | COMPLETED | NA | 2003-05 | 2004-12 | 2004-12 |
| NCT00092456 | Consistency Lots Vaccine Study (V260-009) | COMPLETED | PHASE3 | 2003-05 | 2004-08 | 2004-08 |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | COMPLETED | PHASE1 | 2003-05 | 2009-02 | 2006-05 |
| NCT00543491 | MK0767 and Sulfonylurea Combination Study (0767-027) | TERMINATED | PHASE3 | 2003-05 | 2003-12 | 2003-12 |
| NCT00543361 | Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020) | TERMINATED | PHASE3 | 2003-05 | 2003-12 | 2003-12 |
| NCT00988520 | Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977) | COMPLETED | PHASE3 | 2003-05 | 2003-09 | 2003-09 |
| NCT00894114 | A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) | COMPLETED | PHASE1 | 2003-05 | 2009-06 | 2009-06 |
| NCT00211575 | Instrument Utility for Suspected Asthma (0000-042)(COMPLETED) | COMPLETED | NA | 2003-05 | 2004-12 | 2004-12 |
| NCT00092352 | A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219) | COMPLETED | PHASE3 | 2003-04-29 | 2003-12-01 | 2003-12-01 |
| NCT00092365 | A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED) | COMPLETED | PHASE3 | 2003-04-01 | 2003-11-01 | 2003-11-01 |
| NCT00504608 | A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure | COMPLETED | PHASE1, PHASE2 | 2003-04 | 2004-04 | 2004-04 |
| NCT00210093 | A Pharmacokinetic Evaluation Study in Healthy Volunteers | COMPLETED | PHASE1 | 2003-04 | 2003-05 | 2003-05 |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | COMPLETED | PHASE1 | 2003-04 | 2005-10 | 2005-10 |
| NCT00849680 | A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016) | COMPLETED | PHASE1 | 2003-04 | 2010-02 | 2005-03 |
| NCT00056147 | Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease | COMPLETED | PHASE2 | 2003-04 | 2004-02 | 2004-02 |
| NCT00140933 | A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome | TERMINATED | PHASE3 | 2003-04 | | |
| NCT00256139 | CLEAR Study: Clinical Experience Acquired With Raptiva Study | COMPLETED | PHASE3 | 2003-03 | 2004-10 | 2004-10 |
| NCT00779129 | A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) | COMPLETED | PHASE2 | 2003-03 | 2007-08 | 2007-08 |
| NCT00811967 | Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) | TERMINATED | PHASE3 | 2003-02 | 2006-05 | 2006-05 |
| NCT00227435 | Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C | COMPLETED | PHASE1, PHASE2 | 2003-02 | 2004-07 | 2004-07 |
| NCT00928694 | Fenofibrate Bioequivalence Study (0767-031) | COMPLETED | PHASE1 | 2003-02 | 2004-04 | 2003-04 |
| NCT00970762 | Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED) | COMPLETED | PHASE3 | 2003-02 | 2004-02 | 2004-02 |
| NCT00543517 | Study A - MK0767 Monotherapy Study | TERMINATED | PHASE3 | 2003-02 | 2003-11 | 2003-11 |
| NCT00060476 | Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) | COMPLETED | PHASE3 | 2003-01-08 | 2004-12-08 | 2004-12-08 |
| NCT01381666 | Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701) | TERMINATED | PHASE2 | 2003-01 | 2004-04 | 2004-04 |
| NCT00418366 | A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008) | COMPLETED | PHASE1 | 2003-01 | 2003-03 | 2003-03 |
| NCT00543751 | Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025) | TERMINATED | PHASE3 | 2003-01 | 2003-11 | 2003-11 |
| NCT00076869 | MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) | COMPLETED | PHASE2 | 2003-01 | 2005-08 | 2004-09 |
| NCT00055198 | Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria | TERMINATED | PHASE3 | 2002-12-19 | 2004-01-26 | 2004-01-26 |
| NCT00092846 | A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED) | COMPLETED | PHASE3 | 2002-12-04 | | 2003-09-01 |
| NCT03519854 | Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020). | COMPLETED | PHASE2 | 2002-12-01 | 2003-06-01 | 2003-06-01 |
| NCT00092196 | Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) | COMPLETED | PHASE3 | 2002-12-01 | 2004-12-01 | 2004-12-01 |
| NCT00210015 | A Study in Subjects With Perennial Allergic Rhinitis | COMPLETED | PHASE2 | 2002-12 | 2003-04 | 2003-04 |
| NCT00482417 | Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017) | COMPLETED | PHASE2 | 2002-12 | 2003-05 | 2003-05 |
| NCT00482235 | A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016) | COMPLETED | PHASE2 | 2002-12 | 2003-04 | 2003-04 |
| NCT00050336 | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) | TERMINATED | PHASE3 | 2002-12 | 2004-03 | 2004-02 |
| NCT00092495 | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) | COMPLETED | PHASE3 | 2002-12 | 2009-02 | 2004-09 |
| NCT00210054 | A Pharmacokinetic Evaluation Study in Healthy Volunteers | COMPLETED | PHASE1 | 2002-11 | 2002-12 | 2002-12 |
| NCT00546624 | GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026) | COMPLETED | PHASE2 | 2002-11 | 2003-02 | 2003-02 |
| NCT00543010 | MK0767 Glipizide Comparator Cardiac Safety Study (0767-018) | TERMINATED | PHASE3 | 2002-11 | 2003-11 | 2003-11 |
| NCT00092183 | An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) | COMPLETED | PHASE4 | 2002-10-10 | 2004-02-11 | 2003-12-01 |
| NCT00049842 | Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) | COMPLETED | PHASE3 | 2002-10 | 2009-10 | 2009-10 |
| NCT00113581 | Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | COMPLETED | PHASE1 | 2002-10 | 2007-01 | 2006-05 |
| NCT00092430 | Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) | COMPLETED | PHASE3 | 2002-09-26 | 2003-06-09 | 2003-06-09 |
| NCT00533598 | A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED) | COMPLETED | PHASE2 | 2002-09 | 2003-06 | 2003-06 |
| NCT00703833 | A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019) | COMPLETED | PHASE2 | 2002-09 | 2003-02 | 2003-02 |
| NCT00539578 | Treatment of Patients With Anxiety Disorder (0777-022) | COMPLETED | PHASE2 | 2002-09 | 2003-02 | 2003-02 |
| NCT00092443 | Dose Confirmation Efficacy Study (V260-007) | COMPLETED | PHASE3 | 2002-09 | 2004-06 | 2004-06 |
| NCT00482898 | A Study of MK0359 in Patients With Chronic Asthma (0359-013) | COMPLETED | PHASE2 | 2002-09 | 2003-04 | 2003-04 |
| NCT00140894 | A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) | TERMINATED | PHASE4 | 2002-08-06 | 2004-10-11 | |
| NCT00092339 | A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED) | COMPLETED | PHASE3 | 2002-08-01 | 2002-09-15 | 2002-09-15 |
| NCT00543920 | A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020) | COMPLETED | PHASE2 | 2002-08 | 2003-02 | 2003-02 |
| NCT00048607 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) | COMPLETED | PHASE3 | 2002-07-30 | 2003-12-31 | 2003-12-31 |
| NCT00044486 | Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | COMPLETED | PHASE3 | 2002-07 | 2005-04 | 2004-12 |
| NCT00092482 | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | COMPLETED | PHASE3 | 2002-06-28 | 2008-08-15 | 2004-06-30 |
| NCT00042029 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073) | COMPLETED | PHASE3 | 2002-06-18 | 2003-10-03 | 2003-10-03 |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) | COMPLETED | PHASE3 | 2002-06-14 | 2025-06-13 | 2007-07-31 |
| NCT00048724 | Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) | COMPLETED | PHASE3 | 2002-06 | 2008-04 | 2008-04 |
| NCT00092326 | A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183) | COMPLETED | PHASE3 | 2002-06 | 2002-09 | 2002-09 |
| NCT00092313 | A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) | COMPLETED | PHASE3 | 2002-06 | 2002-09 | 2002-09 |
| NCT00039871 | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | COMPLETED | PHASE3 | 2002-05 | 2007-09 | 2007-09 |
| NCT00092300 | A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED) | COMPLETED | PHASE3 | 2002-05 | | 2002-09 |
| NCT00090272 | A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) | COMPLETED | PHASE3 | 2002-04 | 2005-03 | 2005-03 |
| NCT00037661 | Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye | COMPLETED | PHASE3 | 2002-04 | 2003-03 | 2003-03 |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | COMPLETED | PHASE3 | 2002-03 | 2009-11 | 2009-11 |
| NCT00035360 | Phase III PEG-Intron in HIV-infected Patients (Study P00738) | COMPLETED | PHASE3 | 2002-03 | 2003-10 | 2003-10 |
| NCT00093067 | Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus | COMPLETED | PHASE3 | 2002-03 | 2005-02 | 2004-11 |
| NCT00092170 | An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) | COMPLETED | PHASE2 | 2002-03 | 2004-01 | 2004-01 |
| NCT00092469 | Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) | COMPLETED | PHASE3 | 2002-03 | 2003-08 | 2003-08 |
| NCT00390260 | Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED) | COMPLETED | PHASE3 | 2002-02 | 2003-02 | 2003-02 |
| NCT00034944 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) | COMPLETED | PHASE3 | 2002-01-24 | 2003-12-17 | 2003-12-17 |
| NCT00048594 | Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) | COMPLETED | PHASE3 | 2002-01-03 | 2003-12-22 | 2003-12-18 |
| NCT00451386 | Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) | COMPLETED | PHASE2 | 2002-01 | 2003-12 | 2003-12 |
| NCT00040131 | Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) | TERMINATED | PHASE2 | 2002-01 | 2003-01 | 2002-12 |
| NCT00703690 | MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016) | TERMINATED | PHASE2 | 2002-01 | 2003-12 | 2003-12 |
| NCT00388401 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | COMPLETED | PHASE3 | 2002-01 | 2003-06 | 2003-06 |
| NCT00517309 | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) | COMPLETED | PHASE3 | 2001-12-28 | 2004-06-11 | 2004-06-08 |
| NCT00092404 | Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) | COMPLETED | PHASE2 | 2001-12 | 2005-06 | 2005-06 |
| NCT00481702 | A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802) | COMPLETED | PHASE3 | 2001-12 | 2003-06 | 2003-06 |
| NCT00092521 | Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) | COMPLETED | PHASE3 | 2001-12 | 2009-01 | 2007-07 |
| NCT00388479 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus | COMPLETED | PHASE3 | 2001-12 | 2003-11 | 2003-11 |
| NCT00035048 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) | COMPLETED | PHASE3 | 2001-11-21 | 2003-12-31 | 2003-12-29 |
| NCT00035295 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) | COMPLETED | PHASE3 | 2001-11-08 | 2003-12-05 | 2003-12-05 |
| NCT00109122 | Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) | COMPLETED | PHASE2 | 2001-11 | 2006-07 | 2003-02 |
| NCT00434824 | Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203) | COMPLETED | PHASE2 | 2001-11 | 2004-07 | 2004-07 |
| NCT00034983 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED) | COMPLETED | PHASE3 | 2001-10-29 | 2003-12-29 | 2003-12-29 |
| NCT00543556 | MK0767 in Type 2 Diabetes (0767-012) | TERMINATED | PHASE2 | 2001-10 | 2003-11 | 2003-11 |
| NCT00035009 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059) | COMPLETED | PHASE3 | 2001-09-20 | 2004-03-24 | 2003-12-22 |
| NCT00389987 | Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) | COMPLETED | PHASE3 | 2001-09 | 2004-05 | 2004-05 |
| NCT00504530 | r-hLIF for Improving Embryo Implantation in IVF | COMPLETED | PHASE1, PHASE2 | 2001-09 | 2002-04 | |
| NCT00035282 | Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) | COMPLETED | PHASE3 | 2001-09 | 2003-12 | 2003-12 |
| NCT00540072 | Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae | COMPLETED | PHASE3 | 2001-07-30 | 2002-02-27 | 2002-02-27 |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | COMPLETED | PHASE1, PHASE2 | 2001-07 | 2003-10 | 2003-10 |
| NCT00034697 | Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) | TERMINATED | PHASE2 | 2001-06-28 | 2003-01-30 | 2003-01-30 |
| NCT00040547 | Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED) | COMPLETED | PHASE1 | 2001-06 | 2004-02 | 2004-02 |
| NCT00034515 | A Study in Adult and Pediatric Patients With Cystic Fibrosis | COMPLETED | PHASE1, PHASE2 | 2001-06 | 2002-08 | 2002-08 |
| NCT00551629 | A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002) | COMPLETED | PHASE2 | 2001-05 | 2003-03 | 2003-03 |
| NCT00551915 | A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) | COMPLETED | PHASE2 | 2001-05 | 2003-01 | 2003-01 |
| NCT00210067 | A Study in Subjects With Retinal Detachment | COMPLETED | PHASE1 | 2001-05 | 2002-06 | 2002-06 |
| NCT00034632 | Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) | COMPLETED | PHASE3 | 2001-04 | 2007-03 | 2007-03 |
| NCT00229112 | Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034) | COMPLETED | PHASE3 | 2001-04 | 2004-04 | 2004-04 |
| NCT00210080 | A Study to Diagnose Lung Cancer by Sputum Cytology (01-312) | COMPLETED | PHASE3 | 2001-04 | 2003-12 | 2003-12 |
| NCT00388258 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | COMPLETED | PHASE3 | 2001-03-01 | 2002-12-01 | 2002-12-01 |
| NCT00404131 | Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease | COMPLETED | PHASE3 | 2001-03 | 2001-12 | 2001-12 |
| NCT00543530 | Pediatric Expanded Access Program-Oral Solution (0831-908) | COMPLETED | PHASE3 | 2001-03 | 2002-12 | 2002-12 |
| NCT00403715 | Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease | COMPLETED | PHASE3 | 2001-02 | 2002-09 | 2002-09 |
| NCT00541463 | A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED) | COMPLETED | PHASE2 | 2001-01 | 2003-05 | |
| NCT01731587 | Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer | WITHDRAWN | PHASE1 | 2001-01 | | |
| NCT00034671 | PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893) | COMPLETED | PHASE2 | 2001-01 | 2002-03 | 2001-11 |
| NCT00090233 | Rotavirus Efficacy and Safety Trial (REST)(V260-006) | COMPLETED | PHASE3 | 2001-01 | 2004-10 | 2004-10 |
| NCT00040534 | Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED) | TERMINATED | PHASE1 | 2001-01 | 2004-07 | 2004-07 |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | COMPLETED | PHASE2 | 2000-12-01 | 2006-10-20 | 2006-10-20 |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | COMPLETED | PHASE3 | 2000-12 | 2010-11 | 2010-11 |
| NCT00533650 | Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) | COMPLETED | PHASE2 | 2000-12 | 2002-10 | 2002-10 |
| NCT00538694 | Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia | COMPLETED | PHASE3 | 2000-10-31 | 2001-09-30 | 2001-09-30 |
| NCT00157209 | Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | COMPLETED | PHASE2 | 2000-08 | 2012-07 | 2006-03 |
| NCT00985166 | A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) | COMPLETED | PHASE3 | 2000-08 | 2003-05 | 2002-05 |
| NCT00984295 | Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines | COMPLETED | PHASE3 | 2000-06 | 2001-12 | 2001-10 |
| NCT00365716 | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) | COMPLETED | PHASE2 | 2000-05 | 2009-09 | 2004-05 |
| NCT00985153 | Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) | COMPLETED | PHASE3 | 2000-03 | 2001-05 | 2001-05 |
| NCT00679718 | A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease | COMPLETED | PHASE2 | 2000-01 | 2000-07 | 2000-07 |
| NCT00282386 | A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) | COMPLETED | PHASE3 | 1999-12-23 | 2004-09-01 | 2004-09-01 |
| NCT01735422 | A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women | COMPLETED | PHASE2 | 1999-12 | 2001-07 | 2001-07 |
| NCT00365378 | Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) | COMPLETED | PHASE2 | 1999-09 | 2009-07 | 2004-03 |
| NCT00680108 | A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution | COMPLETED | PHASE2 | 1999-09 | 2000-05 | 2000-05 |
| NCT00002960 | SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) | COMPLETED | PHASE1 | 1999-06 | 2000-07 | 2000-07 |
| NCT00986232 | ProQuad Dose Selection Study (V221-011)(COMPLETED) | COMPLETED | PHASE2 | 1999-04 | 2000-09 | 2000-04 |
| NCT00092391 | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) | COMPLETED | PHASE3 | 1999-02 | 2001-07 | 2001-07 |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | TERMINATED | PHASE2, PHASE3 | 1999-02 | 2001-08 | 2001-08 |
| NCT00034645 | Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease | COMPLETED | PHASE3 | 1999-01 | 2003-02 | 2003-02 |
| NCT00034658 | Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) | COMPLETED | PHASE3 | 1998-12 | 2002-03 | 2002-03 |
| NCT01400698 | Saizen in Intra-uterine Growth Retardation | COMPLETED | PHASE3 | 1998-11 | 2010-02 | 2010-02 |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) | TERMINATED | PHASE2, PHASE3 | 1998-10-22 | 2001-02-20 | 2001-02-20 |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | TERMINATED | PHASE2, PHASE3 | 1998-08-05 | 2001-02-19 | 2001-02-19 |
| NCT00975507 | ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) | COMPLETED | PHASE3 | 1998-03 | 1999-06 | 1999-01 |
| NCT03554005 | Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009) | COMPLETED | PHASE1 | 1997-12-29 | 2001-03-16 | 2001-03-16 |
| NCT03537274 | Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) | COMPLETED | PHASE2, PHASE3 | 1997-08-05 | 1999-07-23 | 1999-07-23 |
| NCT00888355 | MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension | COMPLETED | PHASE3 | 1992-05 | 1993-02 | 1993-01 |
| NCT01066052 | Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years | COMPLETED | PHASE4 | 1992-02-29 | 2010-08-31 | 1999-03-31 |
| NCT00887250 | A Study to Investigate the Antihypertensive Efficacy of MK0954 | COMPLETED | PHASE3 | 1991-12 | 1992-11 | 1992-08 |
| NCT00886600 | A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED) | COMPLETED | PHASE3 | 1991-05 | 1992-08 | 1992-05 |
| NCT00882440 | A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011) | COMPLETED | PHASE3 | 1990-12 | 1992-01 | 1991-08 |
| NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen | WITHDRAWN | PHASE2 | | | |
| NCT00228592 | HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection | TERMINATED | PHASE2 | | 2005-08 | |
| NCT00002208 | A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC | COMPLETED | PHASE3 | | | |
| NCT00002451 | Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs | UNKNOWN | PHASE2 | | | |
| NCT00002241 | Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily | UNKNOWN | PHASE2 | | | |
| NCT00005118 | The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment | UNKNOWN | PHASE2 | | | |
| NCT00005920 | Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole | TERMINATED | PHASE2 | | | |
| NCT00005921 | A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis | COMPLETED | NA | | | |
| NCT00002424 | A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine | SUSPENDED | PHASE2 | | | |
| NCT00002235 | A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors | COMPLETED | PHASE2 | | | |
| NCT00002452 | A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir | COMPLETED | PHASE2 | | | |
| NCT00002375 | Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients | COMPLETED | NA | | | |
| NCT00002361 | Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors | COMPLETED | PHASE2 | | | |
| NCT00002430 | A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations | COMPLETED | NA | | | |
| NCT00002376 | The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients | COMPLETED | PHASE4 | | | |
| NCT00002179 | The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection | COMPLETED | PHASE4 | | | |
| NCT00002386 | Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia | COMPLETED | PHASE4 | | | |
| NCT00002387 | The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz | COMPLETED | NA | | | |
| NCT00002220 | Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir | COMPLETED | PHASE3 | | | |
| NCT00002406 | A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients | COMPLETED | PHASE3 | | | |
| NCT00002225 | A Study of Efavirenz in Combination With Stavudine and Didanosine | COMPLETED | PHASE2 | | | |
| NCT00002227 | A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | COMPLETED | PHASE2 | | | |
| NCT00002410 | A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients | COMPLETED | PHASE3 | | | |
| NCT00002393 | A Study of Indinavir Taken With or Without DMP 266 | COMPLETED | PHASE3 | | | |
| NCT00002443 | The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | COMPLETED | NA | | 1996-01 | |
| NCT00002155 | A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC | COMPLETED | NA | | | |
| NCT00002354 | A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients | COMPLETED | NA | | | |
| NCT00002351 | A Study of L-735,524 in HIV-Positive Children and Adolescents | COMPLETED | PHASE1 | | | |